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Abstract  
 
The thesis focused on data analysis of surface-enhanced laser desorption/ionisation 
time-of-flight mass spectrometry (SELDI-TOF MS) for biomarker discovery and 
cancer classification.  It investigated quantitative measures of reproducibility and 
found that SELDI protein profiles are affected by sample storage and processing 
procedure. Two new peak alignment algorithms were proposed, one of which 
achieved the best performance when compared to the existing methods. The 
assumption of normality of SELDI protein profiles, on which the standard statistical 
methods are based, was examined.  Normality tests and multiple testing procedures 
revealed that SELDI protein profiles do not follow normal distributions, implying 
that it may be reliable to use non-parametric methods for detecting disease-associated 
proteins. A new normalisation algorithm was proposed, and was shown to give a 
better improvement of normality compared with the existing methods. An integrated 
algorithm to discover proteomic biomarkers for cancer diagnosis was proposed and 
applied to two published SELDI data sets. The results demonstrated that the receiver 
operating characteristic (ROC) curve method may be more reliable to determine the 
discriminatory powers of the identified biomarkers compared to Wilcoxon test. The 
methods for proteomic biomarker discovery presented here may be generalisable and 
applicable to other mass spectrometry and genomics approaches. 
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1
1 INTRODUCTION 
 
1.1 Strategy to combat cancer  
The efforts to combat cancer have not been very successful. Firstly, although we 
have seen advances in molecular medicine, genomics, proteomics, and translational 
research, the mortality rates for the most common cancers have not been significantly 
reduced (Diamandis,2004b). One in four of all deaths in the United Kingdom (UK) 
are caused by cancer. There were 153,491 cancer deaths in the UK in 2005 (Cancer 
Research UK,2007; Gavin,2007; General Register Office for Scotland,2007; Office 
for National Statistics,2007). Cancer accounted for 13% (7.6 million out of 58 
million) of deaths worldwide in 2005. Currently, more than 11 million people are 
detected with cancer each year. Cancers are still the main cause of morbidity and 
mortality (Alaoui-Jamali & Xu,2006; Cancerbackup,2007; Semmes et al.,2005). It is 
estimated that there will be 16 million new cases each year by 2020, 9 million people 
dying from cancer in 2015, and 11 million dying in 2030 (Cho,2007).  
 
Secondly, the progress in the understanding of cancer progression has been very slow 
and frustrating due to the complex multifactorial nature and heterogeneity of the 
cancer syndrome (Alaoui-Jamali & Xu,2006). Although progress in bio-technology 
has made it possible to identify genetic patterns that can be used to diagnose cancer 
and to predict cancer progression and treatment response (Assikis et al.,2004; 
Balmain et al.,2003; Curtis et al.,2001; Forrest et al.,2005; Gonzalez et al.,2007; 
Hoheisel,2006; Listgarten et al.,2004; Miyaki et al.,2004; Risch,2000; Rise et 
al.,2004; Rodin & Boerwinkle,2005; Scharpf et al.,2007; Staunton et al.,2001; 
Tomita et al.,2004; Unneberg et al.,2005; van de Vijver et al.,2002; Yoon et al.,2003; 
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Ziauddin & Sabatini,2001), the complexity and diversity of cancer make it difficult 
to interpret the genetic patterns.  
 
Some of the best available options to combat cancer include primary prevention, 
earlier diagnosis, and improved therapeutic interventions. We have been witnessing 
the development of new drugs against cancer that are based on rational instead of 
empirical designs. There is hope that some of these drugs will prove to be more 
effective in the clinic than older generations of medicines (Diamandis,2004b).  
 
Many of the most prevalent human cancers can be prevented to a significant extent 
through medical interventions or life-style changes. For example, smoking control is 
very successful in prevention of lung cancer. Dietary changes can reduce the risk of 
developing large bowel cancer (Henderson et al.,1991). However, the mechanisms of 
cancer initiation and progression are still not well understood (Cavalierie & 
Rogan,2006; Diamandis,2004b; Yu,2002). Fortunately, progress in bio-technology 
provides an opportunity to identify biomarkers, which are substances used as 
indicators of biologic states (Biomarkers Definitions Working Group,2001; 
caBIG,2007; Dalmasso,2008). A combination of biotechnology and bioinformatics 
are indispensable tools in detecting biomarkers that may be useful for earlier 
detection of cancer. There is evidence that the survival rate exceeds 85% when the 
common cancers are diagnosed at early stage and are organ confined (Etzioni et 
al.,2003; Gloeckler Ries et al.,2003; Semmes et al.,2005). Clearly, there is an urgent 
need to unravel novel biomarkers for early detection of cancer.  
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1.2 Biomarker discovery in cancer research 
Identification of cancer biomarkers is one of the most rapidly advancing fields in 
clinical diagnostics. Cancer biomarkers can be used to screen asymptomatic 
individuals in the population, assist diagnosis in suspected cases, monitor treatment 
efficacy and predict treatment response (Diamandis,2002; Editorial,2004; Ludwig & 
Weinstein,2005). A few clinically approved biomarkers (Table 1-1) are available for 
early detection or for successful monitoring of treatment and relapses. Early cancer 
detection is critical in cancer control. Many screening approaches have been studied 
in solid cancers1. Established screening tools for the early detection of cancer include 
mammography for breast cancer, colonoscopy for colorectal cancer, prostate specific 
antigen (PSA) test for prostate cancer, and pap smear for cervix cancer.  
 
However, none of the biomarkers listed in Table 1-1 has adequate sensitivity, 
specificity, and predictive value for population screening (Diamandis,2004b). PSA is 
produced by normal prostate cells in small amounts. The high amount of PSA in 
serum may correlate to the existence of prostate cancer. However, there are reasons 
other than cancer that cause rise in PSA, such as infections within the prostate gland, 
and increased exercise with irritation of the affected area (PacificLife,2007; 
Zimmermann,2007). Cancer antigen 125 (CA-125) can be a biomarker of ovarian 
cancer risk or an indicator of malignancy. However, level of this biomarker can be 
high in subjects who have pancreatitis, liver or kidney disease (PacificLife,2007). 
Imaging techniques such as chest X-ray and spiral computed tomography (CT) are 
also used, but are limited to a tumour size detection limit of 0.5-1.0 cm (representing 
close to 109 cells).  
 
1 Solid cancers are defined as abnormal cellular growths in "solid" organs such as the breast or 
prostate, as opposed to leukaemia, a cancer affecting the blood, which is liquid. 
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Table 1-1 Common cancer biomarkers used in primary care 
Biomarkers Cancer type Clinical use Source 
AFP Hepatoma, testicular Staging (Alaoui-Jamali & 
Xu,2006; 
Diamandis,2004b) 
CA125 
 
Ovarian, cervical, 
uterine, fallopian tube 
Disease 
monitoring 
(Alaoui-Jamali & 
Xu,2006; 
Diamandis,2004b) 
CA15-3 
 
Breast Disease 
monitoring 
(Alaoui-Jamali & 
Xu,2006; 
Diamandis,2004b) 
CA19-9 Gastrointestinal, 
pancreatic, stomach 
Disease 
monitoring 
(Alaoui-Jamali & 
Xu,2006; 
Diamandis,2004b) 
CA27-29 Breast Disease 
monitoring 
(Alaoui-Jamali & 
Xu,2006) 
CEA 
 
Colorectal, breast, 
lung, pancreatic, 
medullary thyroid 
Disease 
monitoring 
(Alaoui-Jamali & 
Xu,2006; Hutchens & 
Yip,1993) 
hCG Testicular cancer, 
trophoblastic tumours 
testis, ovary 
Screening (Diamandis,2004b) 
Epidermal growth 
Factor receptor 
Colon, non-small cell 
lung cancer 
Selection of 
therapy 
(Alaoui-Jamali & 
Xu,2006) 
Her2/Neu Breast, ovarian Disease 
monitoring, 
selection of 
therapy 
(Alaoui-Jamali & 
Xu,2006) 
Human chronic 
gonadotropin-β 
Testicular, ovarian 
 
Staging (Alaoui-Jamali & 
Xu,2006) 
Immunoglobulins B cell dyscrasias Diagnosis 
Disease 
monitoring 
(Diamandis,2004b) 
 
PSA Prostate Screening, 
disease 
monitoring 
(Alaoui-Jamali & 
Xu,2006; 
Diamandis,2004b) 
Steroid hormone  
receptors 
Breast Screening (Diamandis,2004b) 
Thyroglobulin Thyroid Disease 
monitoring 
(Alaoui-Jamali & 
Xu,2006) 
 
 
The targeting of some biomarkers have contributed to reduced mortality rates and 
increased overall survival for cancers (Alaoui-Jamali & Xu,2006; Diamandis,2004b; 
Hutchens & Yip,1993). For example, carcinoembryonic antigen (CEA) has been 
identified as a biomarker for colorectal cancer, pancreas cancer, lung cancer, and 
breast cancer. It has been used for monitoring disease. Human chronic gonadotropin-
β has been identified as a biomarker for ovarian cancer and has a clinical use in 
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cancer staging.  Epidermal growth factor receptor has been identified as a biomarker 
for colorectal cancer and non-small cell lung cancer. It has been used in helping 
determine an appropriate therapy.  
 
Serum biomarkers are produced by body organs or tumours. They can be suggestive 
of tumour activity when detected in high amounts in blood (PacificLife,2007). 
Several serum markers have been identified through the years but, with a few 
exceptions such as PSA for prostate cancers and alpha-fetoprotein (AFP) for 
hepatocellular carcinomas and germ cell tumour, most have failed general integration 
into routine clinical practice. It is therefore important to devise new methods that 
may provide sensitive and reliable diagnostic biomarkers for solid cancers (Finne et 
al.,2001; Menon & Jacobs,2002; Stephan et al.,2003; Tibshirani et al.,2004). The 
absence of selective biomarkers may hamper efforts to improve early detection and 
therapeutic management (Alaoui-Jamali & Xu,2006).   
 
1.3 Potential biomarker discovery for cancer research 
The advanced technologies in microarrays and mass spectrometry, and the 
completion of the sequencing of the human genome have sparked new interest in the 
area of cancer biomarkers. The microarray and mass spectrometry assays allow 
thousands of measurements to be carried out in short periods of time 
(Diamandis,2002; Negm et al.,2002). The sequencing of the human genome can 
provide fundamental structural information about human genes (Diamandis,2002; 
Editorial,2004).  
 
A potential biomarker can be a fragment of deoxyribonucleic acid (DNA) sequence, 
ribonucleic acid (RNA), protein or peptide.  These correspond to the different stages 
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of information flow from genotype to phenotype. The DNA in human cells contains 
long chains of four chemical building blocks, namely adenine (A), thymine (T), 
cytosine (C), and guanine (G). A human cell has more than 3 billion of these 
chemical bases, strung together in 23 pairs of chromosomes (SNP Fact Sheet,2009). 
Single nucleotide polymorphisms (SNPs) are the most frequent form of DNA 
variation present in the human genome. Because of their abundance, even spacing, 
and stability across the genome – they are estimated to occur at one out of every 100-
300 bases (SNP Fact Sheet,2009) – SNPs are considered to be excellent genetic 
markers and offer significant potential for cancer genetic research (HapMap,2007b; 
HapMap,2007a; Risch & Merikangas,1996; Schork et al.,1998). It is estimated that 
there are about 10-30 million of SNPs in human genome (SNP Fact Sheet,2009). 
Detection of genetic SNP variants that underlie cancer means sifting through 
hundreds of thousands of SNPs to identify a relevant subset of markers that could be 
further examined. The identification of SNPs associated with cancer from a huge 
amount of SNPs can be daunting (Breiman & Spector,1992; Bureau et al.,2005; 
Klein et al.,2005; Lunetta et al.,2004; Maraganore et al.,2005; Ozaki et al.,2002; 
Raychaudhuri et al.,2001; Toivonen et al.,2000) and may lead to computational 
problems and difficulties in interpreting results. However, many recent successes 
relating SNPs to disease have been achieved in genome-wide association studies. For 
example, two correlated common variants on chromosome 8q24 associated with 
prostate cancer in European and African populations have benn identified 
(Amundadottir et al.,2006; Gudmundsson et al.,2007). A locus on chromosome 8q24 
close to SNPs rs10505477 and rs6983267 is thought to be associated with colorectal 
cancer susceptibility (Zanke et al.,2007). Five independent SNPs that exhibited 
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strong and consistent evidence of association with breast cancer have been reported 
(Easton et al.,2007). The Wellcome Trust Case Control Consortium has identified 24 
independent association signals for bipolar disorder, coronary artery disease, Crohn’s 
disease, rheumatoid arthritis, type 1 diabetes and type 2 diabetes (The Wellcome 
Trust Case Control Consortium,2007). 
 
Microarray technology has enabled us to quantify the transcript levels of tens of 
thousands of genes simultaneously and is another powerful approach towards 
understanding genome function (Chu et al.,2005; Kelly & Ghosh,2005; Orchekowski 
et al.,2005; Simon et al.,2003; Spellman et al.,1998).  The human genome has been 
estimated to contain 20,000-45,000 genes (Cho,2007; Human Genome Project,2007).  
Microarray is a rapidly growing scientific field, primarily concerned with the 
identification of potential biomarkers. It has provided promising results on genetic 
basis that can help stage cancer, and predict cancer progression and monitor therapy 
response (Datta & Lara,2006; Datta et al.,2004; Notterman et al.,2001). However, 
comparative transcriptional profiling alone is unlikely to fully identify biomarkers 
that are associated with cancer phenotype (Alaoui-Jamali & Xu,2006). The 
investigation of RNA expression obtained from microarray data may be an indirect 
way to understand the aetiology of a disease (Datta & Lara,2006).  
 
Although gene studies have received a lot of attention, it is the proteins that perform 
most life functions and even make up the majority of cellular structures (Human 
Genome Project,2007). The ultimate element to control all the functions of a cell is 
the protein. Proteomics is the large-scale study of protein function and expression. It 
may hold enormous potential for the early detection of cancer (Hartwell et al.,2006; 
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National Cancer Institute,2007a; Negm et al.,2002; Srinivas et al.,2002).  The cancer 
proteome contains information on perhaps every biological process that takes place 
in cancer cells, cancer tissue microenvironment and caner cell-host interaction 
(Alaoui-Jamali & Xu,2006).  Proteomic technologies have a great potential to 
identify biomarkers for cancer diagnosis, to monitor disease progression, and to 
identify therapeutic targets. The proteome contains not only the intrinsic genetic 
information of a cell, but also the impact of its immediate environment. A 
transformation of a healthy cell into a neoplastic cell may cause altered expression 
profile, differential protein modification and activities, and this in turn may affect 
cellular function. Therefore, investigation of the cancer proteome could be a starting 
point in identifying biomarkers (Alaoui-Jamali & Xu,2006; Bensmail & 
Haoudi,2003; Zolg,2007). It has been estimated that 20,000-45,000 human genes 
produce approximately 250,000 spliced variants of RNA, which are translated into 
more than one million proteins as a result of post-translational processing and 
modification (Cho,2007; Ozier et al.,2003). Therefore, there is a need to develop 
sound quantitative methods for measuring proteomic changes caused by a disease. 
 
1.4 Proteomic biomarker discovery for cancer research 
Current progress in proteomics has been mainly due to developments in mass 
spectrometry (Aebersold & Goodlett,2001; Alaoui-Jamali & Xu,2006). There are 
many mass spectrometry technologies, including matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS, 
henceforth it is called MALDI), surface-enhanced laser desorption/ionisation time-
of-flight mass spectrometry (SELDI-TOF MS, it is called SELDI), and liquid 
chromatography mass spectrometry (LC-MS).  
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LC-MS is a powerful method for sensitive detection and quantification of proteins 
and peptides in complex biological fluids like serum (Nyangoma et al.,2007), which 
combines the physical separation capabilities of liquid chromatography with the 
mass analysis capabilities of mass spectrometry.  
 
MALDI is an ionisation technique applied to mass spectrometry and was first 
introduced by Franz Hillenkamp (Karas et al.,1985; Laiko et al.,2000) in 1985. Franz 
Hillenkamp and colleagues found that amino acid alanine2 could be ionised more 
easily if it was mixed with the amino acid tryptophan3 (also called the matrix) and 
irradiated with a pulses 266 nm laser. The ionisation was triggered by a laser beam. 
A chemical matrix was used to protect biomolecules from being destroyed by direct 
laser beam and to facilitate vaporisation and ionisation. The first commercial 
MALDI instruments were introduced in the early 1990s (Karas & Bahr,1990). 
MALDI has been used to profile and quantify individual peptides or proteins from 
mammalian cells and tissue section (Aebersold & Goodlett,2001; Chaurand & 
Caprioli,2002; Cho,2007; Kachman et al.,2002; Kasthuri et al.,2006; McCormack et 
al.,1997; Poon,2007; Stoeckli et al.,2001; Wolters et al.,2001).   
 
Although MALDI has potential for biomarker discovery, it encompasses a complex 
sample preparation procedure. Furthermore, interpretation of in-source fragmentation 
mass spectra has a limitation in the low mass region of the mass spectrum where the 
abundance of intense, low mass matrix ion signals typically dominates the MALDI 
spectra, making it difficult to identify components.  This limits the use of MALDI in 
 
2 Alanine is an α-amino acid with the chemical formula HO2CCH(NH2)CH3 
3 Tryptophan is an amino acid essential in human nutrition. It is one of the 20 amino acids encoded by 
the genetic code. 
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profiling complex protein mixtures. Prefractionation of protein mixtures using 
chromatographic approaches has been used to address this limitation. SELDI 
integrates MALDI and chromatography technology and was first introduced by 
Hutchens & Yip (1993).  
 
SELDI may succeed in discovering new diagnostic modalities for cancers if the 
methods are used properly (Kroczak et al.,2006; Kuwata et al.,1998; Merchant & 
Weinberger,2000; Plebani,2005). Compared to MALDI, SELDI is different in the 
construction of the sample targets, the design of the analyser and the software used to 
interpret the acquired data (Vorderwülbecke et al.,2007). SELDI employs 8- or 16-
spot chip for analysing 8-16 protein samples per chip. Each spot contains a solid-
phase chromatographic surface for binding proteins at a particular binding condition.  
After washing and adding the matrix chemical, the retained proteins or peptides are 
charged and detected as peaks in mass spectra (Poon,2007). The analyser used for 
SELDI is especially adapted to achieve high-sensitivity quantification. The ion 
source and detector are constructed to support efficient ion transmission and ion 
detection over a wide mass range. The precise positioning of the laser beam is 
controlled by software in automatic or manual mode. Software used in SELDI allows 
normalisation of the resulting spectra to their total ion current (TIC) for internal 
quantitative calibration. SELDI is discussed in more details in Chapter 2. In 
summary, by combining selective protein binding with quantitative mass detection, 
SELDI enables the comparative analysis of proteins in a fast and simple process 
(Vorderwülbecke et al.,2007). Advancements in SELDI may lead to the 
identification of potential serum/plasma biomarkers at ng/ml or even lower levels 
(Poon,2007). However, many researchers believe that SELDI has inferior 
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performance. The resolution of SELDI is usually quite low, and the ion peaks of 
interest cannot be directly identified (Petricoin et al.,2006). Another disadvantage of 
SELDI is that protein sequences, and thus specific identifications, are not obtained, 
requiring further biochemical/mass spectrometry analysis to identify differentially-
expressed proteins (Miyamae et al.,2005). 
 
Opportunities also mean challenges.  Unlike genomic studies, proteomic studies have 
technical challenges to acquire proteomic data. Other challenges include lacking of 
standardised methodologies, unknown reproducibility, and intra- or inter-individual 
cancer heterogeneity (Alaoui-Jamali & Xu,2006).  As far as we know, there is no 
evidence to show that the results obtained with SELDI technique are robust and 
reproducible among laboratories. Before the technique can be used for clinical 
purposes, the method needs to be internally and externally validated.  
 
This thesis will investigate the quantitative methods used for biomarker discovery for 
cancer diagnosis using SELDI. We focus on the issue of reproducibility assessment 
and study the influence of important pre-processing steps, including spectrum 
baseline correction, normalisation, transformation, and peak alignment on biomarker 
discovery and cancer classification. We propose three methods to assess the 
reproducibility of SELDI protein profiles. Two improvements to the current peak 
alignment methods, suitable for SELDI mass spectra alignment are proposed. We 
also propose one new normalisation algorithm for pre-processing SELDI data, and an 
integrated algorithm for biomarker discovery using SELDI. 
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1.5 Objectives of the thesis 
The objectives of the thesis are to investigate quantitative methods used in proteomic 
biomarker discovery for cancer diagnosis. In particular, we focus on the following 
issues. 
1. Review the use of SELDI technology in cancer diagnosis and statistical 
methods for SELDI data analysis. 
2. Investigate the methods for assessing reproducibility of SELDI data.  
3. Study the methods for pre-processing SELDI data, including spectrum 
normalisation, transformation, and peak alignment. 
4. Study the normality of SELDI data for selecting appropriate methods to 
identify biomarkers from SELDI data. 
5. Investigate the methods for feature selection and sample classification and 
propose an integrated framework for identifying biomarkers using SELDI 
data.  
 
1.6 Layout of the thesis 
The rest of this chapter is devoted to providing a context for the thesis. Chapter 2 
reviews SELDI technology and the statistical methods for SELDI data analysis. A 
general procedure of applying SELDI to cancer biomarker discovery and cancer 
classification is presented and discussed, which include issues on experiment 
designs, reproducibility analysis, protein profile pre-processing, identification of 
putative biomarkers, and cancer classification. The problems in analysing SELDI 
protein profiles are identified, and the solutions for these problems are outlined. 
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Chapter 3 proposes three quantitative reproducibility measures using Euclidean 
distance, correlation coefficient, and the paired t-test to assess the reproducibility of 
SELDI protein profiles.  The proposed methods are applied to SELDI mass spectra 
generated from identical samples in replicate experimental runs for assessing the 
reproducibility of SELDI protein profiles. 
 
Chapter 4 proposes two new peak alignment algorithms. The performance of the 
peak alignment methods are assessed and compared with other existing peak 
alignment methods. Classifiers are also built to evaluate the effect of peak alignment 
on cancer classification. The prediction accuracy of the classifiers that are trained 
using mass spectra with and without peak alignment is estimated and compared.   
 
Chapter 5 examines the assumption of the normality of SELDI protein profiles, on 
which standard statistical methods (such as t-tests) used for differential expression 
detection are based. Four statistical tests of normality are applied to investigate the 
normality of SELDI protein profiles. The effects of normalisation and data 
transformation on normality of SELDI data are investigated. Our proposed 
normalisation algorithm is compared with the standard methods. The cancer 
classification accuracies using SELDI data with and without logarithmic 
transformation are also evaluated.  
 
Chapter 6 proposes an integrated algorithm for biomarker discovery for early 
detection of cancer using SELDI expression profiles, which consists of two major 
components: feature selection methods and machine learning techniques. Both 
univariate feature selection and multivariate feature selection approaches are 
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assessed. Two published SELDI data sets have been used to demonstrate how the 
algorithm works.  
 
Conclusions and suggestions of possible future work in this area are given in Chapter 
7.   
 
Finally, the programs used in this thesis are listed in appendixes.  
 
1.7 Summary 
Continuous efforts have been made to combat cancer for many years. Cancers are 
still the main cause of morbidity and mortality. Cancer initiation and progression 
have been largely unknown due to the complexity and diversity of cancer genome.  
Although cancer biomarkers are not very effective at screening the population and 
diagnosing cancer early, they are valuable in monitoring patients during and after 
therapy. There has been evidence to show that the availability of a few biomarkers 
have significantly contributed to reduced mortality rates and increased survival of 
cancers. Therefore, there is an urgent need to discover biomarkers for early cancer 
detection and for selection of the most effective treatment from currently available 
therapeutic agents.  
 
Proteome contains both the intrinsic genetic information of cells and the impact of 
their immediate environments. Therefore, investigating the cancer proteome could be 
a starting point in cancer biomarker discovery. The current progress in proteomics 
has been mainly due to the rapid development in mass spectrometry. The next 
chapters will be devoted to investigate SELDI mass spectra and its applications in 
biomarker discovery for early cancer diagnosis. 
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2 SELDI TECHNOLOGY AND DATA ANALYSIS 
2.1 Introduction 
SELDI is a recently developed technology for proteomic research. It couples 
chromatographic separation of samples using reactive surfaces and high-throughput 
mass spectrometry analyses and provides a way to study protein profiles over a wide 
range of molecular weights (0-200kDa) in small biological specimens, such as 
serum. It has great potential for biomarker discovery and for protein-protein 
interaction studies.  In this chapter, the SELDI technology and its applications will be 
reviewed. One approach to biomarker discovery is discussed. This includes the 
following components: experiment design, reproducibility analysis, mass spectrum 
pre-processing, and biomarker identification. The problems in each component are 
discussed. The solutions for these problems are outlined and to be addressed in the 
subsequent chapters. 
 
2.2 SELDI technology 
SELDI technology encompasses two major subsets of MS technology: surface-
enhanced neat desorption (SEND) and surface-enhanced affinity-capture (SEAC) 
(Hutchens & Yip,1993; Poon,2007).  Figure 2-1 outlines the SELDI technology. It 
consists of three major components: the ProteinChip Array, the ProteinChip Reader, 
and the ProteinChip Software.  
 
The ProteinChip array distinguishes this technology from other mass spectrometry-
based analytical systems and has a 10-mm wide x 80-mm long chip with eight or 
sixteen 2-mm spots comprised of a specific chromatographic surface. There are two 
major types of surfaces (Figure 2-2): chemical surfaces and biochemical surfaces. 
The chemically treated surfaces include anionic, cationic, hydrophobic, hydrophilic, 
immobilised-metal affinity metal.  The pre-activated biochemical surfaces are 
available for covalently coupling antibody, receptor, DNA, enzyme, and so on. 
 
 
 
 
Figure 2-1 Diagram of SELDI technology 
 
In the general application, a small volume of protein sample, such as biological fluid, 
is taken from people with or without cancer and applied on the ProteinChip array. A 
diluted sample is added to the pre-processed ProteinChip array and incubated 
(sample will be resolved into a subset of proteins with common properties). The 
ProteinChip is then washed to remove unbounded components, air-dried, and 
crystallised with an energy absorbing molecule (EMA) called “matrix”. The 
ProteinChip array usually binds a subset of proteins in the serum sample and the 
mass spectrum is recorded by the ProteinChip Reader.  
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Figure 2-2 ProteinChip Arrays. 
 
 
The ProteinChip Reader is a laser desorption ionisation (LDI) time-of-flight (TOF) 
MS instrument equipped with a pulsed ultraviolet (UV) nitrogen laser source that 
uses state-of-the-art ion optic and laser optic technology. The bound proteins are hit 
with a laser in the ProteinChip Reader, causing the proteins to desorb and ionise 
when the matrix absorbs the energy produced at the wavelength of the nitrogen laser. 
This produces ionised protein molecules in the gas phase. A brief electric field is 
then applied to accelerate the ions down a flight tube, and a detector at the end of the 
tube records the time of flight. The small proteins fly faster and the large proteins fly 
more slowly. Therefore, the position of an individual protein in spectrum 
corresponds to its time-of-flight. The detected proteins are reported as a series of 
peaks (0-200kDa), with the mass/charge ratio (m/z) values of proteins and their 
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corresponding intensities. The resulting data may be displayed in a two-dimensional 
plane, with m/z values displayed in the x-axis and the corresponding intensities (ion 
currents) on the y-axis (shown in the bottom part of Figure 2-1). The laser optics 
maximise ion extraction efficiency over the greatest possible sample area, and thus 
increases analytical sensitivity and reproducibility. The ProteinChip Reader’s ion 
optics incorporates a four-stage, time-lag-focusing4 ion lens assembly that provides 
precise, accurate molecular weight determination.  Time-lag-focusing is used to 
increase the mass accuracy of the final output. Signal processing is accomplished by 
high-speed analog-to-digital converter, which is linked to a personal computer (Isaaq 
et al.,2002).  
 
The ProteinChip Software controls all aspects of the ProteinChip Reader and 
facilitates data collection and processing. It has the function of loading ProteinChip 
array into the reader, calibrating the reader, analysing samples, normalising mass 
spectra, and presenting the spectra in the user-friendly manner. The quadratic 
equation is employed to convert TOF and its velocity through an ion chamber into 
m/z. 
btTOFa
Voltage
zm +−= 20 )(/        (2.1) 
 
where, the parameters a, b, and t0 can be estimated for known peptides/proteins. The 
equation generated by this process can then be used on mass spectra that are 
collected under the same instrument and conditions.  
                                                 
4 Time-lag-focusing is an experimental technique in time-of-flight mass spectrometry in which 
improved mass resolution is obtained by using a controlled time delay between the initial pulse of ion 
formation and acceleration of the ions into the flight tube of the instrument. 
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2.3 Applications of SELDI technology in cancer studies  
SELDI is currently one of the most rapid and sensitive proteomics analysis tools 
available. With further improvements in resolution and reproducibility, the unlimited 
type of biological material, less complicated protocol and the unique surface 
chemistries of the arrays make SELDI technology an attractive approach to protein 
profiling (Alterovitz et al.,2004; Austen et al.,2000; Cardone et al.,1998; Chernyak et 
al.,2001; Forde et al.,2002; Hampel et al.,2001; Henderson & Steele,2005; 
Hinshelwood et al.,1999; Jock et al.,2004; Li et al.,2002; Pawlik et al.,2006; 
Petricoin et al.,2002a; Petricoin & Liotta,2004; Poon et al.,2003; Reddy & 
Dalmasso,2003; Stoica et al.,2001; Tong et al.,2004; Yu et al.,2004; Zhang et 
al.,2004a; Zhao et al.,2004).  
 
This versatile instrumentation is currently being used in projects ranging from the 
identification of disease biomarkers to the study of bio-molecular interactions. 
SELDI provides a means of evaluating the intensity of many proteins at the same 
time.  The ProteinChip allows for protein profiling from a variety of complex 
biological materials such as serum, blood, plasma, intestinal fluid, urine, cell lysates, 
and cellular secretion products with less complicated sample preparation protocol. 
Some studies have used SELDI to characterise protein-protein interactions 
(Hinshelwood et al.,1999; Stoica et al.,2001), phosphorylation site mapping and 
glycoproteins characterisation (Cardone et al.,1998; Chernyak et al.,2001), and 
transcription factors (Forde et al.,2002). Others used SELDI to profile low molecular 
weight peptides (Sato et al.,2001) and proteins secreted by different cancer cell lines 
grown in serum free medium (Isaaq et al.,2002). SELDI has also been utilised to 
discover biomarkers for different types of cancers, such as ovarian (Petricoin et 
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al.,2002a), bladder cancer (Zhang et al.,2004a), colon cancer (Yu et al.,2004; Zhao et 
al.,2004), hepatocellular carcinoma (HCC) (Poon et al.,2003), prostate cancer (Tong 
et al.,2004), breast cancer  (Li et al.,2002), and renal cancer (Hampel et al.,2001; 
Rogers et al.,2003).  
2.3.1 The use of SELDI in biomarker discovery 
The concept of finding proteomic differences between cancer patients and normal 
subjects was based on an assumption that protein or protein fragments produced by 
cancer cells or their microenvironment may eventually enter into the general 
circulatory system. The biological fluid of interest is first interacted with a protein 
chip that incorporates some kind of affinity separation between “non-informative” 
and “informative” proteins. After washing, the informative proteins can be studied 
using SELDI. The biomarkers may be identified from the mass spectra of these 
protein or protein fragments and have a potential in early cancer diagnosis (Hutchens 
& Yip,1993). Table 2-1 shows the putative cancer biomarkers that have been 
identified using SELDI technology. 
 
Many laboratories have demonstrated the feasibility of using mass spectrometry 
proteomic pattern analysis in the discovery of potential diagnostic markers and 
cancer classification (Adam et al.,2002; Cazares et al.,2002; Kozak et al.,2003; Li et 
al.,2002; Pang et al.,2006; Paweletz et al.,2001; Petricoin et al.,2002a; Petricoin et 
al.,2002b; Poon et al.,2003; Qu et al.,2002; Rosty et al.,2002; Vlahou et al.,2003b; 
Vlahou et al.,2001; Vlahou et al.,2003a; Vlahou et al.,2003c; Wadsworth et al.,2004; 
Won et al.,2003; Wulfkuhle et al.,2001; Xiao et al.,2003; Zhukov et al.,2003). The 
reported cancer classification accuracies are relatively high, with sensitivities varying 
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from 83% to 100%, and specificities varying from 82% to 98% (Li et al.,2002; 
Petricoin et al.,2002a; Poon et al.,2003; Rogers et al.,2003; Tong et al.,2004; Yu et 
al.,2004; Zhang et al.,2004a; Zhao et al.,2004). These results show the potential of 
SELDI technology to discover significant patterns that may permit discrimination of 
cancer from normal samples.   
Table 2-1 Putative cancer biomarkers identified using SELDI technology 
Biomarker Cancer type Source 
Apolipoprotein A1 Ovarian, pancreatic (Alaoui-Jamali & Xu,2006; Kozak et 
al.,2005; Kozak et al.,2003; Zhang et 
al.,2004b) 
a1-antitrypsin and a1-
antichymotrypsin 
Pancreatic (Alaoui-Jamali & Xu,2006; Orchekowski et 
al.,2005; Yu et al.,2005) 
Cytosolic ubiquitin Breast cancer (Cho,2007) 
Ferritin light chain Breast cancer (Cho,2007) 
Heptaglobin a-subunit Ovarian, pancreatic, lung (Alaoui-Jamali & Xu,2006; Ye et al.,2003) 
Inter-alpha-trypsin 
inhibitor fragment 
Ovarian, pancreatic (Alaoui-Jamali & Xu,2006; Zhang et 
al.,2004b) 
Osteopontin Ovarian, prostate (Alaoui-Jamali & Xu,2006; Khodavirdi et 
al.,2006) 
Serum amyloid A Nasopharyngeal, 
pancreatic, ovarian 
(Alaoui-Jamali & Xu,2006; Moshkovskii et 
al.,2005; Orchekowski et al.,2005) 
Transthyretin fragment Ovarian (Alaoui-Jamali & Xu,2006; Kozak et 
al.,2005) 
Vitamin D-binding protein Prostate, breast (Alaoui-Jamali & Xu,2006; Corder et 
al.,1993; Pawlik et al.,2006) 
 
Although SELDI technology has potential use in biomarker discovery and early 
detection of cancer, it also has many limitations. It is not clear whether the identified 
discriminant features were due to the inherent biological differences associated with 
cancer or to artefacts associated with the SELDI technology. The study by 
Diamandis (2004b) raised some open questions related to cancer diagnosis using 
SELDI technology, which include (a) whether the SELDI technologies are 
reproducible (Diamandis,2004a; Diamandis,2003b; Semmes et al.,2005), and (b) 
why the validated serum cancer markers (e.g. PSA, CA125, etc.) that could serve as 
positive controls have not been identified by SELDI technology. Several studies 
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(Adam et al.,2002; Banez et al.,2003; Diamandis,2003b; Gao et al.,2003; Petricoin et 
al.,2002b) concerned whether the use of SELDI can improve the early detection of 
cancer. The studies by Grizzle et al. (2003) and Semmes et al. (2005) suggested that 
these concerns should be addressed in an appropriately designed validation study. 
 
The paper by Poon (2007) summarised the major limitations of SELDI in biomarker 
discovery, which include (a) conventional tumour markers (e.g. α-fetoprotein) have 
not been identified by SELDI, (b) The protein identities of the SELDI peaks cannot 
be obtained directly in the SELDI experiments, (c) The limited detection dynamic 
range causes difficulty in the identification of potential diagnostic proteins present at 
concentration below the μg/ml level in serum/plasma,  (d) High susceptibility to the 
identification of false-significant biomarkers that are caused by systematic bias, (e) 
Quantitative proteomic profile is sensitive to small changes of experimental 
procedures and analytic variables, (f) Poor resolution for analysis of large proteins, 
particularly when resolving proteins with slight differences in post-translational 
modification (>20k Da), and (g) Lack of consensus assay protocols or standard 
operating procedures for SELDI experiments, leading to great variations in 
quantitative patterns and in the quality of the proteomic profiles across laboratories, 
and causing difficulty in cross-laboratory validation.  These questions emphasise the 
need to evaluate the existing quantitative biomarkers discovery tools with the aim of 
deriving the optimal approach to biomarkers detection. 
 
2.4 Methods for SELDI data analysis 
In SELDI, after washing and adding matrix chemicals, the retained proteins will be 
charged and recorded as mass spectra with intensities at different m/z values. Cancer 
biomarkers are proteins or peptides that are differentially expressed across disease 
conditions, which can be identified by comparing the intensity values between the 
cancer and the control groups. However, comparisons of large-scale multivariate 
proteomic patterns are subject to many challenging analytic issues, including 
experimental noise, systematic variations between experimental runs, and the huge 
number of measured features of which many are uncorrelated to cancer (Listgarten & 
Emili,2005). This section will review important mass spectrum acquisition and 
analytic methods that should be considered in comparative proteomic analysis, and 
outlines the procedures for proteomic biomarker discovery using SELDI as shown in 
Figure 2-3.  
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Figure 2-3 One approach for biomarker discovery using SELDI 
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2.4.1 SELDI experiment design  
In SELDI experiments, the serum samples are added to a ProteinChip and resolved 
into subset of proteins with common properties. After washing, only a subset of the 
proteins and peptides present in the original sample is left on the chip to be 
examined. The subset of protein present in the final analysis depends on many 
factors, including the method used to extract proteins, the chip type used, the 
incubation and wash conditions, the type of matrix used and method of application, 
and the laser intensity settings.  
 
Conducting preliminary experiments may be required to identify the best 
combination of the experimental conditions. The study by Cordingley et al. (2003) 
employed factorial experimental design to investigate factors which could affect 
mass spectrum quality and reproducibility during experiment process.  The following 
factors were identified: (a) Urea/thiourea ratio in extraction buffer, (b) protease 
inhibitor, (c) time between crushing and homogenisation, (d) concentration and 
volume of samples, (e) length of washes, (f) number of washes, (g) time between last 
wash and addition of matrix, (h) age of matrix, (i) pipet type used for matrix 
deposition, and (j) number and volume of matrix depositions. The criteria defined to 
judge the performance of the mass spectra included the number of peaks detected, 
peak cleanness (i.e., sharp peaks that were well separated from each other, with 
smooth lines, with no secondary underlying peaks), and more reproducible traces 
(Cordingley et al.,2003). 
 
By conducting experiments with different levels of these factors, many SELDI 
spectra were generated. These spectra were then analysed using a statistical 
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algorithm to find the main effect factors. It was found that six factors, urea/thiourea 
ratio, protease inhibitor, time between crushing and homogenisation, length of 
washes, number of washes, and volume of matrix depositions had a significant 
impact on one or more of the response variables defined above, and that only two 
factors, urea/thiourea ratio, and volume of matrix depositions, had significant main 
effects on the number of peaks (Cordingley et al.,2003; Fung & Enderwick,2002).  
 
In order to find structural features of cancer using SELDI, un-biasing the whole 
process is also extremely important because a small change in the way that the serum 
is collected between cancer patients and healthy subjects may contribute to artefacts 
(Petricoin, III & Liotta,2003). Other issues, such as sample handing (e.g. collection, 
and storage), laboratory environment (e.g. temperature, and humidity), ProteinReader 
calibration, and inadequate data pre-processing, might be the key factors to cause the 
systematic bias. It is vital to ensure that the same conditions are used in intra-assays5 
and inter-assays6, as well as inter-laboratories. 
2.4.2 Reproducibility analysis 
Concern has recently been expressed as to whether SELDI based methods are 
reproducible. This is important as the identification of true biomarkers for cancer and 
the accurate classification of cancer patients from normal individuals largely depend 
on precision and consistency of measurements. Reproducibility refers to the ability 
of a SELDI experiment to be accurately reproduced. It measures the closeness of 
agreement between independent results obtained with the same method on identical 
 
5 Intra-assays refer to assays within a single assay run 
6 Inter-assays refer to assays over a number of different assay runs in one laboratory 
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test material but under different conditions, such as different operators, different 
apparatus, different laboratories, and after different intervals of time (IUPAC,2007). 
 
The studies by Baggerly et al. (2004), Karsan et al. (2005) and Poon (2007) found 
that without a standardised experimental protocol, it is very difficult to compare the 
SELDI protein profiles generated from different laboratories, even though the same 
types of ProteinChip arrays, incubation buffer and washing solution are used. The 
study by Baggerly et al. (2004) assessed the reproducibility of SELDI protein profile 
by re-analysing three data sets of SELDI mass spectra derived from the serum of 
patients with ovarian cancer. The results of the analysis showed poor reproducibility. 
It was found that the separating feature sets were not reproducible across 
experiments. The features identified to discriminate well in one experiment did not 
generalise to other experiments. These results suggests that many of the structural 
features identified in the initial analyses could be due to artefacts of sampling 
process, rather than the underlying biological mechanisms of ovarian cancer 
(Baggerly et al.,2004).  
 
Another example of lack of reproducibility of results from this technology was 
demonstrated in a re-analysis of three prostate cancer studies (Diamandis,2003a). 
The study by Diamandis (2003a) assessed the reproducibility of SELDI protein 
profiles by comparing three prostate cancer studies by Adam et al. (2002), Petricoin 
et al. (2002b), and Qu et al. (2002). The results showed that none of the peaks 
selected in the study by Petricoin et al. (2002b) was identified in the studies by either 
Adam et al. (2002) or Qu et al. (2002). Although the studies by Adam and Qu used 
the same chip for serum extraction and the same instrument to generate mass spectra, 
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their distinguishing peaks were very different. This implies that the identified 
structural features may not be prostate cancer-related (Diamandis,2003b).  
 
The reason for poor reproducibility of SELDI expression profiles is probably that the 
different centres did not adopt any standardised protocol and analysis procedure. The 
lack of agreement might be due to differential handing, processing of samples, 
changes in the type of ProteinChip array, mechanical adjustments to the mass 
spectrometer, or a shift to a different instrument or lab, etc. This indicates a need for 
careful experimental design, for varying experimental conditions, and for better 
methods of external calibration (Baggerly et al.,2004). 
 
The study by Semmes et al. (2005) assessed interlaboratory reproducibility of SELDI 
protein profile by comparing the means, standard deviations, and coefficient of 
variations7 of intensity, mass, signal and noise ratio, and resolution of 14 prostate 
cancer mass spectra and 14 non prostate cancer mass spectra generated from six 
different centres. The results showed that between laboratory reproducibility of 
SELDI serum profiling approached that of within-laboratory reproducibility when a 
standardised experimental protocol and quality control strategy were used 
(Poon,2007; Semmes et al.,2005).  All these results suggest that standardised 
experimental protocols and analysis procedures are needed for biomarker discovery 
using SELDI technology.  
 
Compared with the studies by Diamandis (2003a) and Baggerly et al. (2004), the 
study by Semmes et al. (2005) used a small number of identical serum samples 
across six different centres and the reproducibility analyses were based on only three 
 
7 Coefficient of variation is a normalised measure of dispersion of a probability distribution and 
defined as the ratio of the standard deviation to the mean. 
intensity peaks. Although between-laboratory reproducibility of SELDI serum 
profiling was similar to that of within-laboratory reproducibility, further research on 
reproducibility of SELDI is needed. In the studies of both Diamandis (2003a) and 
Baggerly et al. (2004) reproducibility was measured by agreement in separating 
feature sets. It is not a quantitative measure, making it difficult to identify 
experimental conditions that may affect reproducibility of SELDI expression 
profiles. In order to assess the reproducibility of SELDI expression profiles and to 
facilitate identifying factors that affect the reproducibility of SELDI, it is necessary 
to develop quantitative reproducibility measures. This thesis revisits the issue of 
reproducibility and proposes three other methods for quantitatively assessing the 
reproducibility of SELDI protein profiles using Euclidean distance, correlation 
coefficient, and the paired t-test. The reproducibility of SELDI protein profiles will 
be studied in Chapter 3.  
2.4.3 Mass spectrum pre-processing 
The data generated from SELDI need pre-processing before further analysis. Due to 
matrix and interference of measurement procedure, chemical and/or electronic noise 
may be generated, and these may result in imprecise measurements of both m/z 
values and intensity values. For each SELDI mass spectrum i , we observe protein 
intensities  at , . These protein intensities can be modelled by  Tj ,...,2,1=)( ji tI jt
ijji
i
jiji tSN
tBtI ε++= )(1)()(     (2.2) 
 
where,  is the baseline, representing a systematic artefact in the mass spectrum 
, 
)( ji tB
i  is thought to originate from chemical and/or electronic noise in the SELDI ijε
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detector,  is a normalisation factor, and  is the true signal and consists of a 
set of peaks, corresponding to proteins or peptides (Moriss et al.,2005). 
)( ji tS
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The measurements of m/z values are imprecise by approximately 0.1-0.2% of the 
m/z value and the coefficient of variation of intensity measures is approximately 15-
20% according to the manufacturer’s specification of Ciphergen PBS IIc (Ciphergen 
Biosystems, UK). The variation of these values from spectrum to spectrum, and from 
experiment to experiment is well known. It is not infrequent that the coefficient of 
variation for intensity measures can be as high as 50–60% (Hong et al.,2005). 
Therefore, it is necessary to perform data pre-processing to remove noise and 
improve the quality of SELDI data before further analysis can be carried out. In fact, 
pre-processing is also a crucial factor in determining reproducibility of protein 
profiles from SELDI instruments. Data pre-processing includes baseline correction, 
intensity normalisation and transformation, peak alignment and peak picking.  
 
Ciphergen ProteinChip Software 3.2 (Ciphergen Biosystems, UK), and PROcess 
library of BioConductor Project8 (Bioconductor,2007b) are commonly used mass 
spectrum pre-processing packages. The study by Beyer et al. (2006) compared the 
performance of Ciphergen ProteinChip Software and PROcess for pre-processing 
SELDI mass spectra for rat liver proteome. Comparison of results showed that 
baseline correction and normalisation algorithms implemented in Ciphergen 
ProteinChip Software and PROcess had the same underlying concept and gave fairly 
similar results, but that the results differed after following the peak detection and 
 
8 An open source and open development software project for the analysis and comprehension of 
genomic data 
alignment procedures. The concepts and methods for pre-processing SELDI data are 
discussed as follows. 
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Figure 2-4 A raw spectrum (Gentleman et al.,2005). 
2.4.3.1 Baseline correction 
Baseline correction aims at removing or reducing the baseline artefact characteristics 
 due to matrix and interfering biochemical or physical processes of the 
measurement procedure in the experiment. The study by Malyarenko et al. (2005) 
introduced the idea that the source of the baseline is in the ion detector that gets 
saturated by the matrix molecules at low m/z values. This saturation usually decays 
slowly over time. Thus baseline is a vertical offset as shown in 
)( ji tB
Figure 2-4, which 
significantly elevates the intensity of the peaks for lower m/z values between about 
2,000 and 10,000 Da. At higher m/z, the baseline levels off to a plateau (Gentleman 
et al.,2005). 
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The baseline can be corrected by subtracting from a spectrum an estimate of 
chemical and/or electronic noise. The algorithm implemented in the Ciphergen 
ProteinChip Software fits a piece-wise convex-hull9 that attempts to find the 
chemical and/or electronic noise and to correct the peak height (Beyer et al.,2006). 
The PROcess algorithm estimates the chemical and/or electronic noise using locally 
weighted regression by fitting a curve to the spectrum local minima. The traditional 
weight function used for local regression is the tri-cube weight function defined as 
follows. 
 
33 )1()( xxW −= , otherwise 0    (2.3) 1<x if 
 
xwhere, is the scaled distance between each point to the point of estimation, which 
is calculated by scaling the distance by the maximum distance over all points in the 
local minima set.  
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At each point a polynomial is fitted to a subset of the data using weighted least 
squares, giving more weight to points near the point whose response is being 
estimated and less weight to points further away. The value of the regression 
function for the point is then obtained by evaluating the local polynomial using the 
explanatory variable values for that data point. The spectra are then corrected by 
subtracting the baseline from the raw spectra (Beyer et al.,2006; 
Bioconductor,2007b; Gentleman et al.,2005). The implementation of the PROcess 
baseline correction is summarised as follows (Gentleman et al.,2005).  
 
                                                 
9 The convex hull for a set of points X is the minimal convex set containing X 
1. Segment the m/z range for each spectrum and find local minima for each 
interval. 
2. Fit a local regression to the local minima for each spectrum. 
3. Subtract the estimated baseline from each spectrum. 
 
Figure 2-5 shows the result of a spectrum with baseline removed, where the middle 
curve is the baseline fitted by the weighted least squares. It can be seen that the 
process of baseline correction may introduce negative net intensity values. 
Empirically, using local minima in the regression tends to yield fewer negative 
values (Gentleman et al.,2005). 
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               Figure 2-5 Baseline correction using PROcess (Gentleman et al.,2005). 
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2.4.3.2 Normalisation 
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Intensity normalisation aims at correcting for systematic differences in the total 
amount of protein desorbed from the sample plate. Due to variation in sample 
preparation and heterogeneity of samples on the spots of a chip, the detected 
intensities are only relative rather than absolute measurements of the proteins in the 
samples (Callister,2006). Therefore, prior to differential expression analysis, 
intensities need to be normalised. Normalisation techniques rescale the sample 
intensities by a normalisation factor  and enable the comparison of intensities 
across different spectra by eliminating the difference in the total amount of protein 
desorbed (Bolstad et al.,2003).  
i
 
10The commonly used normalisation methods are the global normalisations . The 
assumption behind the global normalisation is that, on average, the number of 
proteins that are over expressed is approximately equal to the number of proteins 
under expressed and the number of proteins whose expression levels change is few 
relative to the total number of proteins (Sauve & Speed,2003).  Such global 
normalisations assume that the sample intensities are all related by a constant 
coefficient. A common choice for this normalisation coefficient is the spectrum 
median or the mean.  For mass spectrometric data, each protein concentration is 
measured by the area under curve (AUC) of its peak. 
 
The software package PROcess in BioConductor (Bioconductor,2007a) uses the  
median AUC to normalise a set of mass spectra. It consists of the following phases. 
Firstly, for each spectrum, its AUC for a selected m/z range is calculated. The value 
 
10 Global normalisation applies a constant scaling factor to every measurement in a specified m/z 
range. 
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of AUC is proportional to the sum of the intensities in the selected m/z range if 
intensities at m/z values are taken at equally spaced time points (Gentleman et 
al.,2005). Secondly, the median AUC of a set of mass spectra to be normalised is 
obtained. Thirdly, each spectrum is scaled to the median AUC (Beyer et al.,2006; 
Bioconductor,2007b; Gentleman et al.,2005).  
 
Ciphergen ProteinChip Software uses the mean AUC (or called TIC) to normalise a 
set of spectra. It consists of the following phases. Firstly, for each spectrum, the 
average intensity in a specified m/z range, which equals to TIC divided by the 
number of data points in the m/z range, is calculated. Secondly, the overall average 
intensity (mean AUC) across all the spectra to be normalised is calculated. Thirdly, 
each spectrum is normalised by scaling the intensities by the mean AUC (Beyer et 
al.,2006).  
 
Figure 2-6 shows three spectra before normalisation with mocked-up trace data from 
Ciphergen ProteinChip Software 3.2 (Ciphergen Biosystems, UK). Figure 2-7 shows 
the spectra after normalisation. It can be seen that the systematic differences in the 
total amount of protein desorbed can be eliminated by the process of normalisation.  
 
We propose a new normalisation algorithm and will compare it with the existing 
normalisation methods in Chapter 5. 
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Figure 2-6 Three spectra before normalisation 
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Figure 2-7 Three spectra after normalisation 
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2.4.3.3 Peak detection 
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A peak is a local maximum within a spectrum. Peak detection and quantification aim 
at identifying feature locations of the peaks in the true signal  across all 
spectra. Peak detection algorithms eliminate the intensities that are below a specified 
signal-to-noise (S/N) threshold guided for example by the magnitude of the signal to 
noise ratio
ji
11. Peak intensity (signal strength) is computed by determining the local 
maximum on a specified interval where the peak is detected (Beyer et al.,2006; 
Bioconductor,2007b). Figure 2-8 shows the detected peaks for the spectrum shown in 
Figure 2-5 using the PROcess package. Figure 2-9 shows the detected peaks in the 
zoomed region between 5,000 and 10,000 Da. The “local sigma” in Figure 2-8 and 
Figure 2-9 is a local estimate of the variation (Bioconductor,2007b). 
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                           Figure 2-8 The detected peaks (Gentleman et al.,2005). 
 
 
                                                 
11 The ratio of relevant or useful information (signal) to irrelevant information (noise) 
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         Figure 2-9 The detected peaks in a zoomed region (Gentleman et al.,2005). 
 
2.4.3.4 Peak alignment 
Because of the variations in the experimental conditions, such as machine drifts and 
temperature changes, undesirable variation may occur in SELDI mass spectra. This 
often results in differences in positions and shapes of peaks between spectra 
generated in single or multiple experiments. It has been known that the window of 
potential shift for a mass/charge point is approximately 0.1-0.2% of the mass/charge 
value of that point when using the model PBSII reader in external calibration. Figure 
2-10 shows an example of peak shift. The unaligned peak is shifted to the left side of 
the reference peak. These technical variations might affect peak detection 
performance and can obscure biological differences between disease classes, which 
may affect the accuracy of biomarker discovery for cancer diagnosis.   
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Figure 2-10 A reference peak and a sample peak before and after a right shift 
intended for aligning the sample peak. 
 
Peak alignment aims at reducing the imprecise measurements of m/z points due to 
SELDI output shift within an experiment and between experiments and deciding 
which peaks in different samples correspond to the same protein. This can be 
achieved by aligning a mass spectrum to a reference spectrum by deleting or 
inserting data points in the shift regions. However, the two commonly used pre-
processing packages, the Ciphergen ProteinChip Software and the PROcess, lack 
inbuilt functionalities for peak alignment.  
 
Several peak alignment methods (Jeffries,2005; Wong et al.,2005b; Wong et 
al.,2005a) have been proposed for SELDI mass spectra data. These methods can be 
divided into two categories, namely peak-based alignment and segment-wise 
alignment (SWA). The former includes peak alignment by cubic splines (PACS)  
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(Jeffries,2005) and peak alignment by peak matching (PAPM) (Wong et al.,2005a). 
The latter was originally proposed by Forshed et al. (2003) for aligning nuclear 
magnetic resonance (NMR) spectra. In this scheme, the spectra are first divided into 
segments, whose features are then aligned in a piece-wise manner. Each segment is 
shifted sideway and stretched or shrunk by linear interpolation (warped) to fit a 
corresponding piece in the reference spectrum. The correspondence between 
segments is evaluated by the magnitudes of the correlation coefficient and the 
comparison with the largest correlation is declared a match.  Many algorithms have 
been used to find optimal shift values for various MS data sets, which include peak 
alignment by beam search (PABS) (Forshed et al.,2003; Lee & Woodruff,2004) for 
NMR signal and peak alignment by fast Fourier transform (PAFFT) (Wong et 
al.,2005b) for chromatographic and spectral data sets.  
 
The above existing peak alignment methods (Jeffries,2005; Lee & Woodruff,2004; 
Wong et al.,2005b; Wong et al.,2005a) assumed a constant horizontal shift during the 
process of peak alignment, which did not take the instrument resolution into account. 
For SELDI mass spectra, the accuracy in m/z positions is normally within 0.1-0.2% 
of the true m/z value, suggesting that the bigger the m/z value is, and the larger the 
horizontal shift would be. 
 
In order to address this problem, we propose two new peak alignment methods and 
will compare their performance with that of the existing peak alignment methods in 
Chapter 4. The effect of peak alignment on cancer classification will also be assessed 
in Chapter 4. 
2.4.4 Identification of putative biomarkers and cancer classification 
2.4.4.1 Statistical methods for cancer classification 
A number of methods have been proposed for cancer classification. These include 
logistic regression (Bhanot et al.,2006; Morra et al.,2007; Wada-Isoe et al.,2007), 
linear discriminant analysis, quadratic discriminant analysis (Datta & Lara,2006; 
Wagner et al.,2004; Wu et al.,2003), artificial neural network (ANN) (Ball et 
al.,2002; Bensmail & Haoudi,2003; Datta & Lara,2006; Poon et al.,2003; Rogers et 
al.,2003; Yu et al.,2004), random forest (RF) (Wu et al.,2003; Yu et al.,2004), 
support vector machine (SVM) (Yu et al.,2004; Zhang et al.,2006), and k-nearest 
neighbour (kNN) (Marchiori et al.,2005; Wu et al.,2003). Some commonly used 
methods for cancer classification are briefly described as follows. 
2.4.4.1.1 Logistic regression 
Logistic regression is a special form of generalised linear model and is usually used 
when the dependent variable is binary (Bhanot et al.,2006).  It suits well if we want 
to classify cancer from normal subjects using SELDI protein profiles. In logistic 
regression, the dependent variable is a logit12; the regression equation is defined by  
i
i
i Ip
ppLogit ∑
=
+=−= 1)1ln()( βα
n
  (2.4) 
 
where, p  is the probability of cancer.  Logistic regression applies maximum 
likelihood methods to a training data set to estimate the model parameters α  and 
ni ,...,1, = p  from the regression equation 2, .  For a new test sample, we calculate iβ
                                                 
12 A logit is the natural log of the odds, that is logit(p)=ln(p/(1-p))=ln(odds) 
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pand determine the disease status by the proximity of this value to the two values 
for cancer and non-cancer.  
2.4.4.1.2 Linear and Quadratic discriminant analysis 
Linear and quadratic discriminant analyses are based on a Bayesian classification 
rule (Datta & Lara,2006; Wu et al.,2003). Suppose that kπ  denotes the prior 
probability of the class , , representing normal subjects and cancer patients, 
respectively, and that  denotes the density of distribution of the observation 
1,0=k
)| k
k
(Ip
I  (SELDI protein profiles) for class . We can then estimate the posterior 
distribution of class  given the observation of 
k
Ik  by  
)|(
)(
)|(
)|( kIp
Ip
kIpIkp kk ππ ∝=   (2.5) 
 
The allocation rule is determined by choosing the class with maximal  (Wu 
et al.,2003). That is to say, classifying sample with SELDI protein profile 
(kp )| I
I  into 
class  such that the following holds.  k
 (2.6) ))(max(arg))|(ln()max(ln(arg)|(maxarg)( IkIpIkpIy kk λπ =+==
 
Suppose that  follows multivariate normal distribution with mean )|( kIp kμ  and 
covariance Σ , then we can derive the discriminant function )(Ikλ  as follows. k
)()(
2
1)ln(
2
1)ln()( 1 kk
T
kkkk III μμπλ −Σ−−Σ−= −   (2.7) 
 
IIt is a quadratic equation in , therefore called quadratic discriminant analysis. The 
decision boundary between cancer and normal classes can then be determined by  
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When we assume the two classes have common covariance matrix, that is, 
, then quadratic discriminant analysis becomes linear discriminant 
analysis. The linear discriminant function 
Σ=Σ=Σ 10
)(Ikλ  is determined as follows. 
k
T
k
T
kkk II μμμπλ 112
1)ln()( −− Σ+Σ−=   (2.9) 
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                         Figure 2-11 Diagram of a neural network 
 
2.4.4.1.3 Artificial neural network 
An artificial neural network is a classification or regression model and is represented 
by a network diagram, based on the concept of neurons in the human brain. It usually 
consists of at least one hidden layer of neurons (Bensmail & Haoudi,2003; Datta & 
Lara,2006) as shown in Figure 2-11. It has full interconnections from the input 
neurons to the hidden neurons and full interconnections from the hidden neurons to 
the output neurons. An artificial neural network model is trained using K )1( +n  
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The output variable is cancer status and can be expressed as follows. 
 
        (2.10) 
 
where,  is the output weight from a hidden neuron  j  to an output neuron and g  
is an output function. The value of a hidden layer neuron  is given by  jh
     (2.11) H
 
 
where,  is the input weight from an input neuron i  to a hidden neuron j ,  is 
the threshold weight from an input neuron that has a constant value of 1 to a hidden 
neuron 
w j
j ,  are the intensity values at the input neurons, and  H is the number of 
hidden neurons. 
iI
σ  is a sigmoid function and is defined by 
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The weights between neurons are obtained by minimising an error function defined 
by  
∑
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For a new test sample, we calculate the output  of a trained NN model. If  is 
close to 1, then we classify it as cancer, otherwise normal subject. 
newy newy
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2.4.4.2 Statistical methods for biomarker discovery 
Identification of putative biomarkers from SELDI data is not a trivial task. Because a 
large array of data is generated from a single experiment, it is essential to utilise 
algorithms to identify proteomic patterns from large amount of data corresponding to 
a given phenotype from multiple samples (Bensmail & Haoudi,2003). Identification 
of proteomic fingerprints that underlie phenotypes means sifting through hundreds of 
SELDI protein profiles to identify a relevant subset of markers that could be further 
examined.  
 
Many statistical methods have been employed to extract informative protein features 
using SELDI data sets. These methods can be divided into two categories: namely 
univariate feature selection method and multivariate feature selection method. The 
univariate feature selection method, also known as filter-based method, include the t-
test (Bhanot et al.,2006; Datta & Lara,2006; De Torre et al.,2006), signal-to-noise 
(S/N) ratio (Bhanot et al.,2006), receiver operating characteristic (ROC) curve 
(Adam et al.,2002; Ball et al.,2002; Chen et al.,2002; Qu et al.,2002; Yu et al.,2004), 
Kolmogorov-Smirnov test (Levner,2005), and ANOVA F-statistic (Datta & 
Lara,2006; Pavlidis,2003; Wagner et al.,2004). The multivariate feature selection 
method, also known as wrapper-based method, include decision tree (Adam et 
al.,2002), genetic algorithms (Petricoin & Liotta,2004), self-organising-maps 
(Petricoin et al.,2002a), artificial neural networks (Ball et al.,2002), random forest 
(Izmirlian,2004) and support vector machine (Zhang et al.,2006). The univariate 
feature selection methods evaluate the discriminatory power of each feature 
individually, while multivariate feature selection methods evaluate the discriminatory 
power of each feature using a number of possible subset of features which may lead 
to a near optimal classifier. Some commonly used parametric test methods are briefly 
described as follows. 
2.4.4.2.1 T-test 
The t-test (also called Student’s t-test) was introduced by William Sealy Gosset for 
monitoring the quality of beer brews. “Student” was his pen name. The t-test 
assumes that data in each group follows a normal distribution (Rice,1995). It is 
worthwhile to note the effect of sample size on the importance of the assumption. 
The central limit theorem states that the sum of a sufficiently large number of 
independent random variables, each with finite mean and variance, will be 
approximately 
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normally distributed. Let  be a sequence of n  
independent and identically distributed random variables each having finite values of 
mean 
nXXX ,...,, 21
μ  and variance .  According to the central limit theorem, as the sample size 
 increases, the distribution of the sample average of these random variables 
approaches the normal distribution with a mean 
2σ
n
μ  and variance n
2σ  irrespective of 
the shape of the original distribution. That is to say, if sample size is large, then we 
should be more comfortable with using parametric statistics, such as t-test, as the 
central limit theorem guarantees the validity of the test even if the populations are 
non-normal.  However, for small and moderate sample sizes, the validity of the test 
demands that the samples be drawn from normally distributed populations 
(Rice,1995). 
 
We use t statistic to determine if the mean μp and μq of the intensity level of an m/z 
value across the samples in the two different groups (e.g. cancer and normal samples) 
are significantly different and it is defined as follows. 
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where, σp and σq are standard deviation of the intensity levels, np and nq are the 
number of samples in each group. The null hypothesis of t-test is that μp = μq, 
indicating that the mean of the feature values in one group is the same as that of the 
feature values in the other group (Bhanot et al.,2006). A large value of the t statistic 
at an m/z value corresponds to a small p-value. If the p-value is less than a cut-off 
(say 0.05), then the protein profile corresponding to this m/z value is a significant 
feature.  
2.4.4.2.2 ANOVA 
When there exist more than two different groups (e.g. cancer, benign and normal 
samples), ANOVA can be used to identify features from SELDI protein profiles. 
Suppose that  is the observed intensity value of the jth feature of the kth sample in 
the ith group, that g is the number of groups, and  is the number of samples in the 
ith group. The means of  jth feature in ith group is defined as follows.  
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The mean of  jth feature across g groups is defined as follows.  
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The between group sum of squares for jth feature is defined as follows.  
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The within group sum of squares is defined as follows. 
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The ANOVA F-statistic is defined as follows.  
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A large value of the  statistic at an m/z value corresponds to a small p-value 
(Wagner et al.,2004). If the p-value is less than a cut-off (say 0.05), then the protein 
profile corresponding to this m/z value is a significant feature. 
jF
 
It is apparent that these feature selection approaches evaluate the discriminatory 
power of each protein one by one independently.  That is, the statistical tests are 
applied to protein intensities at each protein m/z value to detect changes in 
expression profiles between different groups of samples. The proteins are then 
ranked according to the significance scores of SELDI protein profiles, such as p-
value, t statistic or F statistic, from the most to the least informative. This ranking 
defines a series of protein sets as well as the order in which they are subsequently 
evaluated. More specifically, the first protein set to be evaluated is the best ranked 
protein; the second protein set the best two ranked proteins, and so on.  
 
These feature selection approaches seem to provide a logical step in identifying 
proteomic biomarkers. However, there are three issues we need to consider: (a) how 
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to deal with the problem of multiple hypothesis testing? (b) Are these statistical test 
methods valid for biomarker discovery using SELDI mass spectra? (c) Which 
method should be used to identify proteomic biomarkers? 
2.4.4.3 Adjustment for multiple hypothesis testing 
Because the statistical tests consider a single peak at a time, multiple hypotheses 
testing will lead to many false positives if the commonly used significance level is 
used. Several solutions have been proposed to filter false positives, which include 
family-wise error rate (FWER) (Bender & Lange,2001; Benjamini & 
Hochberg,1995b), Benjamini and Hochberg false discovery rate (FDR) (Bender & 
Lange,2001; Benjamini & Hochberg,1995a) and Bayesian approaches (Bender & 
Lange,2001).  
 
FWER approach includes Bonferroni, Holm, and Westfall and Young permutation 
methods.  Bonferroni method corrects the p-value of each variable by multiplying the 
number of variables in the test list. If the corrected p-value is still below a FWER, 
then the variable is considered to be statistically significant. Bonferroni method is 
simple. However, the price for this simplicity is low power. It was suggested that 
Bonferroni method should only be used in cases where the number of tests is quite 
small and the correlations among the test statistics are quite low (Bender & 
Lange,2001; Perneger,1998). Holm method ranks the p-values of individual variables 
from the smallest to the largest. The corrected p-value for the variable in the first 
rank is obtained by multiplying by the number of variables to its original p-value, the 
corrected p-value for the variable in the second rank multiplying the number of 
variables minus 1. If the corrected p-value is below the FWER, then the variable is 
considered to be statistically significant. The process is repeated until no variable is 
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found to be significant. Unlike Bonferroni and Holm methods, Westfall and Young 
method permutes all the variables at the same time and creates a pseudo data set by 
dividing the data into artificial cancer and control groups. The p-values of variables 
are calculated on the pseudo-data set. The successive minima of the corrected p-
values are retained and compared to the original p-values. The process is repeated a 
large number of times. The adjusted p-value is the proportion of resampled pseudo 
data sets where the minimum corrected p-value is less than the original p-value. If 
the adjusted p-value is below the FWER, the corresponding variable is considered to 
be statistically different.  
 
The Benjamini and Hochberg FDR method ranks the p-values of variables from the 
smallest to the largest. The p-value of a variable is corrected by multiplying the total 
number of variables to its original variable and divided by its rank.  If the corrected 
p-value is below an error rate, the corresponding variable is considered to be 
statistically different. In general, both FWER and FDR decrease the power to detect a 
single variable compared to unadjusted methods (Hunter et al.,2007).  
 
Bayesian method differs from the above methods in estimating the marginal posterior 
probability that the alternative hypothesis is true, rather than controlling type I error 
rates. However, the values of these posterior probabilities depend on prior densities 
(Fayers et al.,1997), which are subjective and not well documented.  
2.4.4.4 Are the parametric statistical test methods valid for biomarker 
discovery using SELDI mass spectra?      
A typical SELDI spectrum may consist of up to 15,000 features.  The high 
dimensional nature of this data has resulted in the popularity of parametric statistical 
test (e.g. t-test and ANOVA) as a method for identifying differentially expressed 
features in many high-throughput data sets, including SELDI and microarray data 
(Ball et al.,2002; Chen et al.,2002; Kerr et al.,2000; Shapiro et al.,1965; Smyth,2004; 
Wu et al.,2003).  However, these tests assume that the data follow a normal or 
Gaussian distribution.  
 
The assumption of normality has been adequately addressed for microarray data sets 
(Chen et al.,2005; Giles & Kipling,2003). However, as far as we know, it has not 
been studied in the case of SELDI data sets although some parametric methods, such 
as t-tests (Levner,2005; Pasinetti,2006; Wu et al.,2003), have been used to identify 
significant peaks from SELDI mass spectra. Therefore, it is necessary to assess the 
normality of SELDI protein profiles, in order to ascertain that the proteins detected to 
be differentially expressed more likely to be true positives.  
 
We investigate the normality of SELDI protein profiles using skewness, kurtosis, 
Shapiro-Wilks test, Kolmogorov-Smirnov test, Cramér-von-Mises test, and Pearson 
 test, including implement of the goodness-of-fit testing. We also assess the effect 
of normalisation and mathematical transformation on the normality of SELDI protein 
profiles in Chapter 
2χ
5.  
2.4.4.5 Which method should be used to identify biomarkers from SELDI-TOF 
mass spectra? 
Published studies have compared the performance of different feature selection and 
classification methods based on the accuracy of the classifiers which were built using 
different feature selection and classification algorithms (Levner,2005; Wu et 
al.,2003). The study by Wu et al. (2003) utilised different feature selection methods 
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(such as t-test) and classification algorithms (including linear discriminant analysis 
and quadratic discriminant analysis) to analyse a MALDI ovarian cancer data set. It 
showed that different feature selection methods identified different sets of features, 
and that different algorithms gave different classification accuracies. The study by 
Levner (2005) examined the performance of classifiers trained using SELDI protein 
profiles identified by different feature selection methods (including t-test) based on 
five SELDI cancer data sets. Again it found that the classifiers trained with different 
feature sets gave different classification accuracies.  
 
In general, it is more likely that different approaches will result in identification of 
different sets of proteins, and that different classification methods have different split 
performance. However, none of the previous studies addressed which approach 
should be used for identifying protein biomarkers from SELDI expression profiles. 
We therefore propose a general algorithm for biomarker discovery from SELDI 
protein profiles using a combination of feature selection methods and classification 
methods, and implement the algorithm using two published SELDI data sets in 
Chapter 6.  
 
2.5 Discussion 
SELDI technology appears to be a useful tool in biomarker discovery and early 
detection of cancer although its value has been limited at present by its inability to 
detect serum/plasma proteins at lower abundance (Poon,2007).  But, SELDI is a new 
technology for proteomic studies. There is an urgent need to investigate how to make 
best use of the technology for biomarker discovery and cancer diagnosis with the 
current development of SELDI techniques.  
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Firstly, a standardised experimental protocol and operating procedure need to be 
established. The study by Poon (2007) demonstrated that the irreproducibility 
problem in MALDI analysis can be addressed when an unbiased acquisition strategy 
(Pang et al.,2004) was utilised. The intra-assay coefficient of variation of normalised 
protein peak intensity varied from 10% to 30%.  The same author, Poon (2007) also 
reported that in SELDI data analysis, the unbiased acquisition strategy and use of 
hydrogel as a support for chromatographic materials could make the normalised 
intensity values of the protein or peptide peaks comparable (Coombes et al.,2003; Li 
et al.,2002; Pang et al.,2006; Poon et al.,2003; Poon et al.,2004; Poon et al.,2005). 
The intra-assay and inter-assay coefficients of variations for the normalised intensity 
of majority of the SELDI peaks varied from 5% to 25% (Ebert et al.,2004; 
Poon,2007; Wadsworth et al.,2004). The inter-laboratory coefficients of variation of 
the normalised SELDI peaks varied from 15% to 36% when a standardised 
experimental protocol and quality control strategy were used (Poon,2007; Semmes et 
al.,2005). This suggests that it is necessary to standardise the methodologies so that 
the results obtained with SELDI technology are robust and reproducible across 
laboratories.  
 
The Human Proteome Organisation (Penfield,2007) is currently developing serum, 
plasma reference standards.  The standard methodology of the SELDI technology 
will be essential for the quality-assurance instrument and the calibration of individual 
assays will make the results obtained from this technique robust and reproducible 
among laboratories. As the improvement of the resolution and reproducibility of the 
current instrument and introduction of sample loading robots, the SELDI technology 
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should achieve more sensitivity and specificity. It has been argued that the rapid 
growth and development in SELDI technology and similar techniques will eventually 
overcome the limitations of SELDI technology in the near future (Poon,2007).  
 
Secondly, raw SELDI data need to be pre-processed to reduce the bias caused by 
systematic variations in the experiments. Data pre-processing includes baseline 
subtraction, intensity normalisation, peak alignment and peak picking. The 
Ciphergen ProteinChip Software and PROcess package are two commonly used 
mass spectrum pre-processing packages. It has been shown that the baseline 
correction, and normalisation algorithms implemented in Ciphergen ProteinChip 
Software and PROcess packages gave similar performance. Although most previous 
studies (Li et al.,2002; Petricoin et al.,2002a; Poon et al.,2003; Rogers et al.,2003; 
Tong et al.,2004; Yu et al.,2004; Zhang et al.,2004a; Zhao et al.,2004) used 
Ciphergen ProteinChip Software to perform mass spectrum pre-processing, PROcess 
can also be used for the purpose of baseline subtraction and intensity normalisation. 
However, both packages only considered peak alignment during the process of peak 
picking. Therefore, further research on peak alignment is needed.  
 
Thirdly, a variety of feature selection methods that have been successfully used in 
other fields, such as microarrays, are candidates for biomarker discovery using 
SELDI expression profiles. Some parametric methods, such as t-test, assume that the 
outcome measure follows a normal distribution. However, the studies by Wu et al. 
(2003) and Levner (2005) used the t-test to select significant peaks without testing 
the normality of SELDI expression profiles. The results were therefore questionable. 
Although there is a wide range of feature selection methods available, none of the 
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previous studies gave a guideline in selecting methods for proteomic biomarker 
discovery. Further research on the normality of SELDI expression profiles and on 
identifying suitable methods for biomarker discovery are needed.  
 
For cancer classification, some studies used non-parametric machine learning 
methods, such as neural networks. This is probably because that some classical 
statistical regression analyses, such as logistic regression, assume a functional form 
for the relation between SELDI expression profiles and the outcome measurement. 
However, precise information about the shape of the relation between SELDI 
expression profiles and the outcome measurement is lacking. Therefore, they often 
fail to deal adequately with the biological complexities and the multidimensional 
problem of variables selection.  
 
Although analysis of single or small numbers of proteomic biomarkers is relatively 
simple task to conduct, the statistical analysis of information from hundreds of 
proteins is challenging. Multifactorial cancers are expected to be characterised by 
multiple proteins. Despite the small effects of some proteins, the effect of the 
combinations of these proteins and the interaction between protein-protein and 
protein-environment may be large enough to predispose a cancer. Therefore, it is 
necessary to handle not only a large number of proteins, but also the interactions 
between proteins and environmental factors. However, none of the previous studies 
investigated the influence of environmental factors on cancer classification accuracy. 
We will consider this issue in Chapter 7.  
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2.6 Summary 
Although SELDI technology has shown a great potential in biomarker discovery and 
early detection of cancer, the validation and the clinical use of the technology is still 
being established. The value of SELDI technology has been limited by lack of 
consensus assay protocol and operating procedure. A general procedure and 
statistical methods for data mining SELDI mass spectra for biomarker discovery and 
cancer diagnosis are studied. Problems related to reproducibility analysis, peak 
alignment, normality test, and biomarker discovery have been identified. The 
solutions for these problems will be addressed in the next chapters. 
 
2.7 Data sets used in the thesis 
In the work that follows, we consider five SELDI data sets for analysis.  
2.7.1 Colon cancer data set 
A colon cancer data includes 15 samples taken from patient with colon cancer and 4 
samples taken from normal individuals. All serum samples were applied on four chip 
surfaces: Q10, CM10, H50, and IMAC30 in 4 replicate experiments over a two-
month period. The chips were analysed in a PBS IIc SELDI-TOF equipped with an 
autoloader (Ciphergen Biosystems, UK). Spectra were collected over 0-20 kDa (low 
range) and 0-200 kDa (high range).  For the purpose of reproducibility analysis, the 
data set was divided into 4 subsets (Set 1, Set 2, Set3 and Set 4) according to the time 
when the sample were assayed. All the 19 samples were assayed in an identical 
fashion at each experimental run. The only difference between Set 1 and Set 2 is that 
the Set 2 was obtained from the samples which were left at room temperature about 
4-5 hours after diluted 5-fold in 9 M urea, 50 mM Tris/HCl (pH 9.0) before diluted 
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10-fold dilution in the binding buffer prior to applied on bioprocessor. Set 3 and Set 
4 were obtained from two different spots in one experimental run after 2 months 
later.  
2.7.2 Pooled non-cancer data set 
A pool of serum contains 26 samples taken from healthy individuals. The pooled 
sample was processed on seven distinct days at intervals over a 4-week period using 
identical handing techniques, the same equipment and personnel. 28 spectra were 
obtained from CM10 chip on a PBS IIc SELDI-TOF equipped with an autoloader 
(Ciphergen Biosystems, UK).  
2.7.3 Lung cancer data set 
A lung cancer data consists of 39 patients with histologically confirmed non-small 
cell lung cancer and 39 patients with no evidence of cancer disease. Sera were 
analysed in duplicate on CM10 ProteinChip arrays using a PBS IIc SELDI equipped 
with an autoloader (Ciphergen Biosystems, UK). Each spectrum was composed of 
peak intensities at 13429 points, which were corresponding to m/z values in the 
range of 0-20kDa. 
2.7.4 Ovarian cancer data set 4-3-02 
An ovarian data set 4-3-02, downloaded from the National Cancer Institutes of 
Clinical Proteomics Program web site (National Cancer Institute,2007b), consists of 
100 samples from ovarian cancer patients and 100 samples from individuals without 
cancer. The spectra of these samples were generated by using WCX2 protein chip, 
and a Protein Biosystem II surface-enhanced laser desorption ionisation–time-of-
flight mass spectrometer (Ciphergen Biosystems). Each spectrum was composed of 
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peak intensities at 15154 points, which were corresponding to m/z values in the 
range of 0-20kDa. 
2.7.5 Prostate cancer data set 7-3-02 
A prostate cancer data set 7-3-02 was downloaded from the National Cancer 
Institutes of Clinical Proteomics Program web site (National Cancer Institute,2007b). 
It includes 69 samples from patients with prostate cancer and 63 samples from 
individuals with no evidence of disease. All spectra of these samples were generated 
using H4 protein chip and a Ciphergen PBS1 SELDI mass spectrometer. Each 
spectrum consists of 15,156 points and the baselines of spectra were subtracted. 
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3 REPRODUCIBILITY ANALYSIS 
3.1 Introduction 
In this chapter, we propose three quantitative measures using Euclidean distance, 
correlation coefficient, and the paired t-test to assess the reproducibility of SELDI 
protein profiles. The results of analysing a colon cancer data set have shown that the 
SELDI protein profiles of the identical samples have significant changes if they are 
left in ice for a period of 4-5 hours at room temperature. This suggests a new 
conjecture that protein profiles are affected by storage.  
 
3.2 Materials and reproducibility assessment methods 
3.2.1 Sample information   
The colon cancer data set, described in Section 2.7.1, is used in this chapter to assess 
the reproducibility of SELDI expression profiles. Each spectrum consists of 13429 
data points in the low mass range and 42426 data points in the high m/z range. All of 
the spectra were baseline-subtracted using Ciphergen ProteinChip Software, and 
normalised by total ion current, starting from the m/z value of 2000 for low range 
molecules (0-20kDa) and 20000 for high range molecules (20k-200kDa), 
respectively.  We define “bioprocessor-to-bioprocessor” for the comparison of the 
difference between Set 1 and Set 2, “month-to-month” for Set 1 and Set 3, and “spot-
to-spot” for Set3 and Set 4 in the following reproducibility analysis.   
3.2.2 Reproducibility assessment methods 
Let us consider a SELDI mass spectrum data set obtained from n samples. This 
spectral data can be put in a )1n(m +×  data matrix, ( , where,  is a 
column vector denoting  measured m/z values and I’s are the corresponding 
vectors of intensities.  
),...,,, IIImz mz
m
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The intensity profile for protein in the th replicate, is denoted by 
, where, , k=1, 2, 3, 4, is the observed protein intensity, 
which is the sum of the true value of the intensity and a measuring error, 
i.e. , where,  is the underlying protein intensity,  may be 
experimental error (or some contaminant) and 
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j  is the sample index. If SELDI mass 
spectra are reproducible, then we expect  to be close to , where, q  indexes 
replicate spectrum of spectrum 
p q
jI jI
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p . That is,  is close to . pjε qjε
 
This suggests a need to construct similarity measures for replicates of the same 
protein. Several approaches including, correlation coefficient, Euclidean distance and 
even conventional statistical methods such as paired t-test, may be considered.  
3.2.2.1 Euclidean distance 
A natural way of comparing measurements is to consider their differences. For 
vectors this means assessing combined differences between corresponding points 
across them. A classical tool for assessing the differences between two vectors is the 
Euclidean distance.  For each sample j , the Euclidean distance between spectrum p  
and its replicate spectrum q  is defined by  
∑
=
−=
m
i
q
j
p
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pq
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2))()(( nj ,...,2,1=    (3.1) , 
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where,  represent the intensities of spectrum )(iI pj p j of sample ,  
denotes  measured m/z values, and  represent the intensities of the replicate 
spectrum q . 
mi ,...,2,1=
)(iI qjm
 
It measures how close the two spectra generated from an identical sample are. The 
smaller the Euclidean distance, the closer the two spectra, suggesting that the 
measurements of the SELDI protein profiles are more reproducible. 
 
It should be noted that the study by Baggerly et al. (2004) also employed the concept 
of the Euclidean distance. But it was used in a different way, rather than directly 
measuring the reproducibility of SELDI protein profiles. In that study, the Euclidean 
distance was used to allocate samples into clusters. Each cluster was then labelled 
“cancer” or “normal” by majority vote, the fitness was defined in terms of the 
number of samples correctly classified. The fitness function was employed for 
selection of feature sets using a genetic algorithm13. The reproducibility was then 
assessed by agreement among different feature sets. 
3.2.2.2 Correlation coefficient 
Correlation coefficient is a commonly used measure of similarity. The 
reproducibility of SELDI mass spectra (i.e. the similarity between replicate spectra) 
can be measured by Pearson’s correlation coefficient, which is defined by 
                                                 
13 A computer algorithm based on the mechanisms of biological natural selection, using populations of 
objects which can reproduce based on the biological concepts of survival of the fittest and mutation. 
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where,  is covariance between  and , and  are the 
standard deviations of  and , respectively. 
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The numerator measures the shared variance between intensities  and , while 
the denominator measures the observed variance (William,2007). The higher the 
correlation coefficient between  and  is, the higher the reproducibility of a mass 
spectrum. 
p
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The correlation is defined only when the two standard deviations are finite and non-
zero. It has a range of [-1, 1]. However, in this context, a correlation of –1 would not 
be acceptable. The closer the correlation coefficient is to 1, the stronger the 
correlation between the replicate spectra. The values between 0 and 1 indicate the 
degree of dependence between the replicate spectra. The coefficient of 0 means that 
the replicate spectra are independent each other, suggesting that the measurements of 
the SELDI protein profiles are not reproducible.  
3.2.2.3 The paired t-test  
Another way of assessing similarities of replicate samples is to determine if the mean 
of the differences of corresponding measurements is zero. The paired t-test can be 
used for this purpose and it is defined by  
N
IISD
IIEt qp
qp
)(
)(
−
−=     (3.3) 
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where,  is the mean difference of the intensity levels at an m/z value 
between spectra and their replicate spectra,  is the standard deviation of 
these differences, and N  is the sample size. The null hypothesis of the paired t-test is 
that the population mean of the differences between the two groups is zero, indicating 
that the measurements of the SELDI protein profiles are reproducible. 
)( qp IIE −
)( qp IISD −
3.2.2.4 Linear mixed-effects models 
Linear mixed-effects models are used to investigate the variations in SELDI protein 
profiles over different sample processing times. Like in the study by Banks et al. 
(2005), a separate model was fitted for each peak, chip type, and mass range. In these 
models, the response variable is the intensity value at each peak, and the independent 
variable is the sample processing time, which is a three-factor variable, having values 
of 0, 4-5 hours, and 2 months, with time 0 as baseline. A random-effect term is used 
to describe individual-specific effects, which takes the correlation between peak 
intensities measured on the same individual into account. 
 
3.3 Results of reproducibility assessment 
3.3.1 Euclidean distance  
For each type of chip, the Euclidean distances of the identical samples between the 
spot-to-spot (between Set 3 and Set 4) groups, the bioprocessor-to-bioprocessor 
(between Set 1 and Set 2) groups, and the month-to-month (between Set 1 and Set 3) 
groups, were calculated through R (CRAN,2007). The same process was repeated for 
all four chips. The means and standard deviations of the Euclidean distances for the 
19 samples were calculated and listed in Table 3-1. The Euclidean distance 
distributions of the 19 samples in the four types of chips with two m/z range (low: 0-
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20k and high: 0-200k) are shown by the Box and Whisker plot depicted in Figure 
3-1. 
Table 3-1 Means and standard deviations of Euclidean distance between mass 
spectra obtained from identical samples in spot-to-spot, bioprocessor-to-
bioprocessor, and month-to-month experiments. 
Chip type Mass range spot-to-spot bioprocessor-to-bioprocessor month-to-month 
Low 1.0749±0.3993 1.7756±0.8795 ** 2.5099±0.5299 *** IMAC30 High 0.5311±0.2665 1.2496±0.6798 *** 1.5651±0.6712 *** 
Low 1.4935±0.4624 2.0509±0.3831 *** 2.4399±0.4359 *** CM10 High 2.2200±0.9226 1.9612±0.7981 2.6537±0.9271 
Low 1.0749±0.3887 1.7757±0.8560 ** 2.5099±0.5157 *** H50 High 0.8609±0.5152 1.3929±1.0327 1.9656±0.3916 *** 
Low 0.8640±0.3789 2.1695±0.8259 *** 2.5824±0.4907 *** Q10 High 1.6128±0.8375 2.2231±0.7257 * 4.4477±1.1324 *** 
Significant levels:  `***'  <0.001,  `**' <0.01,  `*' <0.05. 
 
 
For spot-to-spot comparison (between Set 3 and Set 4), the means of Euclidean 
distances across four chips for both low and high mass ranges varied from 0.5311 to 
2.2200, with a median of 1.0749. For bioprocessor-to-bioprocessor comparison 
(between Set 1 and Set 2), the means of Euclidean distances across the four chips 
vary from 1.2496 to 2.2231, with a median of 1.8685. For month-to-month 
comparison (between Set 1 and Set 3), the means of Euclidean distances across four 
chips vary from 1.5651 to 4.4477, with a median of 2.5099. 
 
It is noteworthy that the mean of Euclidean distances increases from spot-to-spot 
comparison to bioprocessor-to-bioprocessor and month-to-month comparisons, with 
CM10 in the higher range setting a notable exception. The medians (across the four 
chips) of the means of Euclidean distances (19 samples) increase by 75% ((1.868-
1.07)/1.07*100) for the bioprocessor-to-bioprocessor groups and by 135% ((2.510-
1.07)/1.07*100) for the month-to-month groups, compared to the spot-to-spot 
groups.   
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             spot-to-spot        bioprocessor-to-bioprocessor         month-to-month 
Figure 3-1 Box and Whisker plot of Euclidean distance between spot-spot, 
bioprocessor-bioprocessor, and month-2-month comparisons. q1 denoting for 
the first quartile; q3, the third quartile; min, the minimum of distances; max, 
the maximum of distances; median, the median of distances.    
 
For each chip with both high and low mass ranges, we applied the paired t-tests to 
the 19 samples to investigate the difference of the Euclidean distances between the 
spot-to-spot and bioprocessor-to-bioprocessor groups, and between the spot-to-spot 
and month-to-month groups.  The mean differences of Euclidean distances between 
the spot-to-spot and month-to-month groups were highly significant at p-value < 
0.001 for all four chips in two different settings except CM10 in the higher m/z 
range. The mean differences of Euclidean distances between the spot-to-spot and 
bioprocessor-to-bioprocessor groups were significant at p-value < 0.001 for IMAC30 
in the higher m/z range, and CM10 and Q10 in the lower m/z range, significant at p-
value < 0.01 for IMAC30 and H50 in the lower m/z range, and significant at p-value 
< 0.05 for Q10 in the lower m/z range, while the mean differences of Euclidean 
distances between the spot-to-spot and bioprocessor-to-bioprocessor groups were not 
significant with p-values of > 0.05 for H50 and CM10 in the higher m/z range. 
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3.3.2 Correlation coefficients 
For each type of the four chips, the corresponding correlation coefficients of identical 
samples between the spot-to-spot (between Set 3 and Set 4) groups, the bioprocessor-
to-bioprocessor (between Set 1 and Set 2) groups, and the month-to-month (between 
Set 1 and Set 3) groups, were calculated by using R correlation coefficient functions 
(CRAN,2007). The same process was repeated for all four chips. The means and 
standard deviations of the correlation coefficients for the 19 samples were calculated 
and listed in Table 3-2. The distributions of the correlation coefficient of the 19 
samples across four chips with two different range settings are shown in Figure 3-2. 
Table 3-2 Means and standard deviations of correlation coefficients between 
mass spectra obtained from identical samples in spot-to-spot, bioprocessor-to-
bioprocessor, and month-to-month experiments. 
Chip type Mass 
range 
spot-to-spot bioprocessor-to-bioprocessor month-to-month 
Low 0.9861±0.0123 0.9561±0.0417 ** 0.9259±0.0305 *** IMAC30 
High 0.9941±0.0041 0.9634±0.0359 **  0.9710±0.0210 *** 
Low 0.9244±0.0435 0.8891±0.0364 * 0.8328±0.0519 *** CM10 
High 0.6131±0.2284 0.8768±0.1105 ** 0.7862±0.1983 * 
Low 0.9861±0.0119 0.9561±0.0405 ** 0.9259±0.0297 *** H50 
High 0.9863±0.0112 0.9525±0.1442 0.9489±0.0205 *** 
Low 0.9770±0.0183 0.8860±0.0726 *** 0.8367±0.0689 *** Q10 
High 0.9874±0.0149 0.9706±0.0142 ** 0.8877±0.0342 *** 
Significant levels:  `***' <0.001,  `**' <0.01,  `*' <0.05. 
 
 
For spot-to-spot comparison (between Set 3 and Set 4), the means of correlation 
coefficients across four chips for both low and high mass ranges vary from 0.6131 to 
0.9941, with a median of 0.9861. For bioprocessor-to-bioprocessor comparison 
(between Set 1 and Set 2), the means of correlation coefficients across four chips 
vary from 0.8768 to 0.9706, with a median of 0.9543. For month-to-month 
comparison (between Set 1 and Set 3), the means of correlation coefficients across 
four chips vary from 0.7862 to 0.9710, with a median of 0.9068.  
 
It is noteworthy that the mean of correlation coefficients decreases from spot-to-spot 
comparison to bioprocessor-to-bioprocessor and month-to-month comparisons, with 
CM10 in the higher range setting a notable exception. The medians (across the four 
chips) of the means of correlation coefficients (19 samples) decrease by 3% 
((0.9543-0.9861)/0.9861*100) for the bioprocessor-to-bioprocessor groups and by 
8% ((0.9068-0.9861)/0.9861*100) for the month-to-month groups, compared to the 
spot-to-spot groups.   
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            spot-to-spot        bioprocessor-to-bioprocessor         month-to-month 
Figure 3-2 Box and Whisker plot of correlation coefficient between spot-spot, 
bioprocessor-bioprocessor, and month-2-month comparisons. q1 denoting for 
the first quartile; q3, the third quartile; min, the minimum of distances; max, 
the maximum of distances; median, the median of distances.    
 
For each chip with both high and low mass ranges, we applied the paired t-tests to 
the 19 samples to investigate the difference of the correlation coefficients between 
the spot-to-spot and bioprocessor-to-bioprocessor groups, and between the spot-to-
spot and month-to-month groups. The mean differences of the correlation 
coefficients between the spot-to-spot and month-to-month groups were highly 
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significant at p-value < 0.001 for IMAC30, H50, Q10 in both range settings and 
CM10 in the lower range setting, significant at p-value < 0.05 for CM10 in the 
higher range setting. The mean differences of the correlation coefficients between the 
spot-to-spot and bioprocessor-to-bioprocessor groups were highly significant at p-
value < 0.001 for Q10 in the lower range setting, significant at p-value < 0.01 for 
IMAC30 in both range settings, CM10 in the higher range setting, H50 in the lower 
range setting, and Q10 in the higher range setting, while the mean difference of the 
correlation coefficients between the spot-to-spot and bioprocessor-to-bioprocessor 
groups was not significant with a p-value of 0.322 for H50 in the higher range 
setting. These results are in accordance with those obtained from the Euclidean 
distance analyses. 
3.3.3 The paired t-test 
For each chip with both high and low mass ranges, the paired t-tests were performed 
between the spot-to-spot (between Set 3 and Set 4) groups, the bioprocessor-to-
bioprocessor (between Set 1 and Set 2) groups, and the month-to-month (between Set 
1 and Set 3) groups at each m/z point by calling the R function t.test (CRAN,2007). 
The percentages of the m/z points at which the p-values of the paired t-tests were less 
than 0.05 were counted for each of the 19 samples. The average percentages of m/z 
points at which the p-values were less than 0.05 were calculated across the 19 
samples and listed in Table 3-3.  The results of the paired t-tests showed that in 
average, 24% of m/z points in the spot-to-spot groups, 36% of m/z points in the 
bioprocessor-to-bioprocessor groups, and 62% of m/z points in the month-to-month 
groups were significantly different at a significance level of 0.05. This suggests that 
the reproducibility of SELDI mass spectra in the bioprocessor-to-bioprocessor, and 
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the month-to-month groups became worse compared to that in the spot-to-spot 
groups. 
Table 3-3 The average percentages of m/z points at which p-values are < 0.05 in 
paired t-tests between spot-to-spot, bioprocessor-to-bioprocessor, and month-to-
month experiments. 
spot-to-spot bioprocessor-to-bioprocessor month-to-month Chip type Range  (%)  (%)  (%) 
Low 22 42 52 IMAC30 High 26 58 71 
Low 59 45 55 CM10 High 14 1 61 
Low 8 15 51 H50 High 48 10 74 
Low 2 47 61 Q10 High 11 69 67 
Average 24 36 62 
  
3.3.4 Linear mixed-effects models 
The R (CRAN,2007) function lme() in library(nlme) (Pinheiro et al.,2009) is used to 
undertake the analyses of variations in SELDI protein profiles over different sample 
processing times. The number and percentage of peaks at which intensities have 
significant changes with time are shown in Table 3-4. The results of these linear 
mixed-effects models showed that in average, sample processing time 4-5 hours after 
baseline results in 29% of peaks at which intensities have significant changes 
(bioprocessor-to-bioprocessor), and sample processing time 2 months after baseline 
results in 48-49% of peaks at which intensities have significant changes (month-to-
month). This implies that the reproducibility of SELDI mass spectra in the month-to-
month groups became worse compared to that in the bioprocessor-to-bioprocessor 
groups. The indirect comparison of the numbers of peaks at which intensities have 
significant changes between baseline and 2 months later (the last two columns in 
Table 3-4) shows that the spot-to-spot groups may give a better reproducibility 
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compared to the bioprocessor-to-bioprocessor, and the month-to-month groups. To 
estimate the changes of protein profiles between the spectra in Set 3 and their 
replicate spectra in Set 4 (for spot-to-spot comparison), the linear fixed-effects 
models were re-run, taking Set 3 as the baseline. The results show that there are 13% 
of peaks at which intensities have significant changes when comparing spectra in Set 
3 and their replicate spectra in Set 4. 
Table 3-4 The numbers and percentages of peaks at which intensities have 
significant changes over the sample processing times 
Sample processing time 
4-5 hours vs. baseline 2 months vs. baseline 2 months vs. baseline 
Set 2 vs. Set 1 Set 3 vs. Set 1 Set 4 vs. Set 1 
Chip type Range 
m/n  (%) m/n  (%) m/n  (%) 
Low 58/229 (25) 82/229 (36) 70/229 (31) IMAC30 
High 38/105 (36) 52/105 (50) 52/105 (50) 
Low 49/137 (36) 57/137 (42) 63/137 (46) CM10 
High 25/92 (27) 35/92 (38) 61/92 (66) 
Low 8/92 (9) 42/92 (46) 43/92 (47) H50 
High 3/125 (2) 72/125 (58) 60/125 (48) 
Low 51/96 (53) 59/96  (61) 59/96  (61) Q10 
High 37/79 (46) 44/79 (56) 46/79 (58) 
Average 269/922 (29) 443/922 (48) 454/922 (49) 
n: the total number of peaks 
m: the number of peaks at which p<0.05/n 
 
 
3.4 Discussion 
We proposed three quantitative reproducibility measures for SELDI expression 
profiles using Euclidean distance, correlation coefficient, and the p-value of the 
paired t-test. We then assessed the reproducibility of SELDI mass spectrum at each 
m/z point between the nineteen replicated identical samples assayed at different 
times in the same experimental conditions using the colon data set. Highly significant 
differences of SELDI protein profiles between the identical samples that were 
generated in different experimental runs over a short period or a long period of time 
have been found in this data set. The significant difference observed over a short 
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period indicated that the mass spectra of the identical samples had significant 
changes if they were left in ice for a period of 4-5 hours at room temperature. This is 
consistent with the result reported in the study by Marshall et al. (2003), which found 
that when plasma was left sitting at room temperature for 4 or 8 hours, the MALDI 
data, as recorded by a SELDI instrument, changed significantly (Diamandis,2004b; 
Marshall et al.,2003).  The bias of SELDI technology was also discussed in the 
studies by Baggerly et al. (2004) and Diamandis (2003a).  
 
The reproducibility analysis results show that the number of m/z points, where the p-
values of the paired t-tests were less than 0.05, increases from the spot-to-spot, 
bioprocessor-to-bioprocessor, and month-to-month comparisons in chip IMAC30, 
Q10, and H50 with low range setting, while opposite results were observed (the 
higher number of significant m/z points in the spot-to-spot comparison) in chip 
CM10 and H50 with higher setting. These observations were not in accordance with 
the results of Euclidean distances and correlation coefficients. This may be because 
that the number of significant m/z points from the paired t-tests only indicates that at 
how many specific m/z points the difference between assays were significant, while 
the Euclidean distance and correlation coefficient methods took the overall 
difference into account. 
 
These data suggest that the difference between the identical samples over the 
replicate experiments was significantly different in terms of Euclidean distances and 
correlation coefficients. This difference was not due to inherent biological difference, 
but presumably due to artefacts associated with experimental conditions, such as 
time to assay, temperature, humidity, mechanical adjustments to the mass 
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spectrometer itself, differential handing and/or processing of the samples. This 
indicates that careful experimental design is needed, a standard protocol should be 
drawn up to minimise the effect of irrelevant sources of variations (Baggerly et 
al.,2004). The proposed quantitative measures of reproducibility should be useful in 
helping identify important experimental conditions for improving the reproducibility 
of SELDI expression profiles. 
 
3.5 Summary 
The reproducibility of SELDI expression profiles has been investigated by applying 
the proposed quantitative measures of reproducibility to the colon cancer data set. 
The results showed that the differences of SELDI data between identical samples 
over the replicate experiments are statistically significant in terms of Euclidean 
distances and correlation coefficients. The mass spectra generated in different spots 
in one experimental run have a better reproducibility compared to the mass spectra 
generated in different experimental runs. The mass spectra generated in different 
experimental runs over a short period of time have a better reproducibility than the 
mass spectra generated in different experimental runs over a long period of time. The 
results of the linear fixed-effects models have confirmed these reproducibility 
changes for spectra generated in different experimental runs over different periods of 
time. The reproducibility analyses have found that the mass spectra of the identical 
samples had significant changes if they were left in ice for a period of 4-5 hours at 
room temperature. This suggests a new conjecture that protein profiles are affected 
by storage. The reproducibility analysis implies that apart from a standard 
experiment protocol should be adopted; there is also a need for further research on 
SELDI mass spectrum pre-processing. The next chapter will investigate peak 
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alignment methods (one of the data pre-processing procedure) and their effects on 
the reproducibility of SELDI protein profiles and on the accuracy of cancer 
classification. 
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4 PEAK ALIGNMENT  
4.1 Introduction 
In this chapter, we propose two new peak alignment methods based on the SWA 
scheme, in which the maximum sideway shift value is set dynamically according to 
the characteristics of the SELDI mass spectra to allow the search algorithms to find 
the best shift in the search space of interest. The performance of the proposed peak 
alignment algorithms is assessed in terms of correlation coefficient, the number of 
peaks identified and coefficient of variation and compared with that of the existing 
peak alignment methods, peak alignment by beam search (Lee & Woodruff,2004), 
peak alignment by fast Fourier transform (Wong et al.,2005b), peak alignment by 
peak matching (Wong et al.,2005a) and peak alignment by cubic splines 
(Jeffries,2005). We then examine the extent to which different peak alignment 
methods improve the reproducibility of SELDI protein profiles.  
 
The study by Wu et al. (2003) compared the performance of a number of statistical 
methods for the classification of ovarian cancer data sets generated by MALDI 
technology. The methods studied included linear discriminant analysis, quadratic 
discriminant analysis, bagging and boosting classification trees, k-nearest neighbour 
classifier, support vector machine, and random forest. In this analysis, the random 
forest model outperformed other statistical methods. We assess the effects of peak 
alignments on the discriminatory power of random forest classifiers in terms of the 
AUC.  
 
It has demonstrated that one of the newly proposed peak alignment algorithms 
provides the best alignment criterion. 
 
4.2 Materials and peak alignment methods 
4.2.1 Data sets 
The pooled non-cancer data set and lung cancer data set, described in Section 2.7.2 
and Section 2.7.3, respectively, are used for peak alignment analysis. The spectra 
were background corrected and intensity normalised using the Ciphergen 
ProteinChip 3.2 software, and normalised to the total ion current in the range 2k to 
20kDa. The reference spectrum was generated by averaging all spectra in each data 
set and is shown in Figure 4-1. 
 
We also use the ovarian data Set 4-3-02 and prostate cancer data set 7-3-02, which 
were described in Section 2.7.4 and Section 2.7.5, respectively, to test the 
performance of the peak alignment methods.  
 
Figure 4-1 The reference spectrum generated by averaging 28 non-cancer 
spectra. 
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4.2.2 Peak alignment methods 
4.2.2.1 The existing peak alignment methods 
The four previously published peak alignment methods are described as follows.  
4.2.2.1.1 Peak alignment by peak matching algorithm 
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P P
The peak alignment by peak matching algorithm is a peak-based alignment scheme 
(Wong et al.,2005a).  It inserts or deletes data points to shift regions in each spectrum 
to be aligned with the corresponding region in a reference spectrum, guided by the 
so-called reference points. The reference points are mainly automatically (or 
sometimes manually) selected peaks within each spectrum. The reference spectrum 
and the spectrum of interest are first divided into windows of specified sizes and then 
insertions (or deletions) are made, guided by the presence or absence of a match 
between reference peaks across the two spectra within a given window. The window 
size can be varied to ensure no matching peak is omitted within reasonable distance 
of the edge of a specified window. The rules for insertion or deletion are described as 
follows (Wong et al.,2005a). Suppose that there are s spectra with d data points. Each 
spectrum m is to be aligned with the corresponding region in a reference spectrum r, 
as marked by reference points,  and , where, i  and jim jr  are points between 0 
and .  d
1. For each j  in , find the closest matching . If no match is found within 
a window of size , which is specified by the user, then move to the next 
point 
jrP P
w
im
j +1. 
2. If  is found, but not aligned to , find the minima between,  and 
, ( ), and,  and , ( ), where insertions or deletions 
are to be made for alignment of  and  
imP
mi )1−
jrP
m
imP
P( imP iP )1( +
imP
1min − 1min +
jrP
3. If > (for the value of the x-axis), then points are to be deleted from 
 and points to be inserted at . If < , then the reverse applies. 
imP
1min −
jrP
imP jrP1min +
4. Where points are inserted, the y-axis value for the inserted point is estimated 
by a least square quadratic polynomial fit to its adjacent  points. w
4.2.2.1.2 Peak alignment by fast Fourier transform algorithm 
Peak alignment by fast Fourier transform algorithm uses segment-wise alignment 
scheme and fast Fourier transform (FFT) cross-correlation to determine a shift range 
between a segment and its corresponding reference segment (Wong et al.,2005b).  
FFT is an algorithm for converting data from time to the frequency domain and often 
used for measuring correlation and time delay or shift between signals. It provides an 
accurate estimation of the shift between two signals. Suppose that we have two 
functions, one is a reference spectrum ; the other is a sample spectrum  to 
be aligned. At any shift position , their cross-correlation function Corr s 
defined by  
)(xr )(xs
usr ),(  iu
∫∞∞− += dxuxsxrsrCorr u )()(),(    (4.1) 
 
 
The Fourier transformation of  is given by   )(xr
∫∞∞−= dxexrwR iwxπ2)()(    (4.2) 
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where,  is the Fourier transformed function in the inverse wavelength  
domain. The reverse Fourier transformation is given by  
)(wR w
∫∞∞− −= dwewRxr iwxπ2)()(    (4.3) 
 
Similarly, the Fourier transformed function and the reverse Fourier transformation 
for  are given as follows. )(xs
∫∞∞−= dxexswS iwxπ2)()(     (4.4) 
 
∫∞∞− −= dwewSxs iwxπ2)()(    (4.5) 
 
The cross-correlation can then be written as  
∫∞∞− −= dwewSwRsrCorr iwxu π2* )()(),(    (4.6) 
 
where,  represents the complex conjugate of the function. That is to say, we 
can calculate the cross-correlation by applying forward Fourier transformation to 
 and , then multiplying the transformed functions  and , and 
then performing reverse Fourier transformation of this product. 
)(* wS
(xs )(* wS)(xr )(wR)
 
The implementation of this algorithm is described as follows (Wong et al.,2005b). 
1. Calculate the cross-correlation function between a segment and its 
corresponding reference segment using FFT described above. 
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2. Find the optimal shift position  by opu )),((max uuop srCorru =  
3. Shift the segment by that amount using the following formula. 
⎪⎪
⎪
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=
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0]1,[)1(],1,0[)(
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uifNxxs
uifNuNxNsuNxuxs
uifNuxuxsuxs
xs       
(4.7) 
 
where,  is the size of the segment.  N
4.2.2.1.3 Peak alignment by cubic splines algorithm  
The peak alignment by cubic splines algorithm is a peak-based alignment scheme 
that finds peak locations by fitting cubic splines to the ratio of peak locations (m/z 
values) of the spectrum of interest to its target value (Jeffries,2005).   
 
A cubic spline is used to interpolate n  data points, , , …,  with 
a piecewise cubic polynomial. The general form of the cubic spline is  
),( nn yt),( 11 yt ),( 22 yt
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In order to provide a smooth fit between data points, the spline function  
should satisfy the interpolation conditions 
)(tSy =
ii ytS =)(
12 ,..., −ntt
, and continuous first and 
second derivatives at interior data points . The values of the second 
derivative at the endpoints can be arbitrary. A natural cubic spline sets second 
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derivatives to zero at the endpoints  and . The value of 0t nt y  at any point t  in 
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where  are the values of the second derivative at   )( ii tSz ′′= it
 
The coefficients of the cubic spline are determined by applying the interpolation 
conditions, continuity of first derivative and the endpoints conditions of second 
derivative to the above equations. For a natural cubic spline, it is to solve the 
following equations (De Boor,2001).  
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The peak alignment by cubic spline algorithm finds a postulated cubic spline and 
determines the optimal parameters that minimise the distances between the cubic 
spline and the ratio of peak locations of the spectrum of interest to its target value.  
The cubic spline transformation function is then used to recalibrate the peaks. 
Suppose that a single spectrum has a set of N peaks with associated m/z values 
(denoted by ) and a set of target m/z values (denoted by ). The algorithm is 
described as follows (Jeffries,2005). 
ip
1. Let  denote the ratio of the original mass value to its target value, that is, iu
 
80
i
i
m
p=iu . 
2. For given { , , , …, , }, a cubic spline  is fitted such 
that the following error term is minimised.  
Np Nm )( pf1p 1m 2p 2m
dppfpfuE i
N
i
i
22
1
)}("{)}({ ∫∑ +−=
=
β
αλ     (4.11) 
  
where, α  and β  indicate the limits of the m/z range under consideration. λ  
is chosen by cross-validation (by successively leaving out one pair of peak 
location values) and determining what value of  λ  generally yields low 
estimated error, , for the omitted data.  2)}( ii pfu −{
3. Let  denote one of the original m/z and  denote its associated 
intensity. Then a recalibrated mass associated with the original intensity, 
, is calculated as follows. 
origM origI
origI
)( orig
orig
recal Mf
M
M =     (4.12) 
 
where,  denotes the value of the spline function at the mass value of 
. These recalibrated masses are computed for every one of the original 
masses and are associated with the original intensities. 
)( origMf
origM
4. Linear interpolation of the recalibrated masses that are closest to the original 
mass is used to obtain a new intensity for the original mass. 
 
A disadvantage of PACS is that it assumes that the target spectrum and the sample 
spectrum to be aligned have the same number of peaks.   
4.2.2.1.4 Peak alignment by beam search algorithm 
The peak alignment by beam search algorithm uses the SWA scheme and beam 
search algorithm. It aligns a sample spectrum to a reference spectrum by shifting and 
shrinking m/z values so that the correlation coefficient between the corresponding 
segments in the two spectra is maximised. The implementation of the algorithm is 
described as follows (Lee & Woodruff,2004).  
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)}0,0{(1. Establish the set of promising solutions: =S
3/*2 rar =
Ssi ∈),( ), si
,( sri ± 0>i
i
S
3/rr = 1<
 and the search radius 
, where, [-ra, ra] is a pre-specified search range. 
2.  For all , evaluate (  and the solutions in its neighbourhood 
, where, i  is the shrinkage amount (if , then the segment is 
shrunk  points, otherwise it is stretched by - ), and  is the amount of shift 
(if , then right shift, otherwise left shift) 
)r±
i
0>s
s
3. Select the k best solutions evaluated in step 2 to be the next set . 
4. Let . If r  then report the member of  with the best correlation 
coefficient and stop the search, otherwise goto step 2 
S
 
The beam search algorithm is a heuristic method in which a set of likely solutions is 
first created on the edge of a pre-determined search range [-ra, ra] (steps 1 and 2). 
These values are then pruned and the k most promising solutions are selected for 
further evaluation (step 3), where, k is a parametric input, called the beam width. For 
each search step, the search range is reduced until a stop criterion is met and the best 
solution is then reported (step 4).   
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4.2.2.2 Our proposed peak alignment methods 
We propose two new alignment methods, the peak alignment by beam search with 
dynamic maximum sideway movement value (PABSD) and the peak alignment by 
sequential search (PASS). Both methods are based on the SWA scheme, but with 
different search algorithms. The PASS uses a sequential algorithm while the PABSD 
uses a beam search algorithm. In both algorithms, the maximum sideway movement 
value is set dynamically. These algorithms were implemented using MATLAB.   
 
An important step in SWA method is the setting of the maximum range of sideway 
movement value. If this is too large, there could be inconsistencies in peak matching 
between spectral segments (Forshed et al.,2003). If it is too small, then the 
insufficient search range may lead to the failure of the search algorithm to find the 
best movement value to align spectral segments. Thus it is vital to set this parameter 
accurately before peak alignment can be done (Forshed et al.,2003). The current 
alignment algorithms that use the SWA scheme fix this parameter at a constant value 
(Forshed et al.,2003; Forshed et al.,2005; Lee & Woodruff,2004; Viant,2003; Wong 
et al.,2005b). However, in SELDI data sets, the shifts in m/z values are not constant 
and thus using a fixed parameter will not sufficiently align its features.  Depending 
on the instrument resolution and mass calibration methods used, the accuracy in m/z 
positions is normally within 0.1-0.2% of the true m/z value.  Therefore, the 
appropriate maximum range for sidewise movement should vary from segment to 
segment.  To meet this challenge, the maximum sideway movement values are set 
dynamically.  For a given segment, the maximum sideway movement value is set to 
be the minimum m/z value in the segment multiplied by the manufacture’s 
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specification error.  The detailed description of the two proposed algorithms is given 
below. 
4.2.2.2.1 PABSD method 
The peak alignment by beam search with dynamic maximum sideway movement 
value algorithm is adapted from PABS. The difference between PABS and PABSD 
is that for each segment of interest, the maximum sideway movement value is not a 
constant. The implementation of the method is as follows. 
1. Obtain minimum m/z value of the segment to be aligned, minmz. 
2. Calculate the maximum sideway movement value: msmv = minmz *λ, 
where, λ is the instrument resolution (0.1%-0.2%). 
3. Initialise k (1 or 2) temporary best shifts (si, i=1,…, k), and calculate the 
search radius: r = 2*msmv/3 
4. For all of the k temporary best shifts, calculate the correlation coefficient 
between the segments to be aligned in three shifts (si, si ± r) and select 
best k shifts for next iteration of search. Let r = r /3. 
5. Search is stopped when search radius r <1 and the best shift is reported.   
4.2.2.2.2 PASS method 
This method was developed based on “hill-climbing” search algorithm. It calculates 
the correlation coefficient between a reference segment and the segment of interest, 
and the results are compared with the goal in an uphill direction. The procedure is 
repeated at each data point until the maximum correlation coefficient is found and 
the corresponding shift value is the optimal solution. The implementation of the 
method is as follows. 
1. Obtain minimum m/z value of the segment to be aligned, minmz. 
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2. Calculate the maximum sideway movement value: msmv = minmz *λ, 
where, λ is the instrument resolution (0.1%-0.2%). 
3. Initialise search set Ω = (-1, 0, 1) 
4. Calculate the correlation coefficient between the segments to be aligned 
in three shifts in the search set Ω, and find the maximum correlation 
coefficient maxCC 
5. If the maximum correlation coefficient achieves at 0, then set Ω = ( ) 
6. If the maximum correlation coefficient achieves at 1, and if msmv ≥ 2, 
then set Ω = (2,…, msmv), otherwise set Ω = ( ) 
7. If the maximum correlation coefficient achieves at -1, and if msmv ≥ 2, 
then set Ω = (-2,…, -msmv), otherwise set Ω = ( ) 
8. If Ω = ( ), then stop searching, the shift corresponding to maxCC is 
reported, otherwise, 
9. Calculate the correlation coefficient newCC between the segments to be 
aligned in the next shift in the search shift set Ω 
10. If newCC > maxCC, then go to 9, otherwise, 
11. Stop searching, the shift corresponding to maxCC is reported. 
4.2.3 Evaluation and comparison of peak alignment methods 
In the analysis of mass spectrometry data sets, an important pre-processing step is 
peak alignment. However, there is always a risk of introducing errors in data when 
performing peak alignment (Forshed et al.,2003). Therefore, the importance of 
checking the data for errors after peak alignment cannot be overemphasised. Several 
statistical methods, including correlation coefficient, coefficient of variation and 
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classification methods, are used to evaluate the performance of the two new peak 
alignment algorithms and the four published methods.  
4.2.3.1 Effect of peak alignment on reproducibility  
Ideally, all spectra from the pooled serum should be similar (Jeffries,2005). Thus 
they would be expected to be associated with lower coefficient of variation and 
higher correlation coefficients between the spectra of interest and the reference 
spectrum. Both the correlation coefficient and the coefficient of variation are used to 
examine the effect of peak alignment on reproducibility of the SELDI data.  
4.2.3.2 Effect of peak alignment on cancer classification  
Applying peaks alignment to mass spectra will reduce technical variations and 
improve the accuracy of matching proteins across samples. To assess the 
performance of peak alignment methods on cancer classification, models are built 
using RF machine learning algorithm with both un-aligned and the aligned MS data 
generated by various alignment algorithms. The examination was implemented in the 
following steps. 
 
1. Detection of peaks:  Although valuable information might exist in any part of the 
spectrum, because of high measurement variation in SELDI data, peaks are the most 
suitable value to identify biomarker and classify cancer patients from normal 
individuals (Bhanot et al.,2006). Thus all the analyses are based on peaks extracted 
with the BioConductor software package PROcess (Gentleman,2005). To make the 
results comparable, the same parameter settings were applied to both aligned and un-
aligned spectra in selection of peaks. The lower bound for signal/noise ratio is set to 
2, the minimum intensity to1 and total area under the curve is taken as 0.01.   
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2. Identification of significantly different peaks:  In order to assess the effect of peak 
alignment on cancer classification, the RF machine learning algorithm is used to 
build classification models for both aligned and un-aligned lung cancer data sets. 
Due to the large number of variables relative to the sample size, an important issue in 
analysing such data is to extract disease-associated biomarkers using the limited 
number of samples guided by the critical aim of minimising the number of false 
positives (Li et al.,2002). Peaks are ranked and selected using Wilcoxon test at the 
5% significance level (10% FDR) and are then used to build classifiers to 
discriminate cancer from normal samples using RF technique.   
 
3. Cancer classification using RF:  A random forest model consists of multiple 
decision trees, grown in parallel. The R software package called randomForest is 
used, which is based on an algorithm proposed by Breiman (Breiman,2001) that 
combines two powerful machine learning techniques, bagging and random feature 
selection. The classification procedure involves the following steps: firstly, data is 
divided into training and test sets. Secondly, bootstrap samples are drawn from this 
training set. For each bootstrap sample, a tree is built to predict the out-of-bag (OOB) 
samples, which are not present in the bootstrap sample.  When constructing a tree, 
the best split from a randomly selected subset of input variables is used at each node 
splitting.  For each tree grown, about two-thirds of the samples are selected at 
random and used to train model and the rest of the samples are treated as OOB. To 
classify an input vector in the random forest, the vector is submitted as an input to 
each of the trees in the forest and the classification is determined by the majority 
vote.  
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The performance of the resulting models is evaluated using the AUC of the ROC 
curve.  The McNemar test (Agresti,1990) is used to assess the significance of the 
difference between classification models for the aligned and un-aligned spectra.  
 
4.3 Results of peak alignment 
The maximum range of sideway movement was set dynamically from segment to 
segment. For the lung cancer data set, it was set to the minimum m/z value in that 
segment multiplied by 0.2% (manufacture’s specification error). Figure 4-2 shows a 
section of SELDI mass spectra from 7.5kDa to 10kDa before and after peak 
alignment by PABSD (the reference spectrum is shown in Figure 4-1). Two spectral 
profiles n24 (generated on day 1) and n31 (generated on day 2) had differences in 
peak height and peak positions. It can be seen that the peaks were not well aligned 
originally, but clearly aligned after the PABSD algorithm was applied.  Figure 4-2 
also shows that the peaks keep their original shape and intensities after peak 
alignment. This is because the peak alignment only corrects the horizontal shifts 
(eliminates noise) and reserves the spectral composition, the signals of interest. 
 
 
(a) 
 
(b) 
    
Figure 4-2 Two spectral segments generated from a pooled non-cancer sample 
on different days, n24 generated on day 1 and n31 day 2.  (a) before peak 
alignment and (b) after peak alignment. 
 
4.3.1 The parameter settings for peak alignment methods   
For the proposed methods, the number of segments was set to 40 and the maximum 
sideway movement value was set dynamically. The beam width was set to 1 for both 
PABS and PABSD methods. For the PAFFT algorithm, the minimum segment size 
was set to 500 data points and the maximum shift was set to 20 data points for both 
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the PAFFT and PAPM algorithms.  For PACS, the individual calibration equations 
for each spectrum were generated for the pooled non-cancer data set in order to 
achieve higher alignment performance during the calibration and peak alignments. 
The parameters used for peak alignment are summarised in Table 4-1. 
Table 4-1 Parameter setting for each peak alignment methods. 
Alignment methods 
Number of 
segment 
Segment size 
Maximum 
sideway 
movement 
Window size 
PABSD 40 Dynamically Dynamically - 
PASS 40 Dynamically Dynamically - 
PABS 40 Dynamically 20 - 
PAFFT - 500 (minimum) 20 - 
 PAPM - - - 20 
 PACS - - - Dynamically 
 
 
4.3.2 The effect of peak alignment on reproducibility  
The pooled non-cancer data set was used for the reproducibility analysis.  Table 4-2 
shows the CVs and correlation coefficients for the 28 spectra after peak alignment 
using the six methods, the new two and the four published methods. The median CV 
was higher before peak alignment and reduced by aligning the peaks for all the 
methods but PAPM. The possible causes of poor performance of the PAPM method 
are that PAPM uses only local peak information to determine the amount of shift 
(insertion or deletion) and does not consider the correlation coefficient between the 
reference spectrum and the spectrum to be aligned during the process of peak 
alignment. These may introduce further errors into the spectrum after peak 
alignment, and thus gives poor performance, even compared to without peak 
alignment. In contrast, another peak-based method, PACS, determines the optimal 
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parameters that minimise the distance between the cubic spline and the ratios of peak 
locations of the spectrum of interest to their target values, which takes information of 
all peaks into account. The SWA method, PAFFT, finds the optimal shift position by 
calculating the maximum cross-correlation function between a segment and its 
corresponding reference segment, which takes all data points in the spectra into 
account. Similarly, the SWA methods PABS, PABSD, and PASS all determine the 
shift position based on the maximal correlation coefficient between spectra, which 
take all data points in the spectra into account.  
 
It is interesting to note that all inter-quartile ranges (IQR) of CV were in the similar 
range (from 0.485 to 0.508) but PAPM. This makes it comparable among the median 
CVs across the un-aligned and the aligned mass spectra using different peak 
alignment methods. The PASS method performed best. It had both the lowest CV 
(0.360) and the highest correlation coefficient (0.978), with the largest changes in 
median CV (from 0.411 to 0.360) and correlation coefficient (from 0.942 to 0.978) 
compared to those without peak alignment. These changes represent a reduction of 
12% for the median CV, and an increase of about 4% in the correlation coefficient. 
This is consistent with what reported (4-7%) for PABS and PAFFT (Wong et 
al.,2005b). 
 
The results of Wilcoxon tests show that compared to without peak alignment, all 
peak alignment methods, except PAPM, significantly reduce the median CV (p-value 
< 0.0001). However, the newly proposed methods with dynamic maximum sideway 
movement, PABSD and PASS, do not outperform PABS in terms of the median CV 
(p-value > 0.1). The results of Wilcoxon tests also show that none of the peak 
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alignment methods significantly increases the correlation coefficient compared to 
without peak alignment (p-value > 0.05).  
Table 4-2 CVs distribution and correlation coefficient under different peak 
alignment methods based on the pooled non-cancer data set.  
Alignment  
methods 
Median 
(CV) 
IQR 
(CV) 
CV % change 
compared to 
no alignment 
Correlation 
coefficient  
(CC) ±SD 
CC % 
change 
compared to 
no 
alignment 
No alignment 0.411 0.486 - 0.942±0.049 - 
PABSD 0.361 0.485 -12.2 0.976±0.011 3.6 
PASS 0.360 0.489 -12.4 0.978±0.010 3.8 
PABS 0.365 0.488 -11.2 0.976±0.012 3.6 
PAFFT 0.366 0.508 -10.9 0.978±0.010 3.8 
PAPM 0.506 0.599 23.1 0.882±0.092 -6.4 
PACS 0.361 0.495 -12.2 0.977±0.013 3.7 
 
The PASS method was also applied to the two published data sets (ovarian data set 
4-3-02 and prostate data set 7-3-02) (National Cancer Institute,2007b). The average 
of the correlation coefficients between the reference spectrum and spectra of interest 
increased from 0.940 to 0.942 for the ovarian data set and from 0.798 to 0.801 for the 
prostate data set as shown in Table 4-3. 
Table 4-3 The average of correlation coefficients between a reference spectrum 
and a spectrum of interest before and after applying the PASS peak alignment 
(Instrument resolution 0.2%) 
Data sets Before alignment After alignment 
Ovarian data set 4-3-02 0.940 0.942 
Prostate data set 7-3-02 0.798 0.801 
 
 
4.3.3 The effect of peak alignment on the cancer classification  
The six peak alignment methods were applied to the lung cancer data set and the 
performance of cancer classification was evaluated in terms of the classification 
accuracy based on the AUC values.  The results are shown in Table 4-4 and Figure 
4-3.  From Table 4-4
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50.p <
, it can be seen that the number of significantly differently peaks 
( 0 ) remains relatively the same after the peak alignment, for the majority of 
the peak alignment methods (PABSD, PASS, PABS, PAFFT and PACS), but there 
was a huge increase (from 34 to 63) for the PAPM method. The classification 
performance of the RF models using six peak-aligned data sets and one data set 
without peak alignment are summarised using a bar-chart. 
Table 4-4 The number of peaks with p-values of Wilcoxon tests less than 0.05 
after applying different peak alignment methods to the lung cancer data set. 
Alignment 
methods None PABSD PASS PABS PAFFT  PAPM PACS 
Number of 
peaks  34 34 34 34 34 63 35 
 
Figure 4-3 summarises the AUC values of the models. The RF models trained using 
the data set aligned by PASS and PAFFT methods gave the highest AUC values 
(0.84) compared to the RF model trained using raw data set (0.82), representing a 2% 
improvement, which is not statistically significant (p-value = 0.48, McNemar test). 
The RF model trained using data set aligned by PAPM method gave the lowest AUC 
value (0.81), which becomes worse than the model trained using the raw data set. 
Overall, we can see that the performance of the RF models were increased after the 
spectra were aligned by PABSD, PASS, PABS, PAFFT and PACS, but not by 
PAPM. These results are consistent with what was found after these peak alignment 
methods were applied to the pooled non-cancer sample data set.  
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Figure 4-3 Summary of the classification performance of the RF models based 
on AUC. 
 
4.4 Discussion 
The performance of six peak alignment approaches has been examined and compared 
in terms of the reproducibility of the protein profiles and the AUC values of the 
classification models. All methods studied, apart from PAPM, led to a small 
improvement in cancer classification performance. The AUC values increased up to 
2% compared to without peak alignment, which is not significantly different with a 
p-value of 0.48 (McNemar test). All peak alignment methods, except PAPM, 
increased the correlation coefficient up to 4% compared to without peak alignment, 
but these increases are not statistically significant (p-value > 0.05). The peak 
alignment methods, apart from PAPM, also resulted in reductions of 11 to 12% for 
the median CV compared to without peak alignment. These reductions are 
statistically significant (p-value < 0.0001). However, the proposed peak alignment 
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methods with dynamic maximum sideway movement, PABSD and PASS, only made 
a small improvement in the reproducibility of MS data compared to PABS method, 
which is not a significant difference with p-value > 0.1. These analysis results 
suggest that PABSD and PASS methods with dynamic maximum sideway movement 
do not show superior performance compared to the existing SWA method PABS 
with fixed maximum sideway movement. This may be due to the fact that the data 
set used for these analyses were generated on one machine under a stable 
environment within a short period of time. It should be interesting to examine the 
effect of peak alignment on the improvement of the reproducibility of SELDI data, 
which are generated on circumstances when mass spectra are obtained from different 
machines or centres or within a long period of time. However, no data set generated 
on such circumstances can be found. We artificially introduced noise into some 
spectra in the existing pooled non-cancer data set. Suppose that 14 spectra (selected 
at random) were generated by centre 1, and the remaining 14 spectra were generated 
by centre 2. We kept the spectra generated by centre 1 unchanged, while added noise 
into the spectra generated by centre 2. For each spectrum generated in centre 2, 40 
segments were partitioned. At each segment, 50% of data points were shifted left by 
10 points, and 10 data points were inserted at the end of shifts. Table 4-5 shows the 
effect of peak alignment on the reproducibility of mass spectra in the simulated data 
set.  
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Table 4-5 CVs distribution and correlation coefficient under different peak 
alignment methods based on the pooled non-cancer data set.  
Alignment  
methods 
Median 
(CV) 
IQR 
(CV) 
CV % change 
compared to 
no alignment 
Correlation 
coefficient  
(CC) ±SD 
CC % 
change 
compared to 
no 
alignment 
No alignment 0.563 0.594 - 0.798±0.139 - 
PABSD 0.502 0.572 -10.8 0.956±0.011 28.0 
PASS 0.504 0.575 -10.5 0.958±0.010 28.4 
PABS 0.514 0.574 -8.7 0.956±0.011 28.0 
PAFFT 0.519 0.596 -7.8 0.958±0.010 28.4 
PAPM 0.642 0.721 14.0 0.747±0.011 -9.0 
PACS 0.504 0.582 -10.5 0.955±0.012 27.8 
 
Again, apart from PAPM, all the peak methods significantly reduce (p-value < 
0.0001) the median CV down to 0.502 compared to 0.563 without peak alignment, 
leading to a reduction of 11%. They also significantly increase the correlation 
coefficient up to 0.958 compared to 0.798 without peak alignment, leading to an 
increase of 28%. The proposed methods PABSD and PASS outperform PABS in 
terms of the median CV. The p-values of Wilcoxon tests are 0.041 for PABS versus 
PABSD, and 0.037 for PABS versus PASS, respectively. The analysis results from 
the simulation data set demonstrate the potential superior performance of the peak 
alignment methods with dynamic maximum sideway movement over that of the 
existing SWA method with fixed maximum sideway movement.  
 
4.5 Summary 
We have proposed two new peak alignment algorithms and evaluated the 
performance of the two algorithms and other four existing peak alignment methods. 
Five out of six peak alignment methods (including the newly proposed two 
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algorithms) significantly reduce the median CV by more than 10% compared to the 
results of the un-aligned mass spectra, while keeping the IQR in the same range. The 
five peak alignment methods also increase correlation coefficient by more than 3%. 
The two proposed peak alignment methods PABSD and PASS with dynamic 
maximum sideway movement do not show superior performance compared to the 
existing SWA method PABS with fixed maximum sideway movement for the data 
set that were generated on one machine under a stable environment within a short 
period of time. However, they do outperform PABS when a simulated data set that 
was assumed to be generated in different centres with artificially introduced noise 
was used. 
 
The effects of peak alignment on the classification accuracy have been evaluated by 
training RF models using the un-aligned and aligned mass spectra by the six peak 
alignment methods. The results show that five of the six RF models trained using 
data set aligned by the peak alignment methods improve the AUC values by up to 
2% compared to the RF model trained using raw data set, which are not statistically 
significant. The small improvement in cancer classification accuracy may be partly 
due to the fact that the relatively small number of mass spectra generated on one 
machine under a stable environment within a short period of time was used in this 
study. The effects of peak alignment methods on the performance of the 
classification models might not be detected. Further research is needed to assess the 
effects of peak alignment on biomarker discovery and cancer classification using 
large data sets obtained from different machines at different centres. 
 
 
5 NORMALITY ANALYSIS 
5.1 Introduction 
In order to evaluate whether it is valid to apply the parametric statistical tests (such 
as t-test) to identify proteomic biomarkers, we investigate the normality of SELDI 
protein profiles using skewness, kurtosis, Shapiro-Wilks test, Kolmogorov-Smirnov 
test, Cramér-von-Mises test, and Pearson  test. We propose a new normalisation 
method and compare it with the existing normalisation methods in the Ciphergen 
Biosystems Software and PROcess package by evaluating how normality of protein 
profiles is affected by the normalisation methods. We also explore the role of data 
transformation on the normality of SELDI protein profiles.  
2χ
 
It has been conjectured that the level of a gene expression and the pre-processing of 
the gene expression data in microarray are contributing factors to the lack of 
normality (Chen et al.,2005). In order to see if protein profiles exhibit similar 
behaviour, we examine the correlation between normality (as measured by the p-
values from the normality test statistics, such as Shapiro-Wilks statistic) and protein 
expression levels.  
 
The analysis results have shown that the newly proposed normalisation algorithm 
outperforms other existing methods. The rejection of the hypothesis of the normality 
of SELDI protein profiles by the goodness-of-fit tests implies that the SELDI mass 
spectra do not follow normal distributions. Therefore, it is unwise to employ the 
normal-theory based statistical methods to identify biomarkers from SELDI mass 
spectra. 
 
97
 
98
 
5.2 Materials and statistical methods 
5.2.1 Mass spectra 
In this chapter, we use the ovarian data set 4-3-02, described in Section 2.7.4, to 
investigate the distribution of SELDI data at each data point and each peak, and to 
assess the effect of normalisation methods and data transformation methods on the 
distribution of the SELDI proteomic data. The data points with mass less than 2kDa 
were excluded because data points within this mass range were likely affected by 
matrix. 
5.2.2 Intensity normalisation, transformation and normality tests 
There are two ways in which intensities can be normalised. One is to standardise 
intensities, aiming at correcting for systematic differences in the total amount of 
protein desorbed from the sample plate, and another is to create a more normally 
distributed variable, aiming at improving the normality of intensities. We call the 
former intensity normalisation, and the latter intensity transformation. 
5.2.2.1 Intensity normalisation 
In this section we describe the two existing normalisation methods, mean AUC and 
median AUC, and propose a new ion current normalisation method, called median of 
ion current (MIC). 
5.2.2.1.1 Mean AUC (TIC) 
The implementation of the mean AUC normalisation method used in Ciphergen 
ProteinChip Software 3.2 (Ciphergen Biosystems, UK) consists of five steps. It is 
summarised as follows. 
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1. Calculate the TIC, denoted by , is ni ,...,2,1= , where,  is the number of 
spectra to be normalized and i  is the index of a spectrum,  is the sum of 
intensities at all m/z values in the normalisation range for each spectrum. 
n
is
2. Calculate the average ion current by dividing the TIC by the number of m/z 
data points 
i
i
i n
s
a = ,  ni ,...,2,1=
3. Calculate the normalisation coefficient across all selected spectra, 
n
a
ameanC
n
i
i
i
∑
=== 1)(  
4. Calculate the normalisation factor for each spectrum by dividing the 
normalisation coefficient by the average ion current for each spectrum 
i
i a
CN =  
5. Scale each spectrum by multiplying intensities at each m/z data point by its 
normalisation factor. 
5.2.2.1.2 Median AUC 
The implementation of the median AUC normalisation method in the software 
package PROcess in BioConductor (Bioconductor,2007a) consists of four steps. It is 
summarised as follows. 
 
1. Calculate the sum of the intensities for each spectrum for a pre-specified m/z 
range, and denoted as , is ni ,...,2,1= , where, n  is the number of spectra to 
be normalized and  is the index of a spectrum i
),...,2,1( nismedianC i ==2. Calculate the normalisation coefficient  
i
i s
CN =3. Calculate the normalisation factor for each spectrum  
4. Scale each spectrum by multiplying the intensities values at each data point 
by its normalisation factor. 
5.2.2.1.3 MIC 
The MIC algorithm is proposed by adapting the mean AUC and median AUC 
methods. The difference between the mean AUC and the MIC is that the former 
calculates the average of TIC over all m/z values for each spectrum and takes the 
mean of the average of TICs across all spectra to be normalised as the normalisation 
coefficient while the latter calculates the median of the ion currents over all m/z 
values for each spectrum and takes the median of the medians of the ion currents 
across all spectra as the normalisation coefficient. The difference between the 
median AUC and the MIC is that the former calculates the sum of intensities over all 
m/z values for each spectrum and takes the median of the sums of intensities across 
all spectra as the normalisation coefficient while the latter calculates the median of 
the ion currents over all m/z values for each spectrum and takes the median of the 
medians of the ion currents across all spectra as the normalisation coefficient.  
 
For each spectrum selected for normalisation, the MIC method calculates the median 
intensity in a specified m/z range. It then calculates the median intensity, called 
normalisation coefficient, across all the spectra selected for normalisation. The 
algorithm then normalises each spectrum by scaling the intensities by its 
normalisation factor, which is equal to the normalisation coefficient divided by the 
median ion current. The implementation of the MIC algorithm is summarised as 
follows. 
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1. Calculate the MIC, denoted by , this is the median intensity from all m/z 
values in the normalisation range for each spectrum, 
imd
ni ,...,2,1= , where, n  is 
the number of spectra to be normalized and i  is the index of a spectrum. 
2. Calculate the normalisation coefficient across all selected spectra, 
),...,2,1( nimdmedianC i ==  
3. For each spectrum calculate the normalisation factor , by dividing the 
normalisation coefficient by the median ion current for this spectrum, 
obtaining 
iN
i
i md
CN =  
4. Scale each spectrum by multiplying intensities at each m/z data point by its 
normalisation factor. 
 
The MIC normalisation method and the two existing normalisation methods are used 
to normalise the spectra in the ovarian SELDI data. The performance of these 
normalisation methods is then compared. 
5.2.2.2 Intensity transformation  
Data transformations are the commonly used tools for improving the normality of 
data and for removing or reducing systematic bias in the data (Osborne,2002).  We 
study three types of transformation approaches to investigate the effect of 
transformation on the normality of SELDI data: the logarithmic transformation, the 
Box-Cox family transformation, and a variance stabilising transformation based on 
the arsinh function. The performance of these transformations is assessed by 
applying all transformation functions to the normalised and un-normalised protein 
profiles in the data set.   
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5.2.2.2.1 Box-Cox family transformation 
The Box-Cox family transformation is defined as follows.  
⎪⎪⎩
⎪⎪⎨
⎧
=
≠−
=
0),ln(
0,1
)(
λ
λλ
ifY
ifY
YT
λ
   (5.1) 
 
The parameter λ  in formula enables the function to mimic many standard 
transformations. For example, 5.0=λ  is equivalent to the square root 
transformation, and 2=λ  results in the squared transformation.  
5.2.2.2.2 Logarithmic transformation 
Logarithms to base10 have been used in a number of published studies to transform 
MS data prior to statistical analysis (Baggerly et al.,2003; Zhang et al.,2006). The 
logarithmic transformation to base e is a special case of Box-Cox ( 0=λ ) 
transformation. Changing the base of the logarithm has the effect of multiplying by a 
constant and so will not affect the normality test results. However, the study by 
Osborne (2002) investigated the effect of the base of logarithms on the efficacy of 
transformations and demonstrated that a lower base (base 2) logarithmic 
transformation served resolution of the data. Therefore, apart from using logarithmic 
transformations to bases e (Box-Cox ( 0=λ )) transformation, we investigate the 
effect of logarithmic transformations to bases 2 on the SELDI data in this thesis. To 
avoid numerical redundancies arising from taking logarithms of negative intensities, 
we added one plus the absolute value of the smallest negative intensity observed 
before taking logarithms.  The function box.cox in car package of R (Wu,2007) is 
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used to perform the Box-Cox transformation. The λ  values are studied in the range 
between -2 and 2 in steps of 0.5. 
5.2.2.2.3 Arsinh function transformation  
)2(log)1(
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The variant arsinh function with a form of log=)( 222 −++ xxxf  was 
used in analysing SELDI data (Beyer et al.,2006). For large intensities, this 
transformation becomes equivalent to the logarithmic transformations to bases 2 as 
. However, unlike the logarithmic transformations, it does 
not have a singularity at zero, and continues to be smooth in the range of small 
intensities. Furthermore, it stabilises the variance and is well-defined even for 
negative intensity values introduced into the data by baseline corrections (Beyer et 
al.,2006; Huber et al.,2002).   
0))(log)((lim 2 =−∞→ xxfx
5.2.2.3 Normality tests  
5.2.2.3.1 Gaussian (normal) distributions 
Gaussian (normal) distributions are a family of distributions that are characterised by 
a bell-shaped, symmetric curve, with values more abundant around the mean and 
progressively fewer observations towards the tail. This distribution is one of the most 
important probability density functions because many sample populations from 
random events tend to approximate to a normal distribution. The normal distribution 
is defined by two parameters: the mean μ and the standard deviation σ and has a 
density function as follows. 
2
2
2
)(
2
1 σ
μ
πσ
−−=
X
eY      (5.2) 
 
σ
μ−= XZA standard normal variate  has μ = 0 and σ2 =1, and its corresponding 
density function is given by  
2
2
2
1 XeY
−= π              (5.3) 
 
Figure 5-1A plot of this density function is shown in .  The shape of this curve can 
assist in determining whether or not a variable follows a normal distribution. The 
probability density function has notable properties, including (1) symmetry about 
mean μ, (2) the mode and median both equal to the mean μ, and (3) the inflection 
points14 of the curve occur one standard deviation away from the mean, that is σμ −  
and σμ +  (Dekking et al.,2007). 
 
                             Figure 5-1 A standardised normal distribution 
 
                                                 
14 An inflection point is a point on a curve at which the curvature changes sign. 
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XThe protein expression profile can be viewed as a random variable . Suppose that it 
has mean µ, and variance , and that this protein profile is observed across n 
spectra, then the variance is defined by 
2σ
n
X i∑ −= 22 )( μσ               (5.4) 
 
A distribution is symmetric if it looks the same to the left side and right side of the 
centre point (Dekking et al.,2007). One measure that can be used to see whether a 
distribution is symmetric is skewness. More precisely, skewness is a measure of the 
asymmetry of a distribution. The skewness of a distribution with a mean of μ  and a 
standard deviation of σ  is defined by 
3
3
)(
σ
μ
n
X
sk ip
∑ −=                (5.5) 
 
A value of skewness close to zero indicates that data are symmetrically distributed 
around the mean, otherwise it is skewed. A negative value of skewness indicates that 
data are skewed left, implying that the left tail is long relative to the right tail. A 
positive value of skewness indicates that data are skewed right, implying that the 
right tail is long relative to the left tail (Dekking et al.,2007) as shown in Figure 5-2.  
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             Figure 5-2 Positive skew and negative sknew. 
 
Kurtosis is a measure that can be used to see whether the data are peaked or flat 
relative to a normal distribution. A data set with high kurtosis tends to have a distinct 
peak near the mean, declines rather rapidly, and has heavy tails. By contrast, a data 
set with low kurtosis tends to have a flat top, rather than a sharp peak near the mean 
(Dekking et al.,2007). The kurtosis of a distribution with a mean of μ  and a standard 
deviation of σ  is defined by 
3
)(
4
4
−−= ∑ σ
μX
k i            (5.6) 
n
 
The “minus 3” at the end of kurtosis formula is a correction factor to make the 
kurtosis of the normal distribution equal to zero (Dekking et al.,2007; Joanes & 
Gill,1998). A value of kurtosis that is less than zero indicates a platykurtic (flat) 
distribution. A value of kurtosis that is great than zero indicates a leptokurtic 
(peaked) distribution. If the value of kurtosis is close to zero then the intensity 
distribution is normal or mesokurtic.   
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The population mean, standard deviation, skewness and kurtosis are usually 
unknown. They can be estimated by sample mean, sample standard deviation, sample 
skewness, and sample kurtosis. The sample mean, standard deviation, skewness, and 
kurtosis of the proteomic intensities are defined as follows. 
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The parametric methods, such as the t-test, have been used to identify significant 
peaks from SELDI mass spectra (Levner,2005; Pasinetti,2006; Wu et al.,2003). 
These tests make an assumption that SELDI data follows a normal distribution. To 
investigate the validity of these results, we carried out a large-scale SELDI normality 
study using the Shapiro-Wilks, Kolmogorov-Smirnov, Cramér-von-Mises, and 
Pearson  tests.  2χ
5.2.2.3.2 Shapiro-Wilks test 
The Shapiro-Wilks test is a procedure for testing that a random sample comes from a 
normal distribution (Bai & Cheng,2003; Royston,1993; Royston,1995; Shapiro et 
al.,1965). Suppose that nIII <<< ...21  is a vector of ordered random observations 
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to be tested for normality, clearly if  are a normal sample, then  can be 
expressed by 
}{ jI jI
jj xI .σμ += , where, μ and σ  are unknown mean and standard 
deviation of a normal distribution, and x1 x2 nx...≤ ≤  is an ordered random sample 
of size  from a normal distribution with mean 0 and variance 1. The Shapiro-Wilks 
W  test statistic is defined by  
n
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where,  denotes the vector of the expected values of the standard 
normal ordered statistics 
(' mm =
nxx ...2 ≤≤ ),cov()( jiij xxvV == and that  denotes the 
covariance matrix (Royston,1993; Royston,1995; Shapiro et al.,1965).  
 
A small value of W indicates a departure from normality and is the evidence of 
rejection of the null hypothesis (Shapiro et al.,1965). 
5.2.2.3.3 Kolmogorov-Smirnov test 
The Kolmogorov-Smirnov test provides a means of testing whether a set of 
observations are from a completely specified distribution (Birnbaum,1952; Dallal & 
Wilkison,1986; Lilliefors,1967; Massey,1951). Given a sample of n observations, the 
)()( * IFISMaxD nI −=
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Kolmogorov-Smirnov statistic is defined by , where,  
is the sample cumulative distribution function,  is the expected cumulative 
normal distribution with mean 
)(ISn
)(* IF
I=μ (the sample mean), and standard deviation 
s=σ  (the sample standard deviation) (Dallal & Wilkison,1986; Lilliefors,1967; 
Massey,1951).  
 
I  be a random variable with the continuous distribution function defined by Let 
InIII <<< ...21)(Pr iIob)(iSn ≤= , and  be a sample size of  for n ,  can 
then be defined by the following step function (Birnbaum,1952; Juergen,2007a). 
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)(* iF  can be expressed by )/]([)()(* sIIjpiF j −Φ== , whereΦ is the cumulative 
distribution function of the standard normal distribution. The Kolmogorov-Smirnov 
statistic  can then be re-expressed by  D
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 If the p-value of the Kolmogorov-Smirnov test is greater than 0.1, then it is 
computed from the following modified statistic as the test is only reliable when the 
p-value is smaller than 0.1 (Dallal & Wilkison,1986; Juergen,2007a). 
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5.2.2.3.4 Cramér-von-Mises test 
The Cramér-von-Mises test is used to judge the goodness of fit of one probability 
distribution compared to another probability distribution. The Cramér-von-Mises 
statistic is defined by 
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where,  is the sample cumulative distribution function, )(Pr)( iIobiSn ≤=
)/]([)()(* sIIjpiF j −Φ==  is the expected cumulative normal distribution with 
mean I=μ (the sample mean), and standard deviation s=σ  (the sample standard 
deviation),  is the cumulative distribution function of the standard normal 
distribution (Schmid & Trede,1996; Xiao et al.,2006).  
Φ
 
If the value of the Cramér-von-Mises statistic  is larger than the tabulated value 
we can reject the hypothesis that the data come from a normal distribution (Xiao et 
al.,2006).  
2w
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5.2.2.3.5 Pearson  test 2χ
 
111
2χ
k
k
O b E
b
** lu
*
u l
22
The Pearson  test is used to evaluate whether a sample comes from a distribution 
of a given form, by counting the number of observations falling into specified cells 
(Chernoff & Lehmann,1954; Stephens,1986). For the chi-square goodness-of-fit 
computation, the observed data are divided into  bins and the test statistic is 
defined as follows. 
b
b
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1
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where,  is the observed frequency for bin , and  is the expected frequency for 
bin  and is defined by  
b b
   (5.18) ))()(( bbb IFIFnE −=
 
where,  is the expected cumulative normal distribution, n  is the sample size, 
 is the upper limit, and  is the lower limit for bin b .  
)(IF
bI bI
 
The null hypothesis of normality is rejected if , where, ),( ck−> αχχ α  is a 
significant level, k  is the number of classes, and  is the number of estimated 
parameters plus 1 (Chernoff & Lehmann,1954; Juergen,2007b). In the case of 
normality test, c  as there are two parameters (the mean and the standard 
deviation) need to be estimated.  
c
3=
 
We applied the four statistical tests to both the normalised and un-normalised ovarian 
data sets to investigate the normality of the proteomic data.  Some published studies 
also used peaks rather than data points to identify differentially expressed proteins 
and classify disease status (Bhanot et al.,2006; Yasui et al.,2003).  Therefore, the 
normality tests were applied to both peaks and data points in this chapter.  We 
extracted peaks using the BioConductor software package (PROcess) in R 
(Bioconductor,2007a). To make the results comparable, the same parameter settings 
were applied to both normalised and un-normalised spectra in peak selections. The 
lower bound for signal/noise ratio was set to 2, the minimum intensity 1 and the total 
area under the curve 0.01.  The ovarian data set 4-3-02 contains samples of SELDI 
protein profiles generated by each of 10361 m/z values.  A total of 160 peaks were 
detected by the PROcess peak picking program.  
 
All the statistical tests were implemented in R statistical software (CRAN,2007) 
through the packages nortest and stats. A p-value significance threshold of 0.05 was 
used in all tests. 
5.2.2.4 Multiple goodness-of-fit tests 
These normality tests were actually performed at hundreds or thousands of peaks or 
data points, which involve multiple tests. In order to make a decision on whether 
SELDI data follows a normal distribution, we need to assess the goodness-of-fit 
testing. The conventional multiple testing adjustment methods, such as FWER and 
FDR, cannot be used for this purpose because they were designed for controlling 
FWER and FDR. The study by Chen et al. (2005) developed a special procedure of 
multiple testing adjustment for microarray data. The testing procedure involving m  
genes can be thought of as a sequence of  random trials with stochastically 
dependent outcomes (Chen et al.,2005).  Let 
m
p  be the probability of successful 
rejection of the null hypothesis in a given trial and let X  be the number of successes 
in  trials, and let m α  be the significance level. Under the complete null hypothesis, 
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αmthe expected number of rejections is equal to . The proposed resampling 
procedure is to test the hypothesis XEH
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αm(:0 =)  versus the alternative 
hypothesis 15αmXEH >)(:1 . It used the delete-d-jackknife  subsampling to estimate 
the sampling distribution of the shift test statistic T X )(XE= − . The cumulative 
distribution function of the statistic )(xH T  was estimated by 
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Iwhere,  was the number of subsamples, N  was the indicator function, having a 
value of 1 if xTT
jsr
−,
d
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r ≤)( , and 0 otherwise.  was the collection of the 
subsamples of size , which was drawn without replacement from  
, where,  was a subset of  with size ,  was the 
complement of ,  was an integer depending on n , 
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The jackknife estimator  was evaluated at the observed statistic value 
dnr −=
)(ˆ xH JACK
Xx αm= −  under the complete null hypothesis to produce an overall p-value 
associated with multiple tests (Chen et al.,2005). 
 
In order to adjust for multiplicity of the tests, we adapted the method proposed by 
Chen et al. (2005) to evaluate the global null hypothesis of a normal distribution for 
SELDI data. Let 05.0=α  be the significance level. Under the complete null 
hypothesis, the expected number of rejections is equal to 518 (10361*0.05) for data 
points and 8 (160*0.05) for peaks. The proposed resampling procedure is to test the 
                                                 
15 Instead of leaving out one observation at a time, we leave out d observations. Therefore, the size of 
a delete-d jackknife sample is (n - d), and there are jackknife samples. dnC
hypothesis  versus the alternative hypothesis  for 
data points, and  versus the alternative hypothesis  for 
peaks.  
518)(:0 =XEH
)(:0 =XEH
518)(:1 >XEH
8)(:1 >XEH8
 
We evaluate the utility of the four goodness-of-fit test statistics in describing the 
normality of SELDI data with or without pre-processing using various 
transformation and normalisation methods.  
5.2.2.5 Distortion of expression profiles from normality 
Apart from formal quantitative analysis of the normality of SELDI protein profiles 
using the statistical tests, visual inspection was also used to investigate the extent of 
the deviation of the protein profiles from normality. We used frequency histograms 
and Q-Q plots as aids to visual investigation of the normality of the protein profiles. 
Both graphs provide simple and effective visualisation of the data distribution and of 
any deviation from normality.  For a perfect normal distribution, a Q-Q plot would 
show data points in a straight line near the centre with a positive gradient and a 
frequency histogram would show a bell-shaped frequency distribution which is 
symmetrical about the mean. The graphics and stats package in R are used to 
perform this analysis. 
5.2.2.6 Effect of transformation on identification of differentially expressed 
protein profiles 
Differentially expressed proteins can be identified by comparing the intensity for 
each protein using different statistical methods. These proteins could be potential 
biomarkers.  The RF algorithm provides a routine for identifying the biomarkers (as 
described in Section 6.2.2.2.1). We assessed the effect of transformations listed in the 
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previous section on the identification of biomarkers using this routine. Venn 
diagrams were used to explore the protein profiles detected to be differentially 
expressed for both the transformed and the un-transformed data 
5.2.2.7 Effect of transformation on sample clustering 
For many high-throughput assays the technical variance in data tends to rise with the 
measurement level (e.g. the intensity levels in SELDI) (Purohit et al.,2004). For the 
same percentage of error, a bigger value of the intensity means a bigger absolute 
error. The logarithmic transformation of the measured values is a method commonly 
used to convert multiplicative error into additive error and therefore stabilises the 
variance of the data (Thygesen & Zwinderman,2004). The question raised here is 
whether data transformation improves the normality of the data and whether it also 
leads to improvement in the performance of sample clustering. The principal 
component analysis (PCA) and RF were applied to the ovarian cancer data set to 
examine whether the logarithmic transformation improve the sample separation 
performance.  
 
The PCA method constructs new variables known as the principle components that 
are linear combinations of the proteomic profiles. A plot of the projection of the 
sample positions along the first and second principals (also known as the scores plot) 
shows the relationship between the samples. Samples clustered together on the plot 
indicate similar protein profiles. RF classifier is a collection of many decision trees 
based on distribution free statistics and the output of RF is the majority votes of the 
trees, which have been described in Section 4.2.3.2.  The function princomp of MASS 
package and randomForest from R (Wu,2007) are used to perform these analyses. 
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5.2.2.8 Correlation between protein expression level and normality  
In order to investigate whether the level of a protein profile is related to their 
normality, a scatter plot is generated to show the relationship between p-values by 
the normality tests and the median values of protein intensity across all samples for 
the mean AUC normalised SELDI data set. 
 
5.3 Results of normalisation, transformation and normality 
tests 
5.3.1 Normality tests   
The outcomes of the four statistical tests for normality using the un-normalised and 
normalised data sets under different transformation functions are summarised in 
Table 5-1, Table 5-2, Table 5-3, Table 5-4, Table 5-5, Table 5-6, Table 5-7, and 
Table 5-8, respectively. Table 5-1, Table 5-2, Table 5-3, and Table 5-4 summarise 
the percentage of rejections of the null hypothesis of normality for the 160 peaks 
detected in the ovarian cancer data set by PROcess peak detection software and 
Table 5-5, Table 5-6, Table 5-7, and Table 5-8 show the results for the 10361 data 
points. For all data transformations considered, a large proportion of protein profiles 
were not normally distributed, that is, had p-value less than 0.05. A large number of 
rejections were detected in the cancer group for both the normalised and un-
normalised data sets under various data transformations. The asterisk in Table 5-1, 
Table 5-2, Table 5-3, Table 5-4, Table 5-5, Table 5-6, Table 5-7, and Table 5-8 show 
transformations and tests that resulted in the lowest percentage of rejections of the 
null hypothesis of normality in the control and the cancer groups.   
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Table 5-1 shows that among the four normality test results, logarithmic 
transformations give the best improvement of normality for the cancer protein 
profiles, whereas, the Box-Cox transformation (λ=-0.5) gives the best improvement 
for the protein profiles from the control group.  
 
Table 5-2 shows that when the mean AUC normalisation method is used, the 
logarithmic transformations, including log to base 2 and natural logarithm (Box-Cox 
(λ=0)), in general give the best improvement of normality for the control group, 
whereas, Box-Cox (λ=-1, λ=-2) transformations give the best improvement for the 
cancer protein profiles under this normalisation. When the data is normalised by the 
median AUC, it turns out that the logarithmic transformations give the best 
improvement of normality for the protein profiles in the control group, whereas, 
Box-Cox (λ=-1, λ=-2) transformations appear to improve the normality for the 
cancer profiles as shown in Table 5-3.  
 
Table 5-4, which displays the results of the normality analysis for the MIC 
normalised data, shows that the logarithmic transformations give the best 
improvement of normality of protein profiles for both the control and the cancer 
groups. Table 5-5 shows that logarithmic and arsinh transformations give the best 
improvement of normality for the cancer mass spectra and Box-Cox (λ=-0.5) gives 
the best improvement for the control mass spectra. Table 5-6  shows that logarithmic 
and arsinh transformations give the best improvement of normality for the control 
mass spectra and non-transformation gives the best improvement for cancer mass 
spectra.  Table 5-7 shows that logarithmic transformations give the best improvement 
of normality for the control mass spectra and non-transformation gives the best 
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improvement for the cancer mass spectra. Table 5-8 shows that logarithmic 
transformations give the best improvement of normality for the both control and 
cancer mass spectra. In summary, these results indicate that the logarithmic 
transformations give the best improvement of normality of the SELDI data. Table 
5-9 summarised the percentage of rejections of the null hypothesis of the normal 
distribution under the logarithmic transformations with and without normalisation 
based on the data points and peaks. 
 
Comparing the average number of rejections by the four normality tests between the 
data point data set and peak data set, we can see that peak selection can improve the 
normality of SELDI protein profiles generated from the control samples, but this is 
not true for cancer samples. A look at the numbers of rejections across the four 
normality tests for each of the normalisation methods (Table 5-9) indicates that 
normalisation has some effect on the normality of protein profiles. The MIC 
normalisation method appears to results in lower rejection rates across statistical tests 
and tissue types (cancer and normal controls) compared to other normalisation 
methods. However, the generality of this statement needs to be verified by large scale 
studies. On average, rejection rates appear to be higher for the cancer samples 
compared to the normal control samples. The average numbers of rejections by the 
four normality tests (from peaks data set) are 70% for the un-normalised data set, 
90% for the mean AUC normalised data set, 90% for the median AUC normalised 
data set, and 69% for the MIC normalised data set. These figures are much lower for 
the normal control samples. 
 
In summary, the normalisation methods in PROcess (the median AUC) and 
Ciphergen ProteinChip Software (the mean AUC) tend to give similar results. The 
MIC normalisation followed by the logarithmic transformation appears to give lower 
number of rejections and hence, the best performance in improving the normality of 
the SELDI protein profiles.  
5.3.2 Distortion of SELDI expression profiles from normality 
Table 5-9 shows that the rates of normality rejections vary from 55% to 95% by the 
Shapiro-Wilks test, from 38% to 93% by the Cramér-von-Mises test, from 30% to 
87% by the Kolmogorov-Smirnov test and from 25% to 86% by the Pearson test.  
Thus for this data set, the Shapiro-wilks normality test appears to be the most 
conservative, while the Pearson  normality test tends to be liberal.  These are 
summaries of multiple normality tests on the 10361 data points and 160 proteins 
detected for the ovarian cancer data set, and we need to adjust for this multiplicity in 
order to make inference about their significance. Application of the global multiple 
testing procedure (Chen et al.,2005) to these test results, gave very small p-values (p-
value ) for each of them, indicating the overall rejection of the normal 
distribution of the SELDI protein profiles. 
2χ
2χ
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Table 5-10 shows deviation from normality, described by their skewness and kurtosis 
statistics, of six protein profiles with small p-values obtained by the Shapiro-Wilks 
tests on the control and the cancer samples, respectively.  For all the peaks listed in 
that table, the values of the skewness statistics show greater deviations from 0 before 
logarithmic transformation, indicating that the distributions are skewed to the left 
with long right tails. The values of kurtosis for these peaks are also significantly 
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greater than 0, indicating the distributions are leptokurtic, with low spread out peaks 
with data concentred in the tails.  However, the values of skewness and kurtosis are 
much reduced toward zero after logarithmic transformation. To visualise these 
results, we constructed frequency histograms and the Q-Q normal plots. The 
frequency histograms (Figure 5-3 (a)) confirm that the selected proteins are 
characterised by having right-skewed and heavy-tailed distributions. The Q-Q plots 
(Figure 5-3 (b)) show that some data points are far away from a straight line near the 
centre, suggesting that positive skew was evident in the data distribution before and 
after logarithmic transformation. The frequency histograms (Figure 5-3 (c)) and Q-Q 
plots (Figure 5-3 (d)) show that there is improvement in normality of the protein 
profiles after logarithmic transformation. The Shapiro-Wilks test still show evidence 
of lack normality for these peaks (p-value < 0.05), but with decreased significance.  
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Table 5-1 The percentage of rejections of the null hypothesis for 160 peaks (un-
normalised data).   
Group Methods Shapiro-Wilks (%) 
Cramér-von-Mises 
(%) 
Kolmogorov-
Smirnov 
(%) 
Pearson χ2 
(%) 
Raw data 100 99 97 98 
Log2 56 44 33 25 
Arsinh 62 51 41 29 
Box-Cox(-2) 97 92 86 89 
Box-Cox(-1) 59 50 37 34 
Box-Cox(-0.5)* 34* 23* 18* 14* 
Box-Cox(0) 56 44 33 25 
Box-Cox(0.5) 97 92 86 71 
Box-Cox(1) 100 99 97 98 
Control 
Box-Cox(2) 100 80 100 100 
Raw data 93 88 89 85 
Log2* 86* 69* 67* 57* 
Arsinh 87 70 67 59 
Box-Cox(-2) 82 69 69 65 
Box-Cox(-1) 82 77 69 58 
Box-Cox(-0.5) 86 80 67 60 
Box-Cox(0)* 86* 69* 67* 57* 
Box-Cox(0.5) 85 80 73 80 
Box-Cox(1) 93 88 89 85 
Cancer 
Box-Cox(2) 99 88 99 99 
Asterisk indicates the lowest percentage of rejection of the null hypothesis in the control group and the cancer 
group under different transformations. 
Note: the test results for raw data are equivalent to those for the Box-Cox (λ=1) transformed data. 
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Table 5-2 The percentage of rejections of the null hypothesis for 160 peaks 
(mean AUC normalised data).    
Group Methods Shapiro-Wilks (%) 
Cramér-von-Mises 
(%) 
Kolmogorov-
Smirnov 
(%) 
Pearson χ2 
(%) 
Raw data 96 81 73 75 
Log2* 56* 39* 32* 29* 
Arsinh 57 40 32 29 
Box-Cox(-2) 95 88 85 85 
Box-Cox(-1) 72 69 65 52 
Box-Cox(-0.5) 52 50 49 32 
Box-Cox(0)* 56* 39* 32* 29* 
Box-Cox(0.5) 75 54 39 45 
Box-Cox(1) 96 81 73 75 
Control 
Box-Cox(2) 100 86 98 96 
Raw data 96 92 91 91 
Log2 95 93 87 86 
Arsinh 95 94 87 86 
Box-Cox(-2)* 91* 84* 82* 80* 
Box-Cox(-1)* 89* 83* 84* 80* 
Box-Cox(-0.5) 95 88 85 86 
Box-Cox(0) 95 93 87 86 
Box-Cox(0.5) 95 94 92 89 
Box-Cox(1) 96 92 91 91 
Cancer 
Box-Cox(2) 98 84 94 91 
Asterisk indicates the lowest percentage of rejection of the null hypothesis in the control group and the cancer 
group under different transformations. 
Note: the test results for raw data are equivalent to those for the Box-Cox (λ=1) transformed data. 
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Table 5-3 The percentage of rejections of the null hypothesis for 160 peaks 
(median AUC normalised data).    
Group Methods Shapiro-Wilks (%) 
Cramér-von-Mises 
(%) 
Kolmogorov-
Smirnov 
(%) 
Pearson χ2 
(%) 
Raw data 95 80 72 73 
Log2* 55* 38* 30* 28* 
Arsinh 55 39 30 30 
Box-Cox(-2) 94 88 84 82 
Box-Cox(-1) 70 70 66 51 
Box-Cox(-0.5) 51 50 45 30 
Box-Cox(0)* 55* 38* 30* 28* 
Box-Cox(0.5) 74 51 39 45 
Box-Cox(1) 95 80 72 73 
Control 
Box-Cox(2) 100 87 98 95 
Raw data 95 91 91 90 
Log2 95 93 86 85 
Arsinh 95 94 87 85 
Box-Cox(-2)* 91* 82* 82* 79* 
Box-Cox(-1)* 89* 83* 86* 80* 
Box-Cox(-0.5) 95 87 84 85 
Box-Cox(0) 95 93 86 85 
Box-Cox(0.5) 95 94 91 89 
Box-Cox(1) 95 91 91 90 
Cancer 
Box-Cox(2) 98 84 93 90 
Asterisk indicates the lowest percentage of rejection of the null hypothesis in the control group and the cancer 
group under different transformations. 
Note: the test results for raw data are equivalent to those for the Box-Cox (λ=1) transformed data. 
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Table 5-4 The percentage of rejections of the null hypothesis for 160 peaks 
(MIC normalised data).    
Group Methods Shapiro-Wilks (%) 
Cramér-von-Mises 
(%) 
Kolmogorov-
Smirnov 
(%) 
Pearson χ2 
(%) 
Raw data 100 90 80 81 
Log2* 55* 41* 39* 31* 
Arsinh 56 41 39 31 
Box-Cox(-2) 94 86 88 87 
Box-Cox(-1) 78 80 76 59 
Box-Cox(-0.5) 58 52 44 43 
Box-Cox(0)* 55* 41* 39* 31* 
Box-Cox(0.5) 77 55 50 50 
Box-Cox(1) 100 90 80 81 
Control 
Box-Cox(2) 100 86 99 99 
Raw data 98 86 86 86 
Log2* 83* 65* 58* 70* 
Arsinh 83 66 58 70 
Box-Cox(-2) 78 73 69 66 
Box-Cox(-1) 84 77 64 54 
Box-Cox(-0.5) 81 68 55 58 
Box-Cox(0)* 83* 65* 58* 70* 
Box-Cox(0.5) 83 81 68 76 
Box-Cox(1) 98 86 86 86 
Cancer 
Box-Cox(2) 100 88 99 99 
Asterisk indicates the lowest percentage of rejection of the null hypothesis in the control group and the cancer 
group under different transformations. 
Note: the test results for raw data are equivalent to those for the Box-Cox (λ=1) transformed data.  
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Table 5-5 The percentage of rejections of the null hypothesis for 10361 data 
points (un-normalised data).   
Group Methods Shapiro-Wilks (%) 
Cramér-von-Mises 
(%) 
Kolmogorov-
Smirnov 
(%) 
Pearson χ2 
(%) 
Raw data 96 89 92 87 
Log2 80 74 70 63 
Arsinh 81 74 71 64 
Box-Cox(-2) 86 79 76 69 
Box-Cox(-1) 78 71 66 59 
Box-Cox(-0.5)* 73* 66* 64* 58* 
Box-Cox(0) 80 74 70 63 
Box-Cox(0.5) 93 86 85 76 
Box-Cox(1) 96 89 92 87 
Control 
Box-Cox(2) 97 77 95 92 
Raw data 86 79 76 67 
Log2* 76* 68* 64* 55* 
Arsinh 76 69 64 56 
Box-Cox(-2) 79 68 67 61 
Box-Cox(-1) 80 74 68 61 
Box-Cox(-0.5) 80 75 68 59 
Box-Cox(0)* 76* 68* 64* 55* 
Box-Cox(0.5) 74 69 66 59 
Box-Cox(1) 86 79 76 67 
Cancer 
Box-Cox(2) 93 87 90 86 
Asterisk indicates the lowest percentage of rejection of the null hypothesis in the control group and the cancer 
group under different transformations. 
Note: the test results for raw data are equivalent to those for the Box-Cox (λ=1) transformed data.   
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Table 5-6 The percentage of rejections of the null hypothesis for 10361 data 
points (mean AUC normalised data).   
Group Methods Shapiro-Wilks (%) 
Cramér-von-Mises 
(%) 
Kolmogorov-
Smirnov 
(%) 
Pearson χ2 
(%) 
Raw data 88 76 79 72 
Log2* 80* 70* 70* 63* 
Arsinh* 80* 70* 70* 63* 
Box-Cox(-2) 87 81 80 71 
Box-Cox(-1) 85 77 76 64 
Box-Cox(-0.5) 82 72 71 62 
Box-Cox(0) 80 70 70 63 
Box-Cox(0.5) 83 72 73 67 
Box-Cox(1) 88 76 79 72 
Control 
Box-Cox(2) 97 84 92 84 
Raw data* 89* 85* 86* 78* 
Log2 92 89 85 77 
Arsinh 92 89 85 77 
Box-Cox(-2) 94 91 89 81 
Box-Cox(-1) 93 90 87 79 
Box-Cox(-0.5) 92 89 86 78 
Box-Cox(0) 92 89 85 77 
Box-Cox(0.5) 91 86 85 77 
Box-Cox(1) 89 85 86 78 
Cancer 
Box-Cox(2) 92 86 88 81 
Asterisk indicates the lowest percentage of rejection of the null hypothesis in the control group and the cancer 
group under different transformations. 
Note: the test results for raw data are equivalent to those for the Box-Cox (λ=1) transformed data.   
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Table 5-7 The percentage of rejections of the null hypothesis for 10361 data 
points (median AUC normalised data).   
Group Methods Shapiro-Wilks (%) 
Cramér-von-Mises 
(%) 
Kolmogorov-
Smirnov 
(%) 
Pearson χ2 
(%) 
Raw data 88 76 79 72 
Log2* 80* 70* 70* 63* 
Arsinh 80 70 70 64 
Box-Cox(-2) 87 81 80 71 
Box-Cox(-1) 85 77 76 64 
Box-Cox(-0.5) 82 72 71 62 
Box-Cox(0)* 80* 70* 70* 63* 
Box-Cox(0.5) 83 72 73 67 
Box-Cox(1) 88 76 79 72 
Control 
Box-Cox(2) 97 84 92 84 
Raw data* 89* 85* 86* 78* 
Log2 92 89 85 77 
Arsinh 92 89 85 77 
Box-Cox(-2) 94 91 89 81 
Box-Cox(-1) 93 90 87 79 
Box-Cox(-0.5) 92 89 86 78 
Box-Cox(0) 92 89 85 77 
Box-Cox(0.5) 90 86 85 77 
Box-Cox(1) 89 85 86 78 
Cancer 
Box-Cox(2) 92 86 88 81 
Asterisk indicates the lowest percentage of rejection of the null hypothesis in the control group and the cancer 
group under different transformations. 
Note: the test results for raw data are equivalent to those for the Box-Cox (λ=1) transformed data.  
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Table 5-8 The percentage of rejections of the null hypothesis for 10361 data 
points (MIC normalised data).   
Group Methods Shapiro-Wilks (%) 
Cramér-von-Mises 
(%) 
Kolmogorov-
Smirnov 
(%) 
Pearson χ2 
(%) 
Raw 96 92 87 76 
Log2* 79* 72* 67* 57* 
Arsinh 79 72 67 58 
Box-Cox(-2) 85 80 75 64 
Box-Cox(-1) 83 77 70 59 
Box-Cox(-0.5) 79 74 67 56 
Box-Cox(0)* 79* 72* 67* 57* 
Box-Cox(0.5) 90 83 76 66 
Box-Cox(1) 96 92 87 76 
Control 
Box-Cox(2) 97 93 93 84 
Raw 88 76 70 63 
Log2* 76* 68* 65* 58* 
Arsinh 76 68 65 58 
Box-Cox(-2) 84 77 72 64 
Box-Cox(-1) 84 78 73 63 
Box-Cox(-0.5) 83 75 70 60 
Box-Cox(0)* 76* 68* 65* 58* 
Box-Cox(0.5) 76 69 66 59 
Box-Cox(1) 88 76 70 63 
Cancer 
Box-Cox(2) 93 86 86 79 
Asterisk indicates the lowest percentage of rejection of the null hypothesis in the control group and the cancer 
group under different transformations. 
Note: the test results for raw data are equivalent to those for the Box-Cox (λ=1) transformed data.   
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Table 5-9 Summarisation of the percentage of rejection of the null hypothesis of 
the normal distribution under the logarithmic transformation with and without 
normalisation based on the data points and peaks data sets  
Data 
set 
Group Methods Shapiro-
Wilks 
(%) 
Cramér-von-
Mises  
(%) 
Kolmogorov-
Smirnov 
(%) 
Pearson 
χ2 
(%) 
Avg. 
(%) 
Un-normalised  
 56 44 33 25 40 
Mean AUC 
normalised* 56* 39* 32* 29* 39 
Median AUC 
normalised* 55* 38* 30* 28* 38 
Control 
MIC  
normalised* 55* 41* 39* 31* 42 
Un-normalised*  
 86* 69* 67* 57* 70 
Mean AUC 
normalised 95 93 87 86 90 
Median AUC 
normalised 95 93 87 86 90 
Peaks 
Cancer 
MIC 
normalised* 83* 65* 58* 70* 69 
Un-normalised  
 80 74 70 63 72 
Mean AUC 
normalised* 80* 70* 70* 63* 71 
Median AUC 
normalised* 80* 70* 70* 63* 71 
Control 
MIC 
normalised* 79* 72* 67* 57* 69 
Un-normalised* 
 76* 68* 64* 55* 66 
Mean AUC 
normalised 92 89 85 77 86 
Median AUC 
normalised 92 89 85 77 86 
Points 
Cancer 
MIC 
normalised* 76* 68* 65* 58* 67 
Asterisks indicate that of different transformation methods the logarithmic transformation methods 
achieve the lowest percentage of rejections. 
Avg stands for average. 
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Table 5-10 The skewness and kurtosis of peaks with small p-values before 
logarithmic transformation (Shapiro-Wilks test) 
LOG Peaks (m/z) M2234 M2231 M2050 M2237 M2185 M2043 
P-value 
 1.76E-16 4.53E-16 8.03E-16 8.80E-16 1.62E-14 3.16E-14 
Skewness 
 4.2 4.0 4.7 5.3 3.5 2.8 Before 
Kurtosis 
 20.6 19.0 30.2 38.4 16.5 8.1 
P-value 
 6.75E-10 2.57E-9 3.22E-7 2.54E-7 1.46E-8 8.54E-6 
Skewness 
 2.0 1.9 1.6 1.6 1.2 1.1 
Control 
After 
Kurtosis 
 5.7 4.8 4.3 5.4 3.5 0.8 
 Peaks (m/z) M2183 M2114 M2050 M2175 M2185 M3298 
P-value 
 1.34E-16 1.81E-16 5.05E-16 5.86E-16 1.03E-15 1.12E-15 
Skewness 
 4.4 4.0 4.6 4.4 4.7 3.6 Before 
Kurtosis 
 22.7 18.4 27.2 23.4 28.9 13.9 
P-value 
 2.46E-14 1.90E-13 4.17E-11 5.21E-9 1.1E-12 1.09E-11 
Skewness 
 3.5 3.0 2.5 3.3 3.3 2.4 
Cancer 
After 
Kurtosis 
 15.0 10.4 8.4 14.6 15.5 6.6 
 
5.3.3 Effect of transformation on identification of differentially 
expressed protein profiles 
The Venn diagrams in Figure 5-4 show the relationship between the significant 
protein profiles identified after logarithmic transformation to base 2 and those 
identified before the transformation. The Venn diagram in the right panel of Figure 
5-4 (a) shows a huge overlap (11 out of 12 proteins) between the top 12 significant 
protein profiles identified with and without logarithmic transformation. The left 
panel of Figure 5-4 (a) shows the scatter plots of two sets of significant protein 
profiles identified using the data sets with and without logarithmic transformation. 
Each set of significant protein profiles are ranked by the p-values of Wilcoxon tests. 
The lack of linear relationship between the two sets of significant protein profiles 
identified using the data sets with and without logarithmic transformation suggests 
that transformation affects the discriminatory power of the protein profiles.  
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(a) Frequency histograms before logarithmic transformation 
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(b) Q-Q plots before logarithmic transformation 
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(c) Frequency histograms after logarithmic transformation 
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(d) Q-Q plots after logarithmic transformation 
 
Figure 5-3 Frequency histograms and Q-Q plots of proteins with small p-values 
in control group before and after logarithmic transformation (MIC 
normalised). (a) Frequency histograms before logarithmic transformation. (b) 
Q-Q plots before logarithmic transformation. (c) Frequency histograms after 
logarithmic transformation. (d) Q-Q plots after logarithmic transformation.  
 
The right panel of Figure 5-4 (b) also shows a large overlap (22 out of 25 proteins) 
between the top 25 significant proteins identified before and after logarithmic 
transformation. And again we see that there is no linear relationship between the two 
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sets of significant protein profiles identified using the data sets with and without 
logarithmic transformation (the left panel of Figure 5-4 (b)). The right panel of 
Figure 5-4 (c) shows a huge overlap of 45 out of the top 50 significant proteins 
identified with and without logarithmic transformation (or an overlap of 90%). The 
scatter plots (the left panels of Figure 5-4 (c)) show that the significant protein 
profiles have different discriminatory power before and after logarithmic 
transformation.  These results indicated that the logarithmic transformation affects 
the discriminatory power of the protein profiles. It should be of interest to investigate 
whether the logarithmic transformation affects the accuracy of cancer classification.   
5.3.4 RF classification 
We now investigate how classification is affected by the logarithmic transformation 
to base 2. Table 5-11 lists the performance of cancer classification using the RF 
machine-learning algorithm (described in Section 4.2.3.2) based on the significant 
proteins identified from the raw data set and the logarithm-transformed data set. The 
misclassification rate of the RF model trained using the top 12 significant protein 
profiles reduces from 19% to 16%. For the top 25 protein profiles, the 
misclassification rate reduces from 12% to 11%, while using the top 50 protein 
profiles, the misclassification rate reduces from 15% to 14%.  These results indicate 
that logarithmic transformation slightly increases the accuracy of cancer 
classification. 
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Figure 5-4 Concordance of the significant proteins identified using data set with 
and without logarithmic transformation. (a) top 12 proteins, (b) top 25 proteins 
and (c) top 50 proteins. 
 
Table 5-11 Classification performance using RF machine learning algorithm 
Sensitivity Specificity PPV Misclassification Data set (%) (%) (%) rate (%) 
Top 12 proteins 87 75 78 19 
Top 12 proteins (log2) 86 82 83 16 
Top 25 proteins 86 91 91 12 
Top 25 proteins (log2) 86 92 91 11 
Top 50 proteins 84 87 87 15 
Top 50 proteins (log2) 85 88 88 14 
Top 12 proteins means that a data set consists of the top 12 protein profiles. 
Top 12 proteins (log2) means that a data set consists of the top 12 protein profiles that were 
logarithm- transformed. 
 
5.3.5 PCA analysis 
Figure 5-5 shows the results of PCA analysis using the significant proteins identified 
by the RF non-parametric methods based on the data sets with and without 
logarithmic transformation to base 2. The score plots generated using the top 12, 25, 
and 50 significant protein profiles before and after logarithmic transformation are 
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Figure 5-5(a), Figure 5-5(b), and Figure 5-5shown in (c), respectively. These results 
visually show that the logarithmic transformation probably does not affect the 
performance of clustering.  
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(a) Top 12 significant proteins. 
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(b) Top 25 significant proteins. 
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(c) 50 significant proteins. 
Figure 5-5 Scores plot of PCA (Left panel: before logarithmic transform; Right 
panel: after logarithmic transformation) 
 
5.3.6 Correlation between protein expression level and the 
normality 
The relationship between the p-values of normality tests and the protein expression 
levels is shown in Figure 5-6 ((a) and (b) for the control group, and (c) and (d) for the 
cancer group). The x-axis represents the median protein intensities across all samples 
in the data set and the y-axis represents the corresponding p-values obtained from the 
Shapiro-Wilks tests.  For the control group, the correlation coefficient between the p-
values of normality tests and the protein expression levels is -0.001 with a p-value of 
0.51 (Pearson’s product moment correlation coefficient test) for the raw spectra, and 
0.007 with a p-value of 0.47 for the log-transformed spectra. This suggests that no 
correlation between the two variables is observed for the control group. For the 
cancer group, the correlation coefficient between the p-values of normality tests and 
the protein expression levels is 0.38 with a p-value of 1.79x10-6 for the raw spectra, 
and 0.29 with a p-value of 0.0003 for the log-transformed spectra. The observed 
correlation between the two variables implies that the low-expressed proteins from   
-80 -60 -40 -20 0 20 40
-6
0
-4
0
-2
0
0
20
PC1
P
C
2
control
cancer
-6 -4 -2 0 2 4
PC1
P
C
2
control
cancer
Before log transformation
0.00E+00
5.00E-03
1.00E-02
1.50E-02
2.00E-02
2.50E-02
3.00E-02
0 10 20 30 40 50 60 70
Median expression of each proteins
p-
va
lu
e
raw
 
 
                                         (a) Control group 
          
 
After log transformation
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 2 4 6 8
Median expression of each proteins
p-
va
lu
es
log2
 
 
 
                                           (b) Control group 
 
 
 
138
 Before log transformation
0.00E+00
5.00E-02
1.00E-01
1.50E-01
2.00E-01
2.50E-01
0 10 20 30 40 50 60 70
Median expression of each proteins
p-
va
lu
es
raw
 
                                       
                                         (c) Cancer group 
 
 
After log transformation
0.00E+00
1.00E-01
2.00E-01
3.00E-01
4.00E-01
5.00E-01
6.00E-01
7.00E-01
8.00E-01
0 1 2 3 4 5 6 7
Median expression of each proteins
p-
va
lu
es
log2
 
 
                                            (d) Cancer group 
 
Figure 5-6 Scatter-plot of p-values (the Shapiro-Wilks test) and protein median 
expression level. (a) and (b) for the control group and (c) and (d) for the cancer 
group. 
 
139
 
140
the samples of cancer patients do not follow normal distributions. This is consistent 
with what was observed in microarray data (Giles & Kipling,2003). However, the 
reason that the low-expressed proteins do not follow normal distributions is 
unknown. The results also show that the logarithmic transformation seems to reduce 
the correlation between SELDI protein profiles and the rejections of normality, 
especially as shown in Figure 5-6 (c) and (d). 
 
5.4 Discussion 
The outcomes of the four normality tests have shown that the hypothesis of the 
normality is rejected for a substantial number of protein expression profiles. Multiple 
testing procedures that combine the individual test results into a simultaneous 
hypothesis test confirm lack of normality, for both the logarithm-transformed and un-
logarithm-transformed data sets. The standard mathematical transformation method 
for both proteomics and genomics data sets is the logarithm. We have extended this 
idea to include the use of arsinh and Box-Cox family transformations and have 
demonstrated that they have a role in improving the normality of the SELDI data.  
Our conclusions are based on the analysis of the publicly available ovarian cancer 
data set and it should be interesting to carry out large-scale simulation studies to 
generalise our results.  Since goodness-of-fit tests are usually under-powered with 
small sample sizes, it is of critical importance to work with a data set that includes a 
large number of subjects (Chen et al.,2005). The ovarian cancer data set included 100 
cancer samples and 100 control samples. Such a large sample size is rarely used in 
most experiments, and thus we feel that this sample size is large enough to lead to 
rather general conclusions. 
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It has been shown that generalised logarithmic transformations can stabilise the 
variance in NMR signal and microarray gene expression data (Purohit et al.,2004; 
Rocke & Durbin,2003). However, there is no report of its use in normality studies 
and this thesis explored that possibility. The results have shown that the standard 
mathematical transformation functions, such as logarithm and Box-Cox family 
transformation, may improve the normality for only some protein profiles.  The 
results have indicated that the underlying structure of the high-throughput SELDI 
data cannot in general be modelled by a normal distribution even after data 
transformation. This result is consistent with what is described in the study by Giles 
et al. (2003). Giles stated that for many of the large-scale cancer studies, the nature 
of the underlying biology would make it surprising if significant deviations from 
normality were not found (Giles & Kipling,2003). Therefore, testing for normality is 
needed and warranted in every specific application. As large sets of SELDI protein 
expression data become more readily available, non-parametric testing would have 
the power to circumvent the problems raised by data that do not follow a normal 
distribution (Giles & Kipling,2003). Although it is quite common to apply 
logarithmic transformation to SELDI data set to stabilise variance (Coombes et 
al.,2005; Listgarten & Emili,2005), the data transformation can also alter the 
fundamental nature of the data (Osborne,2002). The results derived from this chapter 
have indicated that logarithmic transformation functions cannot convert all variables 
in a data set into normally distributed. Therefore, it may be unwise to apply the 
standard transformation function to SELDI data set and then employ normal-theory 
based statistical methods, such as the t-test.  
 
5.5 Summary 
The normality issues of SELDI mass spectrum have been assessed using the Shapiro-
Wilks, Kolmogorov-smirnov, Cramér-von Mises and Pearson  statistical tests. The 
results from these four tests suggest that a large number of proteins reject the 
hypothesis of the normality of SELDI protein profiles. In addition, the goodness-of-
fit tests reject the null hypothesis of normality, implying that SELDI mass spectra do 
not follow normal distributions. The normalisation results suggested that our 
proposed normalisation algorithm outperforms other existing methods. The 
transformation studies have shown that the logarithmic transformations yield the 
highest improvement of normality of SELDI protein profiles compared to other 
mathematical transformations. But the normalisation and mathematical 
transformations still cannot convert SELDI protein profiles into normally distributed. 
We think that it may be more reliable to use non-parametric methods, such as 
Wilcoxon test and the ROC curve method, as they overcome the many shortcomings 
of their parametric counterparts for high-throughput SELDI data analysis for 
detecting disease-associated proteins.   
2χ
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6 BIOMARKER DISCOVERY FOR CANCER 
CLASSIFICATION  
6.1 Introduction 
The identification of validated biomarkers correlating strongly to disease progression 
would not only classify the cancerous and non-cancerous tissues according to their 
molecular profile, but could also focus attention upon a relatively small number of 
molecules that might warrant further biochemical/molecular characterisation to 
assess their suitability as potential therapeutic targets (Bensmail & Haoudi,2003). 
Due to the complexity and diversity of proteomic patterns, it is essential to utilise 
algorithms to identify the underlying proteomic biomarkers from high dimensional 
data associated with cancer from multiple samples. 
 
However, different feature sets are usually identified when different feature selection 
methods are applied because a set of features is heavily dependent on the 
mathematical framework of the algorithm at hand (Listgarten & Emili,2005).  
Similarly, the classification accuracy usually depends on the classification methods 
used (Datta & Lara,2006; Levner,2005; Listgarten & Emili,2005; Wu et al.,2003). 
 
 In this chapter, we propose an integrated algorithm for biomarker discovery from 
SELDI protein profiles using a combination of multiple feature selection methods 
and classification methods.  Firstly, we used three feature selection methods, namely 
Wilcoxon test, the ROC curve and RF methods to produce three sets of significant 
proteomic features and to investigate how these feature selection methods affect 
identification of proteomic biomarkers. Secondly, we construct classification models 
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using three machine learning algorithms, namely random forest, support vector 
machine, and k-nearest neighbour to investigate the performance of the models built 
on different feature sets, including the union and intersection of the different feature 
sets. Thirdly, we determine an optimal set of proteomic biomarkers from SELDI 
expression profiles. 
 
6.2 Materials and biomarker discovery strategy 
6.2.1 Data sets 
The prostate cancer data set 7-3-02 (described in Section 2.7.4) and ovarian cancer 
data set 4-3-02 (described in Section 2.7.5) were used in this chapter to evaluate 
different feature selection methods for identifying biomarkers. The protein features 
with mass less than 2kDa were excluded for both data sets because data points within 
this mass range were likely affected by matrix. The spectra were normalised using 
the MIC algorithm, which was described in Section 5.2.2.1.3. The peaks of SELDI 
mass spectra were picked using PROcess software through R for both data sets. 
6.2.2 Biomarker discovery strategy 
Although a variety of methods can be used for biomarker discovery and cancer 
classification, there is evidence to show that different methods have identified 
different sets of biomarkers and give different classification accuracies (Geurts et 
al.,2005; Levner,2005; Wu et al.,2003). In order to address the question of which 
method should be used, in this section, we propose an integrated algorithm to 
identify biomarkers using SELDI protein profiles. 
6.2.2.1 Univariate feature selection methods 
Univariate feature selection approaches identify significant protein features by 
evaluating the discriminatory power at each protein m/z value. As demonstrated in 
Section 5.3.2, SELDI protein profiles do not follow normal distributions. Therefore, 
it is invalid to employ the parametric statistical tests (such as t-test) to detect changes 
in SELDI expression profiles between different groups of samples (e.g. control 
versus cancer).  We utilise non-parametric univariate feature selection methods, such 
as Wilcoxon test and the ROC curve method. The criterion for identifying significant 
protein features using the non-parametric approaches is to rank the protein profiles 
according to the p-values of the Wilcoxon tests, or the AUC values of the ROC 
curve, from the most to the least informative.  
6.2.2.1.1 Wilcoxon test 
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21 xn
(1) Wilcoxon test:  Wilcoxon test is also known as “Wilcoxon_Mann-Whitney” test.  
It is one of the best-known non-parametric significance tests. It was proposed 
initially by Wilcoxon in 1945 for equal sample sizes and extended by Mann and 
Whitney in 1947 to arbitrary sample sizes. The Wilcoxon test examines whether the 
samples in two groups come from the same distribution (Dekking et al.,2007). 
Suppose that a sample of  observations  is from one group xn x},...,,{ xxx III  and 
that a sample of  observations  is from another group .  The 
Mann-Whitney test is based on a comparison of every observation  in the first 
sample with every observation  in the other sample. If the samples have the same 
median then each  has an equal chance of being greater or smaller than each . 
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We count the number of times that a  from the group ixI x  is greater than a  from 
the group  and denote this value as . Similarly, the number of times a  from 
the group 
j
yI
i
xIy xU
x  is smaller than a  from the group jyI y  is denoted by . Under the null 
hypothesis we would expect  and  to be approximately equal (Shier,2004).  
The procedure for carrying out the Wilcoxon test is described as follows. 
yU
xU U y
 
1) Arrange all the observations into a single ranked series. That is, rank all the 
observations without regard to which group they are in. 
2) Add up the ranks in group x and denoted by .  xR
2
)1( +−= xxxx nnRU3) is given by xU ,  is the number of observations in the 
group 
xn
x  
x
yxyx
y R
nnnn
R −+++=
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4)  is calculated by yR  ,   is the number of 
observations in the group 
yn
y  
2
)1( +−= yyyy
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RU5) is given by yU  
6) is given by  ),min( yx UUU =U
7) Use statistical tables for the Mann-Whitney U test to find the probability of 
observing value of U or lower. If the test is one-sided, this is your p-value; if 
the test is a two-sided test, double this probability to obtain the p-value 
(Shier,2004).  If the number of observations is such that  is large enough 
(>20), a normal approximation 
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al.,2007; Shier,2004), where, 
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 (2) Multiple hypotheses testing:  As discussed in Chapter 2, FWER and FDR are the 
two commonly used frequentist multiple hypotheses testing correction methods. 
FWER is a very conservative correction method and results in greatly diminished 
power to detect significantly differently expressed variables.  The p-value used for a 
cut-off is computed by dividing the standard p-value (e.g. 0.05) by the number of 
tests. FDR (Baggio & Prodi,2005; Benjamini & Yekutieli,2005) is the expected 
value of the proportion of false positives among rejected null hypotheses.  Compared 
to FWER control, FDR control is less conservative and provides increased power.  It 
generates a good balance between discovery of statistically significant variables and 
limitation of false positive occurrences. In this case, the p-value used for a cut-off is 
computed as follows. 
1. Ranking p-values of individual proteins in ascending order: p1 < p2 < …< 
pk<…<pm  (m is the total number of proteins) 
2. Find the largest k so that pk ≤ FDR*(k/m); 
3. Set the cut-off c= pk, assuming that the k proteins with the lowest p-values 
reject the null hypotheses. 
The cut-off value for the smallest p-value in FDR control method is α/m, which is 
equivalent to Bonferroni adjusted cut-off value. It is known that the Bonferroni 
correction method is too conservative for most biological applications. FDR method 
allows some false positive results, but at a given number or proportion, it may be 
more conductive to scientific application (Birkner et al.,2006). Therefore, FDR 
control method is used in this chapter to select significantly differentially expressed 
proteins for comparing the univariate feature selection methods.   
6.2.2.1.2 The ROC curve 
(1) The ROC curve: The ROC curve was first used during the World War II for the 
analysis of radar signals. Since then, ROC analysis has been extensively used in 
medicine, radiology, psychology and other areas. It has been introduced in data 
mining and machine learning recently. The first application of ROC to machine 
learning was made by Spackman who investigated the area under the ROC curves in 
comparing and evaluating different classification algorithms (Spackman,1989). 
Several studies have since used the ROC curve to select features from SELDI protein 
profiles (Adam et al.,2002; Ball et al.,2002; Chen et al.,2002; Qu et al.,2002; Yu et 
al.,2004). 
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                Figure 6-1 An example of the ROC curves. 
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The ROC curve is a plot of the sensitivity versus 1-specificity as showed in Figure 
6-1. It displays the fraction of the true positives and the fraction of the false positives 
as discrimination thresholds vary in a diagnostic test. The advantage of ROC analysis 
includes the fact that it explicitly considers the tradeoffs in sensitivity and specificity. 
The AUC under the ROC curve actually represents the probability that a classifier 
will rank a randomly chosen positive instance higher than a randomly chosen 
negative one. This probability of correct ranking curve is equivalent to the quantity 
estimated by the Wilcoxon statistic (Bradley,1997; Hanley & McNeil,1982). 
 
(2) The AUC and Figure of merit (FOM):  By calculating the AUC, an 
approximated measure of probability is determined for each model. FOM, which is 
used to assess the discrimination power of each model or test as a function of AUC, 
is assigned as shown in Table 6-1 (Swets,1988). 
Table 6-1 The figure of merit 
AUC 0.91-1.00 0.81-0.90 0.71-0.80 0.61-0.70 0.51-0.60 
FOM Excellent Good Fair Poor Failed 
 
A model or test with the highest AUC will in general have the fewest false positive 
and false negative results, regardless of the final threshold. If the AUC reaches a 
value of 1, then complete separation between the two groups has been achieved.  But 
if the AUC value approaches to 0.5 (as shown by the dashed line in Figure 6-1), then 
there is no discrimination. 
6.2.2.2 Multivariate feature selection methods 
Using the Wilcoxon test and the AUC to select significant protein profiles as 
biomarkers may have some limitations, as they do not take interactions among 
variables into account.  More importantly, the univariate feature selection methods 
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are not stable when sample sizes are relatively small (Kohavi,1997). Some classical 
statistical regression analyses, such as logistic regression, allow investigation of 
interactions between variables, and between variables and environmental factors, but 
may have a problem of the curse of dimensionality. The model becomes unstable as 
more main effects and interaction terms are added, in the sense that the variance of 
the parameter estimates becomes excessively large. Statistical parametric models, 
such as generalised linear models, assume a function for the relation between the 
input variables and the output variables. However, precise information about the 
shape of the relation between the input variables and the output variables is lacking. 
Therefore, they often fail to deal adequately with the biological complexities and the 
multidimensional problem of feature selection (Breiman,1992). 
 
The non-parametric machine learning methods have potential to identify cancer 
susceptibility proteins without making any assumption about relationship between 
protein profiles and disease status.  Several multivariate search strategies have been 
proposed in the literature, all involving combinatorial searches through the space of 
possible feature subsets (Duda et al.,2000; Kohavi,1997).  The search can start with 
one feature, with all features or with a random subset of features. A forward selection 
algorithm chooses one feature as the starting point and then successively adds 
features from this point. A backward elimination algorithm chooses all features as 
the starting point, and successively removes what are considered irrelevant features. 
A random selection algorithm chooses randomly a number of features at the starting 
point, and iteratively adds relevant features and removes irrelevant features 
according to their discriminatory power. All the selection algorithms are based on 
heuristic search methods.  
6.2.2.2.1 Random forest   
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The random forest algorithm combines bagging and random feature selection 
techniques. Bagging is to adaptively resample the original data so that the weights 
are increased for the most frequently misclassified samples. The random feature 
selection makes it possible to improve the predictive accuracy (Wu et al.,2003). A 
random forest model is a group of tree predictors Tj ,...,2,1= , where,  jθ I  
represents  observed protein profiles with associated random vector Il  and tθ  are 
independent and identically distributed random vectors. T  represents the total 
number of trees. The training data set is assumed to be independently drawn from the 
joint distribution of  and comprises ),( YI ( )1+lN ,1= patterns ,  
(sample size for each tree), 
),( ii yI i N,...,2
Y  is the observed cancer status.  represents the vector 
of intensities,  represents the true class. 
iI
yi
 
A random forest classifier reports an importance measure for each variable based on 
the decrease mean accuracy or a decreased Gini distance criterion (Robnik-
Sikonja,2004). These are internal estimates of the decrease in the classifier’s overall 
accuracy if that particular variable is not used in building the classifier.  For each 
protein feature, based on the classification performance in out-of-bag samples, 
random forest model calculates its margin as follows. 
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  (6.1) 
where, ,   represents the number of trees for which individual sample i  
is out-of-bag, 
∑
=
=
j
iji tT
1
iT
j  represents the index of trees, t  is an indicator with a value of 1 if 
individual  is out-of-bag for tree 
ij
j j . i )(If, and  represents the vote for tree ;i jθ
));(( iji yIfU =θ iji yIf =);( θ denotes a indicator function, taking value of 1 if , 
and 0 otherwise.  
 
 In the context of a categorical response, the larger margin indicates the higher 
confidence of the forest prediction.  If a feature is predictive of the response, its 
margin will be decreased when randomly permuting the values of this protein feature 
among the individuals in the out-of-bag samples. The decrease in margin, , is 
used as an index to measure the importance of the protein feature.  
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   (6.2) 
 
where,  is the total number of samples in a data set, and  is the importance 
index obtained by randomly permuting the values of a peak intensity. 
)(PWMN
 
With a specific threshold for the decrease in margin, a set of important features are 
determined. Thus, protein features with large importance measures are thought to 
have more discrimination power.  
6.2.2.2.2 Concordance and discrepancy 
We examine the concordance and discrepancy of the discriminatory feature sets 
extracted using different feature selection methods. The scatter plot matrices and 
Venn diagrams are generated using function pairs in graphics package and 
vennDiagram in limma package through R to implement these analyses. 
 
The effects of different feature selection methods on classification accuracy are also 
assessed using three different machine-learning algorithms. This provides a way to 
identify biomarkers for SELDI data by combining findings from different methods.  
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6.2.2.3 An integrated algorithm for identifying proteomic biomarkers 
We propose an algorithm for identifying proteomic biomarkers based on SELDI data 
(Figure 6-2), which is outlined as follows. 
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(1) Each feature selection method is applied to the same SELDI data set, and a 
set of proteomic biomarkers is generated, which is denoted by , where, i  is 
the th feature selection method. 
i
(2) The intersection set of the protein features identified using these individual 
feature selection methods is found and denoted by , where, . iI II
(3) The union set of the protein features identified using these individual feature 
selection methods are found and denoted by , where, B . iU UU
(4) Several classifiers are trained using the individual proteomic feature set , 
 and . The corresponding performance of the classifiers (e.g. 
misclassification rate) are recorded and denoted by , where, 
i
I U
j j is the j th 
classifier. Note that the classifiers can be trained using one or more methods.  
(5) The optimal set of proteomic biomarkers is determined and denoted by , 
where, 
Bo
)}(min,,,{ jjjo RUIijBB == . 
  SELDI protein profiles 
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Figure 6-2 Diagram of biomarker discovery using SELDI 
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6.2.2.4 Cancer classification 
The high-throughput SELDI mass spectrometry provides a platform to identify 
protein patterns for distinguishing cancer from normal. Due to the high dimensional 
data that is generated from a single experiment, it is essential to use mathematical 
tools to discover the boundaries or relationship between the groups (e.g. cancer 
versus control, treatment versus non-treatment) from SELDI protein profiles. 
Random forest, support vector machine, and k-nearest neighbour are used as 
examples in this chapter to classify cancer from normal subjects. 
6.2.2.4.1 Random forest 
The procedure to classify cancer using the random forest method has been described 
in 4.2.3.2. The software package randomForest in R is used to build classification 
models. The prediction error is evaluated based on out-of-bag estimation. To assess 
the error rate variation, the whole procedure is repeated 100 times and 500 trees are 
grown in each repeat. 
6.2.2.4.2 Support vector machine 
Support vector machine is a machine-learning algorithm. It maps the feature space 
into a hyperplane and performs regression in that space where all class-one points 
(for example cancer patients) are on one side and all class-two points (for example 
normal subjects) on the other side as shown in Figure 6-3, where the line Y=w*X+b 
is the ‘hyperplane’. However, such a hyperplane is not unique.  In order to address 
this problem, SVM introduces a concept called margin (Cristianin & Shawe-
Taylor,2000). The margin of the linear SVM is defined by 
w
M = 2 , which is the 
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distance from the hyperplane to the nearest data point. The unique hyperplane can be 
determined by maximising the margin M .  
 
 Let  if the ith subject is a cancer patient and 1=iy 1−=iy  if the ith subject is 
normal. In order to make correct classifications in a training data set, we need to 
satisfy the following equations: 1)( ≥+ bwXyi i . Training a linear SVM classifier is 
equivalent to solving the following optimisation problem because the solution of 
maximising M w is equivalent to the solution of minimising . 
2
2
1)(wΦ w=                                              Minimise 
          (6.3) 1)( ≥+ byi wxiSubject to 
 
 
 
 Cancer 
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Figure 6-3 A linear SVM classifier 
 
 Normal 
Y=w*X+b 
Y 
X 
The optimisation problem requires that all data points are correctly classified, that is, 
the data set is separable. However, for a data set with noise as shown in Figure 6-4, 
one cannot train a SVM by solving the above optimisation problem. One possible 
solution is to use soft margin classification method by introducing slack variables, 
which measure the degree of misclassifications as shown in Figure 6-5.  
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   Figure 6-4 A problem in training a SVM classifier using a data set with noise 
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     Figure 6-5 A linear SVM classifier with soft margin 
 
Training a linear SVM classifier with soft margin is equivalent to solving the 
following optimisation problem defined by 
                                    Minimise ∑+=Φ iCww ξ22
bwxy
1)(  
iiiSubject to ξ−≥+ 1)( , 0i ≥ξ          (6.4) 
 
The solution of the above optimisation problem is a trade off between maximising 
the margin and minimising the error penalty (Cristianin & Shawe-Taylor,2000) and 
involves constructing a dual problem described as follows.  
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0≠kα , implying that  is a support vector. The classification function is 
defined as follows. 
kx
)()(
1
bxxysignxf Tii
n
i
i += ∑
=
α                    (6.6) 
 
 
For data sets that are not linearly separable, non-linear SVM classifiers can be used. 
For example, the data set shown in Figure 6-6 (a) cannot be separated with one 
hyperplane. However, instead of looking at , we can consider 
, mapping source data into a higher-dimensional space as shown in 
),( ii yx
),,( 22 iiii yxyx +
Figure 6-6 (b), where we can separate the two classes. 
 
 
 
 
 
 
 
 
 
 
Figure 6-6 A non-linear SVM classifier. 
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A non-linear SVM classifier is a hyperplane in the transformed feature space, which 
is generated by kernel functions. The common non-linear kernels include 
polynomial, Gaussian, and sigmoid functions defined as follows, respectively. 
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The solution of the non-linear SVM involves constructing a dual problem described 
as follows. 
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The corresponding classification function is defined by  
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The function svm in e1071 package from R is used to implement the model 
construction. The Gaussian kernel is used. The classification error is estimated based 
on the 10-fold cross validation. The error variance is evaluated by running 100 times. 
6.2.2.4.3 K-nearest neighbour  
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K-nearest neighbour is a simple distance-based method in cluster analysis. A kNN 
model partitions a training data set into a number of categories based on a distance 
measure between two points. We use the following Euclidean distance measure to 
partition a training data set into a number of categories. 
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xI yI yxWhere,  and  are the observed protein profiles from samples  and .  
 
The category centroids are fixed at random positions when the model is initialised. 
For a given set of test samples, the algorithm searches the k nearest neighbours in the 
training set. The sample classification is performed based on the sample status of its 
nearest neighbours in the training data set.  A sample in the test data set is classified 
to cancer or control by votes from its nearest neighbours, which is weighted by the 
rank of the distance between its neighbour and the test sample (Bensmail & 
Haoudi,2003; Wu et al.,2003).  
 
The function knn.cv in class from R is used to build the classification models. Leave-
one-out cross validation scheme is used to estimate the prediction error and the error 
variance is calculated based on 100 runs.  
 
6.3 Results of biomarker discovery 
6.3.1 Feature selection  
6.3.1.1 Wilcoxon test 
The Wilcoxon test was applied to the SELDI protein profiles from the ovarian cancer 
data set and the prostate cancer data set. The cut-off of p-values was set to 10-7 for 
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the prostate cancer data set and 10-15 for the ovarian cancer data set, which were 
calculated using the FDR correction method (FDR = ). A total of 16 out of 
125 protein features with the p-values of the Wilcoxon tests less than 10-7 were 
extracted from the prostate cancer data set; and 26 out of 160 protein features with 
the p-values less than 10-15 were selected from the ovarian cancer data set as shown 
in 
7100.5 −x
Table 6-2. 
6.3.1.2 ROC curve   
Fourteen out of 125 protein features from the prostate cancer data set and 34 out of 
160 protein features from the ovarian cancer data set were identified with the AUC 
values of greater or equal to 0.81 (fair separation performance). They are listed in 
Table 6-2. 
6.3.1.3 Random forest  
Eighteen out of 125 protein features from the prostate cancer data set and 24 out of 
160 protein features from the ovarian cancer data set as shown in Table 6-2 were 
identified with the mean decrease accuracy of greater than 0.005.  
 
Table 6-2 shows that the numbers of the protein features identified by the Wilcoxon 
test, ROC curve and RF methods are quite different for both the prostate cancer data 
set and the ovarian cancer data set. The ROC curve method produced the smallest 
feature set (14) for the prostate cancer data set compared with the other two feature 
selection methods. By contrast, the ROC curve method generated the biggest feature 
set (34) for the ovarian cancer data set, although the same cut-off value (AUC ≥ 
0.81) was applied. 
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Table 6-2 The numbers of protein features identified by the Wilcoxon test, ROC 
curve and RF methods. 
Data set Wilcoxon test ROC curve Random forest 
Prostate cancer 16 14 18 
Ovarian cancer 26 34 24 
 
Figure 6-7 shows the relationship between the feature sets extracted using the 
Wilcoxon test, ROC curve and RF methods. It can be seen that the three methods 
tend to identify some common discriminatory protein features. Thirteen common 
protein features from the prostate cancer data set and 19 common protein features 
from the ovarian cancer data set were identified by all the three methods. For the 
prostate cancer data set, a common protein feature was identified by using the 
Wilcoxon test and ROC curve method, but not by the RF method. For the ovarian 
cancer data set, a common set of seven protein features were identified by using the 
Wilcoxon test and ROC curve method, but not by the RF method. However, five 
protein features were identified by the RF method, but not by either the Wilcoxon 
test or the ROC curve method for each data set. 
 
The protein features identified from the prostate cancer data set by the Wilcoxon test, 
ROC curve and RF methods are listed in Table 6-3. They are ranked according to 
their discrimination powers. The first column lists the features that were identified by 
the Wilcoxon tests and ranked (ascending) by their p-values. The features listed in 
the third column were identified by the ROC curve method and ranked (descending) 
by the AUC values. The features shown in the fifth column were identified by the RF 
method and ranked (descending) by the mean decreases in accuracy.  
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Figure 6-7 The relationship among the feature sets identified using the Wilcoxon 
test, ROC curve and RF methods. (a) for the prostate cancer data set and (b) for 
the ovarian cancer data set.   
 
Sixteen, fourteen and eighteen protein features were identified by the Wilcoxon test, 
ROC curve and RF methods, respectively. The thirteen common features identified 
by the three methods are 3468.89, 3471.09, 3472.19, 3474.39, 3475.49, 3478.79, 
6914.28, 6915.84, 6917.39, 6918.94, 6920.49, 6922.05, and 6925.15. The five 
features, 5250.73, 5257.49, 5260.20, 7633.59, and 7649.10 were identified only by 
the RF method. Two features, 4248.17 and 8469.88 were identified by the Wilcoxon 
test only. One feature 3478.79 was identified by both Wilcoxon test and ROC curve 
method.  
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Table 6-3 The protein features identified by the Wilcoxon test, ROC curve and 
RF methods from the prostate cancer data set. 
Wilcoxon test ROC curve Random forest 
Feature 
(M/Z) 
P-value Feature 
(M/Z) 
AUC Feature 
(M/Z) 
Mean decrease 
accuracy 
6914.28 3.95E-14 6914.28 0.882 3468.89 0.020 
6918.94 3.95E-14 6918.94 0.882 3471.09 0.017 
6915.84 4.09E-14 6915.84 0.882 6915.84 0.017 
6920.49 4.53E-14 6920.49 0.881 3472.19 0.017 
6917.39 4.86E-14 6917.39 0.881 6917.39 0.015 
3468.89 6.66E-14 3468.89 0.879 6914.28 0.015 
3471.09 1.24E-13 3471.09 0.874 5257.49 0.015 
6922.05 1.24E-13 6922.05 0.874 6918.94 0.015 
3472.19 2.14E-13 3472.19 0.871 6920.49 0.015 
6925.15 4.67E-13 6925.15 0.865 6922.05 0.013 
3474.39 8.81E-12 3474.39 0.845 5250.73 0.011 
3475.49 4.07E-11 3475.49 0.833 6925.15 0.011 
3477.69 6.06E-11 3477.69 0.830 5260.2 0.008 
3478.79 1.90E-10 3478.79 0.822 3478.79 0.006 
8469.88 4.06E-09   7633.59 0.005 
4248.17 1.49E-08   7649.1 0.005 
    3475.49 0.005 
    3474.39 0.005 
 
 
Table 6-3 also demonstrates that the Wilcoxon test and ROC curve method yield the 
same discriminatory power for each of the 14 features 6914.28, 6918.94, 6915.84, 
6920.49, 6917.39, 3468.89, 3471.09, 6922.05, 3472.19, 6925.15, 3474.39, 3475.49, 
3477.69, and 3478.79 identified from the prostate cancer data set. The ranks of the 
14 features identified by the ROC curve methods are exactly the same as those of the 
top 14 features identified by the Wilcoxon test. This confirms the fact that the AUC 
under the ROC curve is equivalent to the quantity estimated by the Wilcoxon test. 
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Table 6-4 The protein features identified by the Wilcoxon test, ROC curve and 
RF methods from the ovarian cancer data set.  
Wilcoxon test ROC curve Random forest 
Feature 
(M/Z) 
P-value Feature 
(M/Z) 
AUC Feature 
(M/Z) 
Mean decrease 
accuracy 
3354.96 0 3468.89 0.888 3463.40 0.027 
3362.00 0 3463.40 0.888 3354.96 0.025 
3463.40 0 3471.09 0.881 6912.73 0.018 
3468.89 0 3472.19 0.870 6917.39 0.017 
3471.09 0 3473.29 0.867 3468.89 0.016 
3472.19 0 6912.73 0.864 3471.09 0.016 
3473.29 0 6709.40 0.861 6918.94 0.014 
3474.39 0 6915.83 0.861 6915.83 0.013 
3475.49 0 3354.96 0.861 3362.00 0.012 
6709.40 0 3474.39 0.861 3472.19 0.011 
6710.93 0 6917.39 0.860 6920.49 0.010 
6712.46 0 6918.94 0.859 2040.27 0.010 
6713.99 0 6710.93 0.858 6712.46 0.009 
6912.73 0 6712.46 0.855 6709.40 0.009 
6915.83 0 6920.49 0.853 6710.93 0.009 
6917.39 0 6713.99 0.852 3473.29 0.009 
6918.94 0 6922.05 0.846 3182.12 0.007 
6920.49 0 3475.49 0.842 3699.61 0.006 
6922.05 0 3362.00 0.841 3474.39 0.006 
3367.40 2.22E-16 3368.49 0.836 3367.40 0.006 
3368.49 2.22E-16 6715.52 0.836 3368.49 0.006 
3370.65 2.22E-16 6923.60 0.836 6713.99 0.005 
6715.52 2.22E-16 3370.65 0.835 2114.28 0.005 
6923.60 2.22E-16 3367.40 0.835 2474.29 0.005 
6925.15 4.44E-16 6925.15 0.832   
6717.05 8.88E-16 6717.05 0.830   
  3476.59 0.827   
  6926.70 0.823   
  6718.58 0.822   
  6928.26 0.819   
  3369.57 0.819   
  6929.81 0.812   
  6720.11 0.812   
  6721.64 0.810   
 
 
The protein features identified from the ovarian cancer data set by the Wilcoxon test, 
ROC curve and RF methods are listed in Table 6-4. They are ranked according to 
their discrimination powers. The first column lists the features that were identified by 
the Wilcoxon tests and ranked (ascending) by their p-values. The third column lists 
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the features that were identified by the ROC curve method and ranked (descending) 
by the AUC values. The fifth column lists the features that were identified by the RF 
method and ranked (descending) by mean decreases in accuracy. 
 
Twenty-six, thirty-four and twenty-four protein features were identified by the 
Wilcoxon test, ROC curve and RF methods, respectively, from the ovarian cancer 
data set. The nineteen common features identified by the three methods are 3354.96, 
3362.00, 3367.40, 3368.49, 3463.40, 3468.89, 3471.09, 3472.19, 3473.29, 3474.39, 
6709.40, 6710.93, 6712.46, 6713.99, 6912.73, 6915.83, 6917.39, 6918.94, and 
6920.49.  
 
The five features, 2040.27, 2114.28, 2474.29, 3182.12, and 3699.61, were identified 
only by the RF method. Seven features, 3370.65, 3475.49, 6715.52, 6717.05, 
6922.05, 6923.60, and 6925.15, were identified by both Wilcoxon test and ROC 
curve method. Eight features, 3369.57, 3476.59, 6718.58, 6720.11, 6721.64, 
6926.70, 6928.26, and 6929.81, were identified by the ROC curve method only. 
 
The results from Table 6-4 demonstrates that although the twenty-six features 
3354.96, 3362, 3463.4, 3468.89, 3471.09, 3472.19, 3473.29, 3474.39, 3475.49, 
6709.4, 6710.93, 6712.46, 6713.99, 6912.73, 6915.83, 6917.39, 6918.94, 6920.49, 
6922.05, 3367.4, 3368.49, 3370.65, 6715.52, 6923.6, 6925.15, 6717.05 identified by 
the Wilcoxon test (listed in the first column) were also identified by the ROC curve 
method (listed in the third column), but the ranks of these features in the two feature 
sets identified by the Wilcoxon test and the ROC curve method are different. This 
indicates that if the p-values of the Wilcoxon test are too small (p-value = 0 in this 
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study) to distinguish the discriminatory powers of the protein features, then the ROC 
curve method can be used for this purpose. 
6.3.2 Concordance and discrepancy 
Figure 6-8 plots the distributions of the discriminatory powers of the protein features 
identified by the Wilcoxon test, ROC curve and RF methods from the prostate cancer 
data set. Figure 6-8 (b) shows the zoomed distributions of the discriminatory powers 
of the protein features identified by the ROC curve and RF methods. It can be seen 
that some features can only be identified by one method, but not by the other. For 
example, the features A (5257.49), B (5250.73) and C (5260.20) were identified by 
the RF method, but not by the ROC curve method. By contrast, the feature D 
(3478.79) was identified by the ROC curve method, but not by the RF method. 
 
Figure 6-9 plots the distributions of the discriminatory powers of the protein features 
identified by the Wilcoxon test, ROC curve and RF methods from the ovarian cancer 
data set. Figure 6-9 (b) shows the zoomed distributions of the discriminatory powers 
of the protein features identified by the Wilcoxon test and the RF method. Again the 
results show that some features can only be identified by one method, but not by the 
other. For example, the features E (6925.15) and F (6923.60) were identified by the 
Wilcoxon test, but not by the RF method. By contrast, the feature G (2474.29) was 
identified by the RF method, but not by the Wilcoxon test. 
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(b) 
Figure 6-8 The distributions of the discriminatory powers of the protein 
features identified by the Wilcoxon test, ROC curve and RF methods from the 
prostate cancer data set. 
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(b) 
Figure 6-9 The distributions of the discriminatory powers of the protein 
features identified by the Wilcoxon test, ROC curve and RF methods from the 
ovarian cancer data set.   
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6.3.3 Effect of different feature selection methods on the 
performance of cancer classification 
Classification models were constructed using SVM, RF, and kNN machine learning 
algorithms based on the proteomic biomarkers discovered by the Wilcoxon test, 
ROC curve and RF methods, the intersection set of the biomarkers, and the union set 
of the biomarkers for the prostate cancer data set and ovarian cancer data set, 
respectively. The means and standard deviations of misclassification rates of these 
classifiers are summarised in Table 6-5 and Table 6-7.  
Table 6-5 The means and standard deviations of misclassification rates of the 
classifiers built using the different feature sets and classification approaches for 
the prostate cancer data set. 
Misclassification rates (%) Feature set 
SVM RF kNN 
Wilcoxon test 15.66 ± 1.37 17.11 ± 0.01 22.72 ± 0.00 
ROC 17.85 ± 1.67 18.96 ± 0.01 2121 ± 0.00 
RF 9.87 ± 1.11* 14.15 ± 0.01 16.67 ± 0.00* 
Intersection 18.99 ± 1.52 21.84 ± 0.01 20.45 ± 0.00 
Union 11.04 ± 1.10 13.94 ± 0.01* 22.72 ± 0.00 
 
Table 6-5 shows that the misclassification rates of the SVM classifiers vary from 
10% to 19%. The best performance of the SVM classifiers was achieved with the 
proteomic biomarkers discovered by the RF method.  The misclassification rates of 
the RF classifiers vary from 14% to 22%. The best performance of the RF classifiers 
was achieved with the union of the proteomic biomarkers discovered by the 
Wilcoxon test, ROC curve and RF methods. However, the misclassification rate of 
the RF classifier built using the set of proteomic biomarkers discovered by RF is 
only slightly lower compared with that of the RF classifier built using the union of 
the proteomic biomarkers discovered by the Wilcoxon test, ROC curve and RF 
methods. This suggests that the performance of RF classifiers may be relatively 
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insensitive to changes in individual input variables. The misclassification rates of the 
kNN classifiers vary from 17% to 23%. The best performance of the kNN classifiers 
was achieved with the proteomic biomarkers discovered by the RF method. From 
these analyses, the optimal proteomic biomarkers have been selected from the 
prostate cancer data set and shown in Table 6-6. They are the set of protein features 
discovered by the RF method. The best classification accuracy is 90%. 
Table 6-6 The optimal proteomic biomarkers identified from the prostate 
cancer data set 
Feature (M/Z) Identified by RF Identified by ROC Identified by Wilcoxon test 
3468.89 √ √ √ 
3471.09 √ √ √ 
3472.19 √ √ √ 
3474.39 √ √ √ 
3475.49 √ √ √ 
3478.79 √ √ √ 
5250.73 √ X X 
5257.49 √ X X 
5260.20 √ X X 
6914.28 √ √ √ 
6915.84 √ √ √ 
6917.39 √ √ √ 
6918.94 √ √ √ 
6920.49 √ √ √ 
6922.05 √ √ √ 
6925.15 √ √ √ 
7633.59 √ X X 
7649.10 √ X X 
√ represents Yes; X represents No 
 
Table 6-7 shows that the misclassification rates of the SVM classifiers vary from 
11% to 19%. The best performance of the SVM classifiers was achieved with the 
union of the proteomic biomarkers discovered by the Wilcoxon test, ROC curve and 
RF methods.  The misclassification rates of the RF classifiers vary from 13% to 20%. 
The best performance of the RF classifiers was achieved with the union of the 
proteomic biomarkers discovered by the Wilcoxon test, ROC curve and RF methods.  
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However, the misclassification rate of the RF classifier built using the union of the 
proteomic biomarkers discovered by the Wilcoxon test, ROC curve and RF methods 
is only slightly lower compared with that of the RF classifier built using the set of 
proteomic biomarkers discovered by RF. Again, this suggests that the performance of 
RF classifiers may be relatively insensitive to changes in individual input variables.  
The misclassification rates of the kNN classifiers vary from 19% to 27%. The best 
performance of the kNN classifiers was achieved with the union of the proteomic 
biomarkers discovered by the Wilcoxon test, ROC curve and RF methods.  
Table 6-7 The means and standard deviations of misclassification rates of the 
classifiers built using the different feature sets and classification approaches for 
the ovarian cancer data set. 
Misclassification rates (%) Feature set 
SVM RF kNN 
Wilcoxon test 18.75 ± 0.90 19.53 ± 0.01 26.75 ± 0.00 
ROC 17.38 ± 1.05 18.80 ± 0.01 23.73 ± 0.00 
RF 16.21 ± 1.21 13.09± 0.01 22.71 ± 0.00 
Intersection 19.37 ± 0.83 20.42 ± 0.01 27.27 ± 0.00 
Union 10.61 ± 0.19 * 12.94 ± 0.01 * 19.00 ± 0.00 * 
 
From these analyses, the optimal proteomic biomarkers have been selected from the 
ovarian cancer data set and shown in Table 6-8. They are the union of the proteomic 
biomarkers discovered by the Wilcoxon test, ROC curve and RF methods. The best 
classification accuracy is 89%. 
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Table 6-8 The optimal proteomic biomarkers identified from the ovarian cancer 
data set 
Feature (M/Z) Identified by RF Identified by ROC Identified by Wilcoxon test 
2040.27 √ X X 
2114.28 √ X X 
2474.29 √ X X 
3182.12 √ X X 
3354.96 √ √ √ 
3362.00 √ √ √ 
3367.40 √ √ √ 
3368.49 √ √ √ 
3369.57 X √ X 
3370.65 X √ √ 
3463.40 √ √ √ 
3468.89 √ √ √ 
3471.09 √ √ √ 
3472.19 √ √ √ 
3473.29 √ √ √ 
3474.39 √ √ √ 
3475.49 X √ √ 
3476.59 X √ X 
3699.61 √ X X 
6709.40 √ √ √ 
6710.93 √ √ √ 
6712.46 √ √ √ 
6713.99 √ √ √ 
6715.52 X √ √ 
6717.05 X √ √ 
6718.58 X √ X 
6720.11 X √ X 
6721.64 X √ X 
6912.73 √ √ √ 
6915.83 √ √ √ 
6917.39 √ √ √ 
6918.94 √ √ √ 
6920.49 √ √ √ 
6922.05 X √ √ 
6923.60 X √ √ 
6925.15 X √ √ 
6926.70 X √ X 
6928.26 X √ X 
6929.81 X √ X 
√ represents Yes; X represents No 
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6.4 Discussion  
SELDI technology is a rapid growing scientific field. The highly promising 
proteomic patterns generated by SELDI suggest that this technology could be used 
clinically for biomarker discovery, early detection of cancer, and the prediction of 
treatment response. However, identification of huge number of proteins from 
complex biological samples is still a challenge in the field of quantitative proteomics.  
 
Several studies (Datta & Lara,2006; Levner,2005; Listgarten & Emili,2005; 
Marchiori et al.,2005; Wu et al.,2003) investigated the performance of different 
feature identification and classification methods and reported that better performance 
does not necessarily correspond to stability of the method and interpretability of 
results. Although there are a variety of feature selection methods available, including 
both univariate and multivariate methods, a robust feature selection method for the 
identification of proteomic biomarkers from SELDI expression profiles does not 
exist. In addition, there is no prior for deciding which feature selection methods 
should be used. 
 
We have proposed an integrated algorithm to address this problem. The algorithm 
has been tested using three feature selection methods and three machine learning 
approaches for the two published SELDI data sets. The analysis results did show that 
different feature selection methods identified different sets of biomarkers, and that 
different machine learning approaches lead to different classification accuracy. The 
three feature selection methods selected a total of 39 biomarkers from 160 peaks for 
the ovarian cancer data set. Nineteen out of the 39 biomarkers were selected by all 
the three feature selection methods, suggesting that the common biomarkers 
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identified by the three feature selection methods account for 49% for the ovarian 
cancer data set. The three feature selection methods selected a total of 18 biomarkers 
from 125 peaks for the prostate cancer data set. Fifteen out of the 18 biomarkers 
were selected by all the three feature selection methods, suggesting that the common 
biomarkers identified by the three feature selection methods account for 72% for the 
prostate cancer data set.  The misclassification rates of the classification models built 
using SVM, RF, and k-NN varies from 11% to 27% for the ovarian cancer data set, 
and 10% to 23% for the prostate cancer data set. The results also show that the 
biomarkers that fail to be discovered by some feature selection methods could be 
identified by others. The discrepancies among the biomarker sets identified by 
different methods make it very difficult to decide which set of proteomic biomarkers 
should be reported and used for cancer diagnosis. By applying our proposed 
algorithm, the optimal set of proteomic biomarkers has been selected for both data 
sets. However, we should be cautious in interpreting the optimal set of proteomic 
biomarkers. Firstly, the integrated algorithm is based on the process of optimisation. 
The optimal set of proteomic biomarkers is selected if a classifier built with these 
proteomic biomarkers achieves the best classification performance. However, the 
second best classification performance may not be remarkably different from the best 
classification performance. That is to say, the identified optimal set of proteomic 
biomarkers may be un-unique. As showed in the results of applying the algorithm to 
the published SELDI data sets, this is especially the case for RF classifiers. Taking 
the classification performance of different types of classifiers into account can solve 
this problem. For example, for the ovarian cancer data set, if only RF classifiers were 
used it would be very difficult to determine the optimal set of proteomic biomarkers 
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as the RF classifiers built using the set of proteomic biomarkers discovered by RF 
and the union of the proteomic biomarkers discovered by the Wilcoxon test, ROC 
curve and RF methods gave relatively similar classification accuracy. However, both 
SVM and kNN classifiers confirm that the set of proteomic biomarkers discovered 
by RF feature selection method is an optimal one. Similarly, for the prostate cancer 
data set, SVM and kNN classifiers confirm that the union of the proteomic 
biomarkers discovered by the Wilcoxon test, ROC curve and RF methods is an 
optimal set of proteomic biomarkers. Secondly, due to the instrument resolution, 
some proteomic biomarkers in the optimal set might represent the same protein. This 
needs further experiments to verify. 
 
It is worthwhile to mention that although only three feature selection methods and 
three machine learning approaches have been applied to the proposed algorithm in 
this chapter, the algorithm for proteomic biomarker discovery for cancer diagnosis 
itself has no any limit on the use of feature selection and classification methods. In 
general, any existing feature selection method and data-mining tool as well as future 
developed methods will fit into the algorithm.  The algorithm has an advantage that it 
does not exclude any method before exploring it. It might be reasonable to assume 
that it is wise to use the multivariate methods to analyse genomics and proteomics 
data as genes usually work in a collaborative way, rather than in an independent way. 
However, the study by Zhang et al. (2006) reported that although the multivariate 
SVM-based method outperformed the univariate method in terms of the performance 
of classification, univariate methods can reveal more of the differentially expressed 
features especially when they are correlated. This suggests that univariate methods 
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are still useful in the identification of proteomic biomarkers from SELDI protein 
profiles. 
 
However, lack of normality of SELDI protein profiles encourages the use of non-
parametric approaches, such as Wilcoxon test and the ROC curve method, for 
biomarker discovery. The results have demonstrated and confirmed that the AUC 
values under the ROC curve is equivalent to the p-values of the Wilcoxon tests. But 
in a case when it is impossible to rank the protein features according to the p-values 
of the Wilcoxon test, the AUC values under the ROC curve can be used to 
distinguish the discriminatory powers of these protein features.  
 
6.5 Summary 
We have investigated the feature selection and cancer classification methods, 
including both univariate and multivariate approaches. We argue that both the 
univariate and multivariate methods should be useful in the identification of 
proteomic biomarkers from SELDI protein profiles. However, none of the previous 
studies provided a guideline in selecting methods for feature selection and cancer 
classification.  
 
We have proposed an integrated algorithm for proteomic biomarker discovery from 
SELDI protein profiles. It has been applied to two published SELDI data sets to 
show how it works. In addition, the results have also demonstrated that the ROC 
curve method may be more reliable to detect proteomic biomarkers, especially to 
determine the discriminatory powers of the identified biomarkers, compared to the 
Wilcoxon test. 
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Although only three feature selection methods and three machine-learning 
approaches were used in this study, the proposed algorithm for proteomic biomarker 
discovery presented here may be generalisable and applicable to other mass 
spectrometry and genomics approaches. It should be interesting to further test the 
proposed algorithm using a large SELDI data set generated within a centre or across 
different centres. 
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7 CONCLUSIONS AND FUTURE WORK   
 
This chapter draws together the main points made in the thesis. This is followed by 
suggestions for possible future work. 
 
7.1 Conclusions 
The conclusions drawn from this thesis consists of the following components:  
 
(a) Cancer research and needs for identifying biomarkers,  
(b) SELDI technology and data analysis 
(c) Quantitative measures of reproducibility 
(d) SELDI mass spectrum peak alignment 
(e) Normalisation and normality test of SELDI protein profiles 
(f) Detection of proteomic biomarkers for cancer diagnosis 
(g) Cancer prognosis and prediction of treatment response using SELDI 
proteomic biomarkers 
(h) Integration of environmental factors with SELDI proteomic biomarkers.                                      
7.1.1 Cancer research and needs for identifying biomarkers 
The progress in the understanding of cancer initiation and progression has been 
frustrating. The mortality rates for the most common cancers have not been 
significantly reduced. Some of the best available options to combat cancer include 
primary prevention, earlier diagnosis, and improved therapeutic interventions. The 
progress in biotechnology provides an opportunity to detect biomarkers, which could 
facilitate the understanding of the mechanisms of initiation, prevention, diagnosis 
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and prognosis of cancer. Functional genomics, such as microarray technology, has 
attracted a great interest because it provides the potential ability to monitor the 
expression of the whole genome on a single chip. However, comparative 
transcriptional profiling alone is unlikely to fully identify biomarkers that are 
associated with cancer phenotype. The investigation of RNA expression obtained 
from microarray data may be an indirect way to understand the aetiology of cancer. 
Proteomics is the latest functional genomics technology and is really a main target of 
our interest to understand biological systems, detect biomarkers for cancer diagnosis, 
monitor disease progression, and identify therapeutic targets. The proteome contains 
not only the intrinsic genetic information of a cell, but also the impact of its 
immediate environment. A transformation of a healthy cell into a neoplastic cell may 
cause altered expression profile, differential protein modification and activities, and 
this in turn may affect cellular function. Therefore, investigation of the cancer 
proteome could be a starting point in the identification of biomarkers. Current 
progresses in proteomics, especially in SELDI, have demonstrated the potential for 
biomarker discovery and early cancer diagnosis.  It is important to note that the 
protein identities of SELDI expression profiles are unknown. However, this might 
not prevent SELDI technology from becoming a clinical tool because each protein 
has a unique m/z value and the combination of specific SELDI protein profiles could 
form proteomic patterns.  
7.1.2 SELDI technology and data analysis 
We have reviewed SELDI technology and the statistical methods for SELDI data 
analysis. One approach to biomarker discovery for cancer classification has been 
presented and discussed. It includes issues on experiment designs, reproducibility 
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analysis, SELDI protein profile pre-processing, identification of putative biomarkers, 
and cancer classification. We have identified the problems in analysing SELDI 
protein profiles, especially in reproducibility analysis, peak alignment, data 
normalisation and transformation, and selection of statistical methods for detection of 
proteomic biomarkers and cancer diagnosis. 
7.1.3 Quantitative measures of reproducibility 
We have proposed three quantitative measures of reproducibility using Euclidean 
distance, correlation coefficient, and the paired t-test. The reproducibility of SELDI 
protein profiles has been investigated using a colon cancer data set. The results 
showed that the differences of SELDI protein profiles between identical samples 
over replicate experiments are statistically significant in terms of Euclidean distances 
and correlation coefficients. The mass spectra generated in different spots in one 
experimental run have a better reproducibility compared to the mass spectra 
generated in different experimental runs. The mass spectra generated in different 
experimental runs over a short period of time have a better reproducibility than the 
mass spectra generated in different experimental runs over a long period of time. The 
reproducibility analyses have found that the mass spectra of the identical samples 
had significant changes if they were left in ice for a period of 4-5 hours at room 
temperature. This suggests a new conjecture that protein profiles are affected by 
sample storage and processing procedures. The reproducibility analysis results 
suggest that standardised experiment protocol and analysis procedure should be 
adopted. The proposed quantitative measures of reproducibility should be useful to 
identify important experimental conditions for improving the reproducibility of 
SELDI protein profiles. 
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7.1.4 SELDI mass spectrum peak alignment 
We have proposed two peak alignment algorithms and compared them with another 
four existing peak alignment methods. Five out of six peak alignment methods 
(including the newly proposed two algorithms) reduce the median CV by more than 
10% compared to the results of the un-aligned raw mass spectra, while keeping the 
IQR in the same range. The five peak alignment methods also increase correlation 
coefficient by more than 3%. One of the two proposed peak alignment methods 
achieves the best performance in terms of correlation coefficient and coefficient of 
variance.  The effects of peak alignment on the classification accuracy have also 
been evaluated by training RF models using the un-aligned and aligned mass spectra 
using the six peak alignment methods. The results show that five of the six RF 
models trained using data set aligned by the peak alignment methods improve the 
AUC values by up to 2% compared to the RF model trained using raw data set.  
 
These results demonstrate that the peak alignment algorithms have a positive effect 
on reducing systematic bias in producing SELDI mass spectra. A small improvement 
in cancer classification accuracy has been observed, which is not statistically 
significant. However, because the relatively small number of mass spectra generated 
on one machine under a stable environment within a short period of time was used in 
this study, the effects of peak alignment methods on the performance of the 
classification models might not be detected.  
7.1.5 Normalisation and normality test of SELDI protein profiles 
We have examined the assumption of normality of SELDI protein profiles, on which 
the standard statistical methods are based. The results from the Shapiro-Wilks, 
Kolmogorov-smirnov, Cramér-von Mises and Pearson  statistical tests suggest that 
a large number of protein profiles do not follow normal distribution. Furthermore, 
the goodness-of-fit tests reject the null hypothesis of normality, implying that SELDI 
protein profiles do not follow normal distributions. The normalisation analysis has 
shown that our proposed intensity normalisation algorithm outperforms other 
existing methods. The intensity transformation studies have shown that the 
logarithmic transformations yield the highest improvement of normality of SELDI 
protein profiles compared to other mathematical transformations. However, the 
intensity normalisation and transformations still cannot convert SELDI protein 
profiles into normally distributed data. Therefore, it may be unwise to apply the 
standard transformation function to SELDI data set and then employ normal-theory 
based statistical methods, such as the t-test. We think that it may be more reliable to 
use non-parametric methods, such as Wilcoxon test and the ROC curve method, as 
they overcome the many shortcomings of their parametric counterparts for high-
throughput SELDI data analysis for detecting disease-associated proteins. 
2χ
7.1.6 Detection of proteomic biomarkers for cancer diagnosis 
We have investigated the feature selection and cancer classification methods, 
including both univariate and multivariate approaches. The advantage of the 
univariate feature selection methods is that they are simple. However, multiple 
testing on a large number of SELDI protein profiles will generate many false 
positives if the standard significance level is used. The commonly used multiple 
hypotheses testing correction methods have been studied to address this problem. 
The advantage of multivariate feature selection methods is that they take the 
interactions between SELDI protein profiles into account. However, they may reveal 
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less of the differentially expressed features compared to the univariate methods if 
some SELDI protein profiles are correlated. That is to say, both the univariate and 
multivariate methods should be useful in the identification of proteomic biomarkers 
from SELDI protein profiles. 
 
There is evidence to show that different feature selection methods usually discover 
different sets of proteomic biomarkers, and that different cancer classification 
algorithms often produce different classification accuracies. However, none of the 
previous studies provided a guideline in selecting methods for proteomic biomarker 
discovery and cancer classification.  
 
We have proposed an integrated algorithm for proteomic biomarker discovery from 
SELDI protein profiles. It has been applied to two published SELDI data sets. The 
optimal sets of biomarkers were found for both data sets. In addition, the results have 
also demonstrated that the ROC curve method may be more reliable to detect 
proteomic biomarkers, especially to determine the discriminatory powers of the 
identified biomarkers, compared to the Wilcoxon test. 
 
Although only three feature selection methods and three machine-learning 
approaches were used in this study, the proposed algorithm for proteomic biomarker 
discovery presented here may be generalisable and applicable to other mass 
spectrometry and genomics approaches. It should be interesting to further test the 
proposed algorithm using a large SELDI data set generated within a centre or across 
different centres. 
7.1.7 Cancer prognosis and prediction of treatment response using 
SELDI proteomic biomarkers                                                    
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The proposed algorithm for biomarker discovery and cancer classification using 
SELDI technology can be easily adapted for cancer prognosis and for predicting 
treatment response. The prediction of clinical response can be modelled as follows: 
, where, =2121 lm i  are the identified proteomic 
biomarkers,  are the available treatment regimens, and y is a 
continuous response variable of interest, for example, the cancer survival time. The 
algorithm for cancer prognosis and the prediction of treatment response is outlined 
below. 
ljrj ,...,2,1, =
 
(1) Each feature selection method is applied to the same SELDI data set, and a 
set of proteomic biomarkers is generated, which is denoted by, , where, i  
is the th feature selection method. 
iB
i
B BB =
B B=
B B B
E
(2) The intersection set of the protein features identified using these individual 
feature selection methods is found and denoted by , where, . iI II
(3) The union set of the protein features identified using these individual feature 
selection methods are found and denoted by , where, B . iU UU
(4) Mathematical models are trained using each supervised machine learning 
algorithm and the individual proteomic feature set ,  and . The 
corresponding performance of the models (e.g. the residual errors) are 
recorded and denoted by , where 
Ii U
j  is the j j th trained model. Note that the 
models can be trained using one method or combination of different methods.  
(5) The optimal set of proteomic biomarkers is determined and denoted by , 
where, 
oB
)}(min,,,{ jjjo EUIijBB == . 
(6) Simulation analysis is carried out using the optimal set of proteomic 
biomarkers and the best trained model to search for the best available 
treatment regimen for a given cancer patient based on her/his proteomic 
patterns. 
7.1.8 Integration of environmental factors with SELDI proteomic 
biomarkers 
So far the thesis has focused on cancer biomarker discovery and on capturing the 
underlying relationship between the identified proteomic patterns and the cancer 
status or the therapeutic response. However, most common cancers and clinical 
quantitative traits are extremely complex and result from interactions between many 
proteins and various environmental factors.  For example, the proteomic patterns 
may contain information that influences human’s physical traits, one’s likelihood of 
suffering from cancer, and the responses of one’s body to substances that one 
encounters in the environment. It is therefore desirable to incorporate environmental 
factors in the classification and prediction models. To our knowledge, none of the 
published SELDI studies considered the interactions among proteins and between 
proteins and environmental factors, and investigated the influence of environmental 
factors on the performance of classification or prediction models.  
 
Our proposed algorithms for proteomic biomarker discovery and for cancer 
prognosis can be readily extended to integrate environmental factors. For example, 
the prediction of clinical response with consideration of environmental factors can be 
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),...,,,,...,,,,...,,( 212121 slm eeerrrIIIfy =modelled as follows: , where, 
 are the identified proteomic biomarkers,  are the 
available treatment regimens, 
niI i ,...,2,1, = jrj ,...,2,1, =
stt ,...,2,1,
l
e =  are the environmental factors, and y is a 
response variable of interest. 
 
7.2 Future work 
• The reproducibility of SELDI technology needs further investigation within a 
centre and across different centres.  
• The proposed peak alignment and normalisation algorithms, and the 
normality issues need to be further tested using a large set of mass spectra 
generated from different SELDI machines at different times. 
• It needs further tests on the proposed algorithm for proteomic biomarker 
discovery, and cancer diagnosis and prognosis using other commonly used 
feature selection, classification and prediction methods, such as wavelet 
decomposition, multivariate adaptive regression spline, Bayesian network, 
and artificial neural network. 
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Appendix 8-2 Programs for reproducibility analysis 
 
### To generate average of duplicate spectra 
 
rm(list=ls()) 
aveInten <- function(multiple) { 
    Nrow <- nrow(multiple) 
    ave = matrix(nrow = Nrow, ncol = 1) 
    for(i in 1:Nrow){ 
          ave[i] <- mean(as.numeric(multiple[i,2:3])) 
    } 
    Ave 
} 
 
## read in data 
files<-dir("./PABS", pattern="*.csv", full.names=TRUE) 
fn <- "blank" 
flag <- 0 
 
for(file in files) { 
         data <- read.table(file, header = TRUE, sep = ",") 
         fileN <-gsub("_d", "", file) 
         if (fn != fileN){# meet this file firstly 
            if (fn != "blank") {# save average file 
                data2 <- aveInten(data1) 
                data3 <- cbind(data1[,1], data2[,1]) 
                write.table(data3, file = basename(fn), sep = ",", append = FALSE, 
col.names = FALSE, row.names = FALSE) 
                fn <- "blank" 
            } 
            fn <- fileN 
            data1 <- data 
          } else if (fn == fileN) {# meet same file nth times 
                 data1 <- cbind(data1, data[,2]) 
          } 
} 
## last spectrum 
data2 <- aveInten(data1) 
data3 <- cbind(data1[,1], data2[,1]) 
write.table(data3, file = basename(fn), sep = ",", append = FALSE, col.names = 
FALSE, row.names = FALSE) 
 
 
191
 
### To merge single spectrum file into one spectra file 
# files: list of files to be read in. 
# mzStart: the M/Z value from which the intensity will be read in. 
# heager: indicating whether the file contains the header in its first line.  
#1 represents TRUE and 0 FALSE. 
# output: one matric which contains all the data. 
 
GetIntens <- function(files, mzStart, header) { 
    flag <- 0 
    for(fname in files) { 
        f <- basename(fname) 
        ff <- gsub("low good spectra ", "", f) 
        fff <- gsub(".csv", "", ff) 
        flag <- flag + 1 
        if( header == 1) { 
            single<-read.table(fname, header = TRUE, sep = ",", col.names = 
c("M/Z",fname)) 
        } else { 
              single<-read.table(fname, header = FALSE, sep = ",", col.names = 
c("M/Z",fname)) 
        } 
        single<- subset(single, single[1] > mzStart) 
        if (flag == 1) { 
           multiple <- single[,1] 
           multiple <- cbind(multiple, single[,2]) 
           names <- fff 
 } else { 
          multiple <- cbind(multiple, single[,2]) 
          names <- c(names, fff) 
        } 
    } 
    colnames(multiple) <- c("M/Z", names) 
    Multiple 
} 
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Appendix 8-3 Programs for peak alignment study 
 
### To calculate correlation coefficients and Euclidean distance of the duplicate 
spectra 
 
# spectrumA. 
# spectrumB: duplicate spectrum of "spectrumA". 
CorDisDuplicate <- function(spectrumA, spectrumB) { 
       numSample <- ncol(spectrumA) - 1 #first column is m/z value 
       cordis = matrix(nrow = numSample, ncol = 4) 
       numRow <- nrow(spectrumA) 
       for (i in 1:numSample) { 
           j <- i+1 
           cordis[i,1] <- colnames(spectrumA)[j] 
           cordis[i,2] <- colnames(spectrumB)[j] 
           cordis[i,3] <- cor(spectrumA[1:numRow,j], spectrumB[1:numRow,j]) 
           cordis[i,4] <- sqrt((spectrumA[1:numRow,j]- 
                                 spectrumB[1:numRow,j])%*%(spectrumA[1:numRow,j]- 
                                 spectrumB[1:numRow,j])/numRow) 
      } 
      colnames(cordis) <- c("ID", "ID_D", "Cor", "Dis") 
      Cordis 
} 
 
### for control group before alignment 
files <- dir("./data/befor_alignment/control", pattern = "(low good spectra)[ ][0-9]*[  
             ](n).csv",full.names=TRUE) 
filesD <- dir("./data/before_alignment/control", pattern = "(low good spectra)[ ][0-
9]*[  
             ](n_d).csv",full.names=TRUE) 
ins <- GetIntens(files,2000,1) 
insD <- GetIntens(filesD,2000,1) 
cordis <- CorDisDuplicate(ins, insD) 
write.table(cordis, file = "result/CorDisControl.csv", sep = ",", append = FALSE,  
                 col.names = TRUE, row.names = FALSE) 
 
 
 
### To perform McNemar's chi-squared test. 
### ref: http://www.medcalc.be/manual/mpage06-15.php 
 
per <- matrix(c(31, 7, 11, 29), nr = 2, dimnames = list("pabsd" = c("cancer", 
"control"), 
"before" = c("cancer", "control"))) 
mcnemar.test(per) 
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### To perform spectrum alignment (MATLAB) 
 
Clear 
seldi_input_parameters  % Load parameters for analysis; 
 
% Fast peak alignment of spectra using a beam search algorithm 
% REFERENCE: G.-C. Lee and D.L. Woodruff, Beam Search for Peak Alignment 
of NMR Signals 
% submitted to Analytica Chimica Acta (2004). 
 
% read in reference spectrum 
refName = input('Enter directory name of reference spectrum: ', 's'); 
cd (refName); 
MZ_Inten_ref = csvread('reference.csv',1); %data includes mz and intensity 
MZ = MZ_Inten_ref(:,1); % get mz ratio value 
 
% Read in spectra to be aligned 
directoryName = input('Enter directory name of SELDI spectra to be aligned: ', 's'); 
 
% Spectra in MATLAB working directory. 
cd (directoryName); 
files = dir('*.csv'); 
 
% Preallocate some space for the data. 
numSamples = numel(files); 
numDataPoints = numel(MZ); 
Intens = zeros(numDataPoints,numSamples); 
 
% Loop over the files and read in the data. 
for i = 1:numSamples 
    MZ_Inten = csvread(files(i).name, 1); 
    Intens(:,i) = MZ_Inten(:,2); 
End 
disp (' '); 
cd ../ % for protecting orig data 
 
% Start peak alignment based upon linear distribution 
% Calculate segmentation positions. 
ref_spec = MZ_Inten_ref(:,2); 
raw_length = length (ref_spec); 
start_point = 1; 
segment = input('Enter number of segments [default = 50]: '); 
if isempty(segment) 
    segment = 50; 
End 
disp (' '); 
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si = raw_length; 
s_index = round (raw_length / segment); 
s = [s_index : s_index : raw_length]; 
 
% Call peak alignment algorithm         
% calculate "ra" "rb" 
% ra: maximum range of sideway movement 
% rb: maximum range searched forward to find local minimum in ref and target 
ra_state = input('Maximum sideway movement range dynamica or fixed? [dynamica 
= 1 (default) and fixed = 2]: '); 
if isempty(ra_state) 
    ra_state = 1; 
End 
methods = input('Enter alignment methods. [PAES = 1 (default); PABS = 2; 
PAFMCC = 3]: '); 
if isempty(methods) 
    methods = 1; 
End 
if methods == 2 
    bw = input('Enter beam width 1 or 2. [beam width = 1 (default)]: '); 
    if isempty(bw) 
        bw = 1; 
    End 
else bw = 0;  
End 
 
for n = 1 : numSamples    
    [spec_shift,optima,cc] = 
seldi_fastpa(Intens(:,n),ref_spec,s,MZ(:,1),ra_state,rb,bw,fig,si, methods); 
    %spec_shift = [files(i).name spec_shift']' 
    Intens_aligned(:,n) = spec_shift; 
    cc_matrix = [cc_matrix cc]; 
    shift_matrix = [shift_matrix optima(:,1)]; 
End 
 
cc_av = mean (cc_matrix'); 
disp (['Average correlation coefficient for all alignments = ' num2str(cc_av)]); 
cc_std = std (cc_matrix'); 
disp (['Std deviation of correlation coefficients for all alignments = ' 
num2str(cc_std)]); 
 
%save the aligned spectra on directory named "data_aligned' 
cd (directoryName); 
cd ../; 
if (exist('data_aligned')== 7) 
        rmdir('data_aligned','s'); 
End 
mkdir data_aligned; 
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cd data_aligned; 
for i = 1:numSamples 
    mz_intens_aligned = [MZ_Inten_ref(:,1) Intens_aligned(:,i)]; % plus mz value 
    csvwrite(files(i).name, mz_intens_aligned); 
End 
cd ../ 
 
 
 
 
### To generate ROC curve and calculate AUC. 
### Original author: Hemant Ishwaran. ishwaran@bio.ri.ccf.org 
### Modified by Yaping Cheng. YXC466@bham.ac.uk 
 
rocValue <- function(group,ordinal)  
{ 
        group.uniq <- sort(unique(group)) 
        neg <- ordinal[group==group.uniq[1]] 
        pos <- ordinal[group==group.uniq[2]] 
        n.neg <- length(neg) 
        n.pos <- length(pos) 
        range.data <- range(neg,pos) 
 #xtxt <- 'Test Results' 
 
###   Find all distinct atoms generated by pos and neg 
###   test values. 
        atoms <- unique(sort(c(neg,pos))) 
        atoms.neg <- unique(sort(neg)) 
        atoms.pos <- unique(sort(pos)) 
        n.atoms <- length(atoms) 
        tp <- rep(0,n.atoms) 
        fp <- rep(0,n.atoms) 
        #cdf.neg <- rep(0,length(atoms.neg)) 
        #cdf.pos <- rep(0,length(atoms.pos)) 
 
###   Compute tp and fp values for each distinct atom 
        for ( i in 1:n.atoms) { 
            if (mean(atoms.pos) > mean(atoms.neg)) { 
        tp[i] <- sum(pos >= atoms[i])/n.pos 
        fp[i] <- sum(neg >= atoms[i])/n.neg 
     } else { 
        fp[i] <- sum(pos >= atoms[i])/n.pos 
        tp[i] <- sum(neg >= atoms[i])/n.neg 
     } 
 } 
 
###   Nice touch is to add end values for tp,fp values and cdf's 
 tp <- c(1,tp,0) 
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 fp <- c(1,fp,0) 
 delta <- (range.data[2]-range.data[1])/20 
 atoms.neg <- c(atoms[1]-delta,atoms.neg,atoms[n.atoms]+delta) 
 atoms.pos <- c(atoms[1]-delta,atoms.pos,atoms[n.atoms]+delta) 
 
###   (1) Calculate area under curve using Wilcoxon U-statistic 
###   (2) Estimate its standard error 
 tp.mean <- (tp[1:(n.atoms+1)] + tp[2:(n.atoms+2)])/2 
 fp.diff <- -diff(fp) 
 area.U <- sum(fp.diff*tp.mean) 
 area.S <- sqrt((area.U*(1 - area.U)+(n.pos - 1)*(area.U/(2 - area.U) 
              - area.U^2) + (n.neg - 1)*((2*area.U^2)/(1 + area.U) 
              - area.U^2))/(n.pos*n.neg)) 
        result <- list(fp = fp, tp = tp, areaU = area.U, areaS = area.S, Natoms = n.atoms) 
        Result 
} 
 
rocPlot <- function(fp, tp, nbreaks=15, area.U, area.S, n.atoms, 
minAtom.plot=25,mtxt="ROC plot for ",...) 
{ 
 if(n.atoms>=minAtom.plot){ 
 plot(fp,tp,type="l",xlim=c(0.0,1.0), 
                ylim=c(0.0,1.0),xlab="1-Specificity", 
                ylab="Sensitivity",main=mtxt) 
 text(0.7,0.1,paste('Area=',format(round(area.U,3)))) 
        } 
 else{ 
      plot(fp,tp,type="b",xlim=c(0.0,1.0), 
                 ylim=c(0.0,1.0),xlab="1-Specificity", 
                 ylab="Sensitivity",main="mtxt") 
      text(0.7,0.1,paste('Area=',format(round(area.U,3)), 
                       '+/-',format(round(area.S,3)))) 
 } 
} 
 
###  modified 
rocPeak <- function (peaks) { 
        nn <- nrow(peaks) 
        ll <- ncol(peaks) 
        auc_peak <- matrix(nrow = ll-2, ncol = 2) 
        group <- as.numeric(peaks[,2]) 
        ### first column: sample ID; second column: group info. 
        senSpe <- c() 
        senSpeNames <- c() 
        protein_names <- colnames(peaks)[3:ll] 
        for (i in 3:ll) { 
            j <- i-2 
            auc_peak[j,1] <- protein_names[j] 
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            ordinal <- peaks[,i] 
            rocV <- rocValue(group,ordinal) 
            rocPlot(rocV$fp, rocV$tp,nbreaks=15, area.U=rocV$areaU, 
area.S=rocV$areaS,n.atoms = rocV$Natoms, 
minAtom.plot=25,mtxt=colnames(peaks)[i]) 
            auc_peak[j,2] <- rocV$areaU 
            senSpe <- cbind(senSpe, rocV$fp, rocV$tp) 
            senSpeNames <- c(senSpeNames, protein_names[j], protein_names[j]) 
        } 
        colnames(auc_peak) <- c("Peak", "AUC") 
        colnames(senSpe) <- senSpeNames 
        result <- list(auc = auc_peak, ss = senSpe) 
        Result 
} 
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Appendix 8-4 Programs for normality test 
 
### To perform goodnees-of-fit test for normality test 
### Original autor: Linlin Chen (for microarray data) 
### Modfied by Yaping Cheng (for proteomic SELDI data) 
rm(list=ls()) 
### Read in the data set (row: protein  column: sample ID) 
f <- dir("../data/peaks", pattern = "peak_median_cancer.csv", full.names=TRUE) 
da <- read.table(f, header=TRUE, sep=",", row.name = 1) 
da <- t(da) 
 
### number of proteins 
NN <- nrow(da) 
### number of samples 
LL <- ncol(da) 
### number of resampling steps 
SN <- 1000 
 
### log transformation 
ndata <- da 
small <- min(ndata) 
small <- 1-small 
### replace values with "smallest" to make all datas >= 1 
sdata <- ndata + small 
da <- sdata 
 
### to record the number of the rejection  for each sampling 
yyn <- 1:SN 
s <- 1:LL 
size <- LL-10 
 
library(nortest) 
for(i in 1:SN) 
{ 
       yyn[i] <- 0 
       ### do the resampling, without replacement, 
       ### size is LL-10, instead of LL 
       ss <- sample(s, size) 
       dd <- da[,ss] 
        for(j in 1:NN) # for each gene 
        { 
               ### to perform the Pearson chi-square test for normality 
               P <- pearson.test(dd[j,])$p.value 
               if(p < 0.05) 
                      yyn[i]  <- yyn[i] +1 
       } 
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} 
 
r <- size 
d <- 10 
nd <- LL 
 
### calculate t 
### number of the rejections for each resampling 
yy <- yyn 
### 0.05*NN: the expected number of rejections under the complete null hypothesis. 
### mean(yy): average number of rejection under each resampling 
tt <- (mean(yy) - 0.05*NN) 
aa <- sqrt(r/d)*(yy-mean(yy)) 
dd <- aa[aa > tt] 
length(dd) 
 
 
 
### Functions for normalisation, transformation and normality test 
 
### row: m/z values 
### column: samples 
 
### Ciphergen: TIC 
meanAUC <- function(data) { 
      nc <- ncol(data) 
      mea <- colMeans(data) 
      nor_cor <- mean(mea) 
      for(i in 1:nc) { 
            data[, i] <- data[, i] * nor_cor/mea[i] 
      } 
      Data 
} 
 
### The newly proposed normalisation algorithm 
medianAUC <- function(data) { 
      nc <- ncol(data) 
      medi <- matrix(nrow=1, ncol=nc) 
      for(i in 1:nc) { 
          medi[1,i] <- median(data[, i]) 
      } 
      nor_cor <- median(medi) 
      for(i in 1:nc) { 
            data[, i] <- data[, i] * nor_cor/medi[i] 
      } 
      Data 
} 
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### PROcess 
library(PROcess) 
 
### shapiro-will_test 
swt <- function(data) { 
    npv <- 0 
    nr <- nrow(data) 
    pvalue <- matrix(nrow=nr, ncol=1) 
    for(i in 1:nr) { 
        ss <- shapiro.test(as.numeric(data[i, ])) 
        if(ss$p.value < 0.05) { 
            npv <- npv +1 
        } 
    pvalue[I,1] <- ss$p.value 
    } 
    rownames(pvalue) <- rownames(data) 
    results <- list(num_rej = npv, pvalues = pvalue) 
    Results 
} 
 
library(nortest) 
### Cramér-von-miss_test 
cvmt <- function(data) { 
    npv <- 0 
    nr <- nrow(data) 
    pvalue <- matrix(nrow=nr, ncol=1) 
    for(i in 1:nr) { 
        ss <- cvm.test(as.numeric(data[i, ])) 
        if(ss$p.value < 0.05) { 
            npv <- npv +1 
        } 
    pvalue[I,1] <- ss$p.value 
    } 
    rownames(pvalue) <- rownames(data) 
    results <- list(num_rej = npv, pvalues = pvalue) 
    Results 
} 
 
### kolmogorov_test 
klg <- function(data) { 
    npv <- 0 
    nr <- nrow(data) 
    pvalue <- matrix(nrow=nr, ncol=1) 
    for(i in 1:nr) { 
        ss <- lillie.test(as.numeric(data[i, ])) 
        if(ss$p.value < 0.05) { 
            npv <- npv +1 
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        } 
    pvalue[I,1] <- ss$p.value 
    } 
    rownames(pvalue) <- rownames(data) 
    results <- list(num_rej = npv, pvalues = pvalue) 
    Results 
} 
 
### pearson_test 
pers <- function(data) { 
    npv <- 0 
    nr <- nrow(data) 
    pvalue <- matrix(nrow=nr, ncol=1) 
    for(i in 1:nr) { 
        ss <- pearson.test(as.numeric(data[i, ])) 
        if(ss$p.value < 0.05) { 
            npv <- npv +1 
        } 
    pvalue[I,1] <- ss$p.value 
    } 
    rownames(pvalue) <- rownames(data) 
    results <- list(num_rej = npv, pvalues = pvalue) 
    Results 
} 
 
### skewness&kurtosis 
ske_kur <- function(data, id, num) { 
    library(e1071) 
    ske <- c() 
    kur <- c() 
    for (i in 1:num) { 
        ske <- cbind(ske, skewness(as.numeric(data[id[i],]))) 
        kur <- cbind(kur, kurtosis(as.numeric(data[id[i],]))) 
    } 
    results <- list(skew = ske, kurto = kur) 
    Results 
} 
 
 
 
### PCA analysis 
 
rm(list=ls()) 
library(MASS) 
 
### read in data 
 
202
f <- dir("../data/peaks/pca", pattern = "peaks_imp10.csv", full.names=TRUE) 
data <- read.table(f, header=TRUE, sep=",", row.name = 1) 
 
ins <- subset(data, select=-class) 
group <- as.numeric(data[,1]) 
group.uniq <- sort(unique(group)) 
control <- row.names(ins)[group==group.uniq[1]] 
cancer <- row.names(ins)[group==group.uniq[2]] 
 
###### log transformation ###### 
small <- min(ins) 
small <- 1-small 
### replace values with "smallest" to make all datas >= 1 
ins <- ins + small 
ins <- log2(ins) 
 
 
###### scores ###### 
pc <- princomp(ins) 
plot(pc$scores[,1:2],col="red", xlab="PC1", ylab="PC2") 
plot(pc$scores[,1:2],col="red", , type="n", xlab="PC1", ylab="PC2") 
points(pc$scores[, 1:2][row.names(pc$scores[, 1:2]) %in% control,], col="blue", 
pch=19,lwd=0.5) 
points(pc$scores[, 1:2][row.names(pc$scores[, 1:2]) %in% cancer,], col="red", 
pch=19,lwd=0.5) 
 
text(3,3.5,"control", col="blue") 
text(3,3.2,"cancer", col="red") 
 
###### loadings ###### 
plot(pc$loadings[,1:2],col="red", xlab="PC1", ylab="PC2") 
plot(pc$loadings[,1:2],col="red", , type="n", xlab="PC1", ylab="PC2") 
 
num_var <- nrow(pc$loadings) 
num_com <- ncol(pc$loadings) 
for(i in 1:num_var) { 
text(pc$loadings[i,1], pc$loadings[i,2],row.names(pc$loadings)[i] , col="blue") 
} 
 
 
 
### To find peaks using PROcess package through R 
 
rm(list=ls()) 
library(PROcess) 
f <- dir("../data/normalised", pattern="nor_process_ovarian.csv", full.names=TRUE) 
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ins <- read.table(f, header = TRUE, row.names = 1, sep = ",") 
inss <- as.matrix(ins) 
peakfile <- paste(tempdir(), "testpeakinfo.csv", sep = "/") 
getPeaks(inss, peakfile, SoN = 2,span = 81,sm.span=11, zerothrsh=1, area.w = 0.003, 
ratio = 0.01) 
bmkfile <- paste(tempdir(), "testbiomarker.csv", sep = "/") 
testBio <- pk2bmkr(peakfile, inss, bmkfile) 
write.table(testBio, file = "peak_process.csv", sep = ",", append = FALSE, col.names 
= TRUE, row.names = TRUE) 
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Appendix 8-5 Programs for feature selection and cancer classification 
 
### Wilcoxon test 
 
rm (list=ls()) 
### To calculate p value of Wilcoxon test 
pValueOfTW <- function (data){ 
        cNames <- colnames(data) 
        nRow <- nrow(data) 
        nCol <- ncol(data) 
        cancer <- subset(data, data[,2] >= 1) 
        control <- subset(data, data[,2] < 1) 
        TWP <- matrix(nrow = 2, ncol = nCol-2) 
        for (i in 3:nCol) { 
                 wtestF <- wilcox.test(control[,i], cancer[,i] , paired=F) 
                 wtestT <- wilcox.test(control[,i], cancer[,i], paired=T) 
                 j <- i-2 
                 TWP[1,j] <- wtestF$p.value 
                TWP[2,j] <- wtestT$p.value 
        } 
        colnames(TWP) <- colnames(data)[3:nCol] 
        rownames(TWP) <- c("unpaired", "paired") 
        TWP 
} 
 
 
### To find important variables based on RF modelling 
 
rm (list=ls()) 
library(randomForest) 
set.seed(166) 
 
### read in data 
f <- dir("../data/", pattern = "prostate_peaks_rf.csv",full.names=TRUE) 
intens <- read.table(f, header = TRUE, sep = ",", row.name = 1) 
 
### to find the importance variables based on "mean descreas accuracy" measurment 
varImp <- randomForest(class~., data=intens, ntree = 500, importance = TRUE) 
write.table(varImp$importance[,3], file = "rf_err_prostate.csv", sep = ",", append = 
FALSE, col.names = TRUE, row.names = TRUE) 
 
 
### SVM modelling 
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rm (list=ls()) 
library(e1071) 
 
### read in 
f <- dir("../results/classification", pattern="^prostate_common_peaks.csv", 
full.names=TRUE) 
ins <- read.table(f, header=TRUE, sep=",", row.names =1) 
 
### building 
acc <- c() 
for (i in 1:100) { 
      m <- svm(class~., data = ins, cross =10, gamma=0.02, cost=64) 
      acc <- c(acc, m$tot.accuracy) 
} 
write.table(acc, file = "common_svm_model.csv", sep = ",", append = FALSE, 
col.names = TRUE, row.names = FALSE) 
 
### RF modelling 
 
rm (list=ls()) 
library(randomForest) 
set.seed(366) 
 
### read in 
f <- dir("../results/classification", pattern="prostate_common_peaks.csv", 
full.names=TRUE) 
ins <- read.table(f, header=TRUE, sep=",", row.names =1) 
 
### modeling 
acc <- c() 
for (i in 1:100) { 
    rf <- randomForest(class~., data=ins, ntree = 500, importance = TRUE) 
    acc <- c(acc, mean(rf$err.rate[,1])) 
} 
write.table(acc, file = "common_rf_model.csv", sep = ",", append = FALSE, 
col.names = TRUE, row.names = FALSE) 
 
 
### kNN modelling 
 
rm (list=ls()) 
library(class) 
 
### read in 
f <- dir("../results/classification", pattern="prostate_common_peaks.csv", 
full.names=TRUE) 
ins <- read.table(f, header=TRUE, sep=",", row.names =1) 
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train <- subset(ins, select=-class) 
group <- factor(c(rep("n",63), rep("c",69))) 
 
### buinding 
acc <- c() 
for (i in 1:100) { 
    kn <- knn.cv(train, group, k = 3, l = 0, prob = TRUE) 
    k <- 0 
    for(j in 1:132) { 
      if(kn[j] != group[j]) { 
         k <- k+1 
      } 
    } 
    acc <- c(acc, k/132) 
} 
write.table(acc, file = "common_knn_model.csv", sep = ",", append = FALSE, 
col.names = TRUE, row.names = FALSE) 
 
 
To draw matrix of scatter plot and Venn diagram 
rm (list=ls()) 
library(limma) 
 
### read in data ### 
 
f<- dir("../results/venn", pattern = "Pvalue_ovarian_data.csv",full.names=TRUE) 
Wilcoxon_test <- read.table(f, header = FALSE, sep = ",") 
f<- dir("../results/venn", pattern = "auc_ovarian_data.csv",full.names=TRUE) 
ROC_curve <- read.table(f, header = FALSE, sep = ",") 
f<- dir("../results/venn", pattern = "rf_err_ovarian.csv",full.names=TRUE) 
Random_forest <- read.table(f, header = FALSE, sep = ",") 
 
### scatter plot ### 
imp <- t(rbind(Wilcoxon_test, ROC_curve, Random_forest)) 
pairs(imp, pch=20, labels=c("Wilcoxon test", "ROC curve", "Random forest"), 
col="red", font.labels=1.5, cex.labels=1.5) 
 
### venn diagram ### 
set1 <- sort(as.matrix(Wilcoxon_test)) 
set2 <- sort(as.matrix(ROC_curve)) 
set3 <- sort(as.matrix(Random_forest)) 
names <- c("Wilcoxon", "ROC", "RF") 
Venn3(set1, set2, set3, names) 
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